US20230287412A1 - Oligonucleotide Agonists Targeting Progranulin - Google Patents

Oligonucleotide Agonists Targeting Progranulin Download PDF

Info

Publication number
US20230287412A1
US20230287412A1 US17/986,101 US202217986101A US2023287412A1 US 20230287412 A1 US20230287412 A1 US 20230287412A1 US 202217986101 A US202217986101 A US 202217986101A US 2023287412 A1 US2023287412 A1 US 2023287412A1
Authority
US
United States
Prior art keywords
seq
progranulin
antisense oligonucleotide
agonist
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/986,101
Inventor
Ravi Jagasia
Lars JOENSON
Soren Rasmussen
Disa TEHLER
Dorthe Vang LARSEN
Jesper Worm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE INNOVATION CENTER COPENHAGEN A/S
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JAGASIA, RAVI
Assigned to ROCHE INNOVATION CENTER COPENHAGEN A/S reassignment ROCHE INNOVATION CENTER COPENHAGEN A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEHLER, Disa, JOENSON, LARS, WORM, JESPER, RASMUSSEN, SOREN, VANG, Dorthe
Publication of US20230287412A1 publication Critical patent/US20230287412A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Definitions

  • the present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
  • Progranulin is a highly conserved secreted protein that is expressed in multiple cell types, both in the CNS and in peripheral tissues.
  • GNN neurodegenerative disease fronto temporal dementia
  • TDP-43 is a common denominator.
  • TDP-43 pathology is associated with cytoplasmic TDP-43 aggregation. For example, more than 95% of ALS patients display pathological mislocalization of TDP-43 and several mutations in its gene cause familial ALS.
  • TDP-43 aggregates The presence of cytoplasmic TDP-43 aggregates is associated with a concomitant loss of nuclear TDP-43, and there is evidence of both loss of function and gain of function associated pathophysiologies.
  • progranulin regulates lysosomal function, cell growth, survival, repair, and inflammation.
  • Progranulin has a major role in regulation of lysosomal function associated microglial responses in the CNS.
  • Autosomal dominant mutations of the progranulin (GRN) gene leading to protein haploinsufficiency are linked to familial frontotemporal dementia with neuropathologic frontotemporal lobar degeneration (FTLD) associated with accumulation of TAR-DNA binding protein of 43kDA (TDP-43) inclusions (FTLD-TDP).
  • FTLD neuropathologic frontotemporal lobar degeneration
  • Homozygous GRN mutations are linked to neuronal ceroid lipofuscinosis (NCL) (Townley, et al., Neurology. 2018 Jun. 12; 90(24): 1127).
  • GRN progranulin gene
  • WO 2020/077165 reports on AAV particle delivery of therapeutic nucleic acids, and lists progranulin as a potential gene of interest.
  • the invention provides antisense oligonucleotide agonists of progranulin or antisense oligonucleotide progranulin agonists—i.e. antisense oligonucleotides which are complementary to a progranulin nucleic acid sequence, and which are capable of up-regulating the expression of progranulin.
  • antisense oligonucleotide positive modulators i.e. agonists
  • the antisense oligonucelotides of the invention may therefore be used to restore progranulin expression in cells which exhibit progranulin haploinsufficiency, or to enhance expression of progranulin in cells.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA transcript a human progranulin precursor-mRNA
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA transcript a human progranulin precursor-mRNA
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA transcript a human progranulin precursor-mRNA
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA transcript a human progranulin precursor-mRNA
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA transcript a human progranulin precursor-mRNA
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to a to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • the invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • the antisense oligonucleotide progranulin agonist may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
  • the antisense oligonucleotide, or contiguous nucleotide sequence thereof is 8-40, 12-40, 12-20, 14-18, 12-18 or 16-18 nucleotides in length.
  • the contiguous nucleotide sequence may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
  • the contiguous nucleotide sequence is of a length of at least 12 nucleotides in length, such as 12-16 or 12-18 nucleotides in length.
  • the contiguous nucleotide sequence is the same length as the antisense oligonucleotide progranulin agonist.
  • the antisense oligonucleotide consists of the contiguous nucleotide sequence.
  • the antisense oligonucleotide is the contiguous nucleotide sequence.
  • the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 343-682.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to the human progranulin mature mRNA (SEQ ID NO: 1).
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to the human progranulin precursor-mRNA (pre-mRNA) (SEQ ID NO: 3949).
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a 5′UTR region of a human progranulin mature mRNA transcript.
  • the 5′ UTR is defined as nucleotides 38 to 241 according to RefSeq NM_002807.3 (SEQ ID NO 1).
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to nucleotides 38-246 of SEQ ID NO 1.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 689.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 2.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 683.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 343-586.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584, & SEQ ID NO 586.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 8 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 9 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 10 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 11 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 12 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 13 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 14 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 15 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 16 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is selected from SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241 or at least 8 or at least 10 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is SEQ ID NO 106.
  • the contiguous nucleotide sequence is SEQ ID NO 110.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a 3′UTR region of a human progranulin mature mRNA transcript.
  • the 3′ UTR is defined as nucleotides 2044 to 2346 according to RefSeq NM_002807.3 (SEQ ID NO 1).
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to nucleotides 2039-2346 of SEQ ID NO 1.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 587-682.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 8 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 9 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 10 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 11 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 12 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 13 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 14 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 15 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 16 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2322, SEQ ID 2324, SEQ ID 2328, SEQ ID 2329, SEQ ID 2331, SEQ ID 2334, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2340, SEQ ID 2341, SEQ ID 2342, SEQ ID 2345, SEQ ID 2346, SEQ ID 2347, SEQ ID 2348, SEQ ID 2349, SEQ ID 2350, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2356, SEQ ID 2357, SEQ ID 2358, SEQ ID 2359, SEQ ID 2360, SEQ ID 2361, SEQ ID 2362, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2348, SEQ ID 2349, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2358, SEQ ID 2360, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2369, SEQ ID 2371, SEQ ID 2373, SEQ ID 2375, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2394, SEQ ID 2403, SEQ ID 2426, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2435, SEQ ID 2440
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 8 contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 9 contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 10 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 11 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 12 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 13 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 14 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 15 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 16 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • the antisense oligonucleotide progranulin agonist is or comprises an antisense oligonucleotide mixmer or totalmer.
  • the contiguous nucleotide sequence is a mixmer or a tolalmer.
  • the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence thereof is 10-20 nucleotides in length.
  • the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID NOs 3-342.
  • the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID NOs 693-2039.
  • the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 694, SEQ ID 696, SEQ ID 700, SEQ ID 701, SEQ ID 703, SEQ ID 706, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 712, SEQ ID 713, SEQ ID 714, SEQ ID 717, SEQ ID 718, SEQ ID 719, SEQ ID 720, SEQ ID 721, SEQ ID 722, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 728, SEQ ID 729, SEQ ID 730, SEQ ID 731, SEQ ID 732, SEQ ID 733, SEQ ID 734, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 740, SEQ ID 7
  • the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 720, SEQ ID 721, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 730, SEQ ID 732, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 741, SEQ ID 743, SEQ ID 745, SEQ ID 747, SEQ ID 758, SEQ ID 759, SEQ ID 760, SEQ ID 761, SEQ ID 766, SEQ ID 775, SEQ ID 798, SEQ ID 800, SEQ ID 801, SEQ ID 802, SEQ ID 803, SEQ ID 804, SEQ ID 807, SEQ ID 812, SEQ ID 813, SEQ ID 8
  • the invention provides for a conjugate comprising the antisense oligonucleotide progranulin agonist according to the invention, and at least one conjugate moiety covalently attached to said antisense oligonucleotide progranulin agonist.
  • the invention provides an antisense oligonucleotide progranulin agonist covalently attached to at least one conjugate moiety.
  • the invention provides for a pharmaceutically acceptable salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • the invention provides for an antisense oligonucleotide progranulin agonist according to the invention wherein the antisense oligonucleotide progranulin agonist is in the form of a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt may be a sodium salt or a potassium salt.
  • the invention provides for a pharmaceutically acceptable sodium salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • the invention provides for a pharmaceutically acceptable potassium salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • the invention provides for a pharmaceutical composition
  • a pharmaceutical composition comprising the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • the invention provides for a pharmaceutical composition
  • a pharmaceutical composition comprising the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, and a pharmaceutically acceptable salt.
  • the salt may comprise a metal cation, such as a sodium salt or a potassium salt.
  • the invention provides for a pharmaceutical composition according to the invention, wherein the pharmaceutical composition comprises the antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the pharmaceutically acceptable salt of the invention; and an aqueous diluent or solvent.
  • the invention provides for a solution, such as a phosphate buffered saline solution of the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, or the pharmaceutically acceptable salt of the invention.
  • a solution such as a phosphate buffered saline solution of the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, or the pharmaceutically acceptable salt of the invention.
  • the solution such as phosphate buffered saline solution, of the invention, is a sterile solution.
  • the invention provides for a method for enhancing the expression of progranulin in a cell which is expressing progranulin, said method comprising administering an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention in an effective amount to said cell.
  • the method is an in vitro method.
  • the method is an in vivo method.
  • the cell is either a human cell or a mammalian cell.
  • the invention provides for a method for treating or preventing neurological disease, comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention to a subject suffering from or susceptible to neurological disease.
  • the neurological disease may be a TDP-43 pathology.
  • the invention provides for a method for treating progranulin haploinsufficiency disease, comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention to a subject suffering from progranulin haploinsufficiency or a related disorder.
  • the invention provides for an antisense oligonucleotide progranulin agonist, for use as a medicament.
  • the invention provides for an antisense oligonucleotide progranulin agonist, for use in therapy.
  • the invention provides for the antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention, for use as a medicament.
  • the invention provides an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in therapy.
  • the invention provides for an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in the treatment of a neurological disease.
  • the neurological disease may be a TDP-43 pathology.
  • the invention provides for an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in the treatment of progranulin haploinsufficiency, or a related disorder.
  • the invention provides for the use of an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention, for the preparation of a medicament for treatment or prevention of a neurological disease
  • the neurological disease may be a TDP-43 pathology.
  • the invention provides for the use of the antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention, for the preparation of a medicament for treatment of progranulin haploinsufficiency or a related disorder.
  • the method or use of the invention is for the treatment of fronto temporal dementia (FTD), neuropathologic frontotemporal lobar degeneration or neuroinflammation.
  • FTD fronto temporal dementia
  • the method or use of the invention is for the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Autism, Hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases, spinocerebellar ataxia 3, myopathies or Chronic Traumatic Encephalopathy.
  • the invention includes an oligonucleotide progranulin agonist having the structure:
  • the invention also includes an antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
  • FIG. 1 shows progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 16-mer oligos targeting the progranulin 5′ UTR uORF region. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 2 shows localization of compounds #105, #106, #110 and #114 to the 5′ UTR of the proganulin mature mRNA transcript, targeting the uORF region.
  • FIGS. 3 and 4 show progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 16-mer oligos targeting 5′ UTR uORF region.
  • Progranulin expression levels were evaluated in cell lysate (RIPA lysis and extraction buffer from Pierce cat. No. 89900) using the WES platform (ProteinSimple) and GRN antibody Invitrogen PA5-27275 diluted 1:25 and HPRT1 antibody ab109021 (Abcam) diluted 1:50.
  • FIG. 5 shows the level of progranulin expression in hiPSC derived micoglia following 5 days of treatment with Compound #106. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 6 shows progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 18-mer oligos targeting the progranulin 5′ UTR uORF region. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 7 shows the structure of Compound ID #106 (SEQ ID NO 106).
  • FIG. 8 shows progranulin expression in H4 neuroglioma cells following treatment with Compound #106, Compound #106 full 2′MOE, and Compound #106 full 2′oMe.
  • FIG. 9 shows heat maps indicating genes upregulated and down regulated relative to PBS control treated cells. Left is compound #106, middle is Compound #106 full 2′oMe and right is Compound #106 full 2′MOE.
  • FIG. 10 is a plot showing the position of oligos within the progranulin precursor-mRNA (pre-mRNA) sequence (SEQ ID NO 3949) relative to the activity of the oligo. Oligos complementary to exon-exon junctions are plotted downstream of the schematic figure of the pre-mRNA
  • progranulin agonist refers to a compound which is capable of enhancing the expression of progranulin transcripts and/or protein in a cell which is expressing progranulin.
  • a TDP-43 pathology is a disease which is associated with reduced or aberrant expression of TDP-43, often associated with an increase in cytoplasmic TDP-43, particularly hyper-phosphorylated and ubiquitinated TDP-43.
  • TDP-43 pathology diseases associated with TDP-43 pathology include amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer's disease, Parkinson's disease, Autism, Hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases, such as spinocerebellar ataxia 3, myopathies and Chronic Traumatic Encephalopathy.
  • ALS amyotrophic lateral sclerosis
  • FTLD frontotemporal lobar degeneration
  • Alzheimer's disease Parkinson's disease
  • Autism Hippocampal sclerosis dementia
  • Down syndrome Huntington's disease
  • polyglutamine diseases such as spinocerebellar ataxia 3
  • myopathies myopathies and Chronic Traumatic Encephalopathy.
  • oligonucleotide as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers.
  • Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification and isolation. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides.
  • the oligonucleotides of the invention are man-made, and are chemically synthesized, and are typically purified or isolated.
  • the oligonucleotides of the invention may comprise one or more modified nucleosides such as 2′ sugar modified nucleosides.
  • the oligonucleotides of the invention may comprise one or more modified internucleoside linkages, such as one or more phosphorothioate internucleoside linkages.
  • antisense oligonucleotide as used herein is defined as an oligonucleotide capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid. Antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs or shRNAs. The antisense oligonucleotides of the present invention may be single stranded.
  • single stranded oligonucleotides of the present invention can form hairpins or intermolecular duplex structures (duplex between two molecules of the same oligonucleotide), as long as the degree of intra or inter self-complementarity is less than approximately 50% across of the full length of the oligonucleotide.
  • the single stranded antisense oligonucleotides of the invention may not contain RNA nucleosides.
  • the antisense oligonucleotides of the invention comprise one or more modified nucleosides or nucleotides, such as 2′ sugar modified nucleosides. Furthermore, in some antisense oligonucleotides of the invention, it may be advantageous that the nucleosides which are not modified are DNA nucleosides.
  • contiguous nucleotide sequence refers to the region of the oligonucleotide which is complementary to a target nucleic acid, which may be or may comprise an oligonucleotide motif sequence.
  • target nucleic acid which may be or may comprise an oligonucleotide motif sequence.
  • contiguous nucleobase sequence In some embodiments all the nucleosides of the oligonucleotide constitute the contiguous nucleotide sequence.
  • the contiguous nucleotide sequence is the sequence of nucleotides in the oligonucleotide of the invention which are complementary to, and in some instances fully complementary to, the target nucleic acid or target sequence, or target site sequence.
  • the target sequence is SEQ ID NO 2.
  • SEQ ID NO 2 TAGCCCTGATCCCTGGCCAATGGAAACTGAGGTAGG
  • the target sequence is selected from the group consisting of SEQ ID NO 343-682.
  • the target sequence is nucleotides 38-246 of SEQ ID NO 1.
  • the target sequence is selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584 & SEQ ID NO 586.
  • the target sequence is SEQ ID NO 683.
  • SEQ ID NO 683 TGGCCAATGGAAACTGAGGTAGG
  • the target sequence is SEQ ID NO 684.
  • SEQ ID NO 684 CCCTAGCACCTCCCCCTAACCAAATTCTCCCTG
  • the target sequence is SEQ ID NO 685.
  • SEQ ID NO 685 CCCATTCTGAGCTCCCCATCA
  • the target sequence is SEQ ID NO 686.
  • SEQ ID NO 686 AGGGGGTTGTGGCAAAAGCCA
  • the target sequence is SEQ ID NO 687.
  • SEQ ID NO 687 CCATCCCCTCCCCGTTTCAGT
  • the target sequence is SEQ ID NO 688.
  • SEQ ID NO 688 ATCCACAGGGGTGTTTGT
  • the target sequence is SEQ ID NO 689.
  • SEQ ID NO 689 TAAGTAGCCAATGGGAGCGGGTAGCCCTGATCCCTGGCCAATGGAAACT GAGGTAGG
  • SEQ ID NO 689 is in the human progranulin mature mRNA 5′ UTR from position 119 to 158 according to RefSeq NM_002087 (SEQ ID NO 1), as targeted by SEQ ID NOs 207 to 246 and identified herein as an advantageous region to target for progranulin agonist activity.
  • the target sequence is nucleotides 2039-2346 of SEQ ID NO 1.
  • the target sequence is selected from the group consisting of SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 683, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • the target sequence is selected from the group consisting of SEQ ID NO 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • the target sequence is selected from the group consisting of SEQ ID NO 2040-3386.
  • the target sequence is selected from the group consisting of SEQ ID 2321, SEQ ID 2322, SEQ ID 2324, SEQ ID 2328, SEQ ID 2329, SEQ ID 2331, SEQ ID 2334, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2340, SEQ ID 2341, SEQ ID 2342, SEQ ID 2345, SEQ ID 2346, SEQ ID 2347, SEQ ID 2348, SEQ ID 2349, SEQ ID 2350, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2356, SEQ ID 2357, SEQ ID 2358, SEQ ID 2359, SEQ ID 2360, SEQ ID 2361, SEQ ID 2362, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2368, SEQ ID 2369, SEQ ID 2370,
  • the target sequence is selected from the group consisting of SEQ ID 2321, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2348, SEQ ID 2349, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2358, SEQ ID 2360, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2369, SEQ ID 2371, SEQ ID 2373, SEQ ID 2375, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2394, SEQ ID 2403, SEQ ID 2426, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2435, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2444,
  • the oligonucleotide comprises the contiguous nucleotide sequence, and may optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group (e.g. a conjugate group) to the contiguous nucleotide sequence.
  • the nucleotide linker region may or may not be complementary to the target nucleic acid. It is understood that the contiguous nucleotide sequence of the oligonucleotide cannot be longer than the oligonucleotide as such and that the oligonucleotide cannot be shorter than the contiguous nucleotide sequence.
  • Nucleotides and nucleosides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides and nucleosides.
  • nucleotides such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides).
  • Nucleosides and nucleotides may also interchangeably be referred to as “units” or “monomers”.
  • the antisense oligonucleotide progranulin agonist of the invention may comprise one or more modified nucleoside.
  • modified nucleoside or “nucleoside modification” as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety.
  • one or more of the modified nucleosides of the antisense oligonucleotides of the invention may comprise a modified sugar moiety.
  • modified nucleoside may also be used herein interchangeably with the term “nucleoside analogue” or modified “units” or modified “monomers”. Nucleosides with an unmodified DNA or RNA sugar moiety are termed DNA or RNA nucleosides herein.
  • Nucleosides with modifications in the base region of the DNA or RNA nucleoside are still generally termed DNA or RNA if they allow Watson Crick base pairing.
  • Exemplary modified nucleosides which may be used in the antisense oligonucleotide progranulin agonists of the invention include LNA, 2′-O-MOE, 2′oMe and morpholino nucleoside analogues.
  • the antisense oligonucleotide progranulin agonist of the invention comprises one or more modified internucleoside linkage.
  • modified internucleoside linkage is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couple two nucleosides together.
  • the antisense oligonucleotide progranulin agonists of the invention may therefore comprise one or more modified internucleoside linkages such as one or more phosphorothioate internucleoside linkage.
  • At least 50% of the internucleoside linkages in the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90% or more of the internucleoside linkages in the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • all the internucleoside linkages of the contiguous nucleotide sequence of the antisense oligonucleotide progranulin agonist may be phosphorothioate, or all the internucleoside linkages of the antisense oligonucleotide progranulin agonist may be phosphorothioate linkages.
  • nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization.
  • pyrimidine e.g. uracil, thymine and cytosine
  • nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but which are functional during nucleic acid hybridization.
  • nucleobase refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.
  • the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2′thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.
  • a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-brom
  • the nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function.
  • the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine.
  • 5-methyl cytosine LNA nucleosides may be used.
  • the antisense oligonucleotide progranulin agonist of the invention may be a modified oligonucleotide.
  • modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages.
  • chimeric oligonucleotide is a term that has been used in the literature to describe oligonucleotides comprising sugar modified nucleosides and DNA nucleosides.
  • the antisense oligonucleotide progranulin agonist of the invention may be a chimeric oligonucleotide.
  • Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U).
  • oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-paring between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).
  • % complementary refers to the proportion of nucleotides (in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are complementary to a reference sequence (e.g. a target sequence or sequence motif).
  • the percentage of complementarity is thus calculated by counting the number of aligned nucleobases that are complementary (from Watson Crick base pairs) between the two sequences (when aligned with the target sequence 5′-3′ and the oligonucleotide sequence from 3′-5′), dividing that number by the total number of nucleotides in the oligonucleotide and multiplying by 100.
  • nucleobase/nucleotide which does not align is termed a mismatch. Insertions and deletions are not allowed in the calculation of complementarity of a contiguous nucleotide sequence. It will be understood that in determining complementarity, chemical modifications of the nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5′-methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • the term “complementary” requires the antisense oligonucleotide progranulin agonist to be at least about 80% complementary, or at least about 90% complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • the antisense oligonucleotide progranulin agonist may be at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% complementary to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • pre-mRNA human progranulin precursor-mRNA
  • an antisense oligonucleotide progranulin agonist of the invention may include one, two, three or more mis-matches, wherein a mis-match is a nucleotide within the antisense oligonucleotide progranulin agonist of the invention which does not base pair with its target.
  • the antisense oligonucleotide progranulin agonists of the invention are advantageously complementary to the human progranulin precursor mRNA (pre-mRNA) or the human prograulin mature mRNA sequence.
  • pre-mRNA human progranulin precursor mRNA
  • pre-mRNA human progranulin mature mRNA sequence
  • SEQ ID NO 3949 The human progranulin precursor-mRNA (pre-mRNA) sequence is exemplified herein as SEQ ID NO 3949.
  • SEQ ID NO 1 and SEQ ID NO 3949 are provided herein as reference sequences and it will be understood that the target progranulin nucleic acid may be an allelic variant of SEQ ID NO 1 or SEQ ID NO 3949, such as an allelic variant which comprises one or more polymorphism in the human progranulin nucleic acid sequence.
  • identity refers to the proportion of nucleotides (expressed in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are identical to a reference sequence (e.g. a sequence motif).
  • nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5-methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • hybridizing or “hybridizes” as used herein are to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex.
  • the affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (T m ) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions T m is not strictly proportional to the affinity (Mergny and Lacroix, 2003 , Oligonucleotides 13:515-537).
  • ⁇ G° is the energy associated with a reaction where aqueous concentrations are 1M, the pH is 7, and the temperature is 37° C.
  • ⁇ G° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965 , Chem. Comm. 36-38 and Holdgate et al., 2005 , Drug Discov Today .
  • ITC isothermal titration calorimetry
  • the skilled person will know that commercial equipment is available for ⁇ G° measurements.
  • ⁇ G° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998 , Proc Natl Acad Sci USA. 95: 1460-1465 using appropriately derived thermodynamic parameters described by Sugimoto et al., 1995 , Biochemistry 34:11211-11216 and McTigue et al., 2004 , Biochemistry 43:5388-5405.
  • antisense oligonucleotide progranulin agonists of the present invention hybridize to a target nucleic acid with estimated ⁇ G° values below ⁇ 10 kcal for oligonucleotides that are 10-30 nucleotides in length.
  • the degree or strength of hybridization is measured by the standard state Gibbs free energy ⁇ G°.
  • the oligonucleotides may hybridize to a target nucleic acid with estimated ⁇ G° values below the range of ⁇ 10 kcal, such as below ⁇ 15 kcal, such as below ⁇ 20 kcal and such as below ⁇ 25 kcal for oligonucleotides that are 8-30 nucleotides in length.
  • the oligonucleotides hybridize to a target nucleic acid with an estimated ⁇ G° value of ⁇ 10 to ⁇ 60 kcal, such as ⁇ 12 to ⁇ 40, such as from ⁇ 15 to ⁇ 30 kcal, or ⁇ 16 to ⁇ 27 kcal such as ⁇ 18 to ⁇ 25 kcal.
  • a high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (T m ).
  • a high affinity modified nucleoside of the present invention preferably results in an increase in melting temperature between +0.5 to +12° C., more preferably between +1.5 to +10° C. and most preferably between +3 to +8° C. per modified nucleoside.
  • Numerous high affinity modified nucleosides are known in the art and include for example, many 2′ substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).
  • the antisense oligonucleotide progranulin agonist of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.
  • nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.
  • Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA).
  • HNA hexose ring
  • LNA ribose ring
  • UPA unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons
  • Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of
  • Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2′-OH group naturally found in DNA and RNA nucleosides.
  • Substituents may, for example be introduced at the 2′, 3′, 4′ or 5′ positions.
  • a 2′ sugar modified nucleoside is a nucleoside which has a substituent other than H or —OH at the 2′ position (2′ substituted nucleoside) or comprises a 2′ linked biradicle capable of forming a bridge between the 2′ carbon and a second carbon in the ribose ring, such as LNA (2′-4′ biradicle bridged) nucleosides.
  • the 2′ modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide.
  • 2′ substituted modified nucleosides are 2′-O-alkyl-RNA, 2′-O-methyl-RNA (2′oMe), 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-F-ANA nucleoside.
  • 2′ substituted sugar modified nucleosides does not include 2′ bridged nucleosides like LNA.
  • a “LNA nucleoside” is a 2′-modified nucleoside which comprises a biradical linking the C2′ and C4′ of the ribose sugar ring of said nucleoside (also referred to as a “2′-4′ bridge”), which restricts or locks the conformation of the ribose ring.
  • These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.
  • BNA bicyclic nucleic acid
  • the locking of the conformation of the ribose is associated with an enhanced affinity of hybridization (duplex stabilization) when the LNA is incorporated into an oligonucleotide for a complementary RNA or DNA molecule. This can be routinely determined by measuring the melting temperature of the oligonucleotide/complement duplex.
  • Non limiting, exemplary LNA nucleosides are disclosed in WO 99/014226, WO 00/66604, WO 98/039352, WO 2004/046160, WO 00/047599, WO 2007/134181, WO 2010/077578, WO 2010/036698, WO 2007/090071, WO 2009/006478, WO 2011/156202, WO 2008/154401, WO 2009/067647, WO 2008/150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81, and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, and Wan and Seth, J. Medical Chemistry 2016, 59, 9645-9667.
  • LNA nucleosides are beta-D-oxy-LNA, 6′-methyl-beta-D-oxy LNA such as (S)-6′-methyl-beta-D-oxy-LNA (ScET) and ENA.
  • a particularly advantageous LNA is beta-D-oxy-LNA.
  • the antisense oligonucleotide progranulin agonist of the invention comprises or consists of morpholino nucleosides (i.e. is a Morpholino oligomer and as a phosphorodiamidate Morpholino oligomer (PMO)).
  • morpholino nucleosides i.e. is a Morpholino oligomer and as a phosphorodiamidate Morpholino oligomer (PMO)
  • Splice modulating morpholino oligonucleotides have been approved for clinical use—see for example eteplirsen, a 30nt morpholino oligonucleotide targeting a frame shift mutation in DMD, used to treat Duchenne muscular dystrophy.
  • Morpholino oligonucleotides have nucleobases attached to six membered morpholine rings rather ribose, such as methylenemorpholine rings linked through phosphorodiamidate groups, for example as illustrated by the following illustration of 4 consecutive morpholino nucleotides:
  • morpholino oligonucleotides of the invention may be, for example 20-40 morpholino nucleotides in length, such as morpholino 25-35 nucleotides in length.
  • the RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule.
  • WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH.
  • an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10%, at least 20% or more than 20%, of the initial rate determined when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Examples 91-95 of WO01/23613 (hereby incorporated by reference).
  • recombinant RNase H1 is available from Lubio Science GmbH, Lucerne, Switzerland.
  • DNA oligonucleotides are known to effectively recruit RNaseH, as are gapmer oligonucleotides which comprise a region of DNA nucleosides (typically at least 5 or 6 contiguous DNA nucleosides), flanked 5′ and 3′ by regions comprising 2′ sugar modified nucleosides, typically high affinity 2′ sugar modified nucleosides, such as 2-O-MOE and/or LNA.
  • gapmer oligonucleotides which comprise a region of DNA nucleosides (typically at least 5 or 6 contiguous DNA nucleosides), flanked 5′ and 3′ by regions comprising 2′ sugar modified nucleosides, typically high affinity 2′ sugar modified nucleosides, such as 2-O-MOE and/or LNA.
  • the antisense oligonucleotide progranulin agonists of the invention are not RNaseH recruiting gapmer oligonucleotide.
  • RNaseH recruitment may be avoided by limiting the number of contiguous DNA nucleotides in the oligonucleotide—therefore mimxes and totalmer designs may be used.
  • Advanateously the antisense oligonucleotide progranulin agonistd of the invention, or the contiguous nucleotide sequence thereof do not comprise more than 3 contiguous DNA nucleosides.
  • advanateously the antisense oligonucleotide progranulin agonists of the invention, or the contiguous nucleotide sequence thereof do not comprise more than 4 contiguous DNA nucleosides.
  • the progranulin agonist antisense oligonucleotide agonists of the invention, or contiguous nucleotide sequence thereof do not comprise more than 2 contiguous DNA nucleosides.
  • RNaseH activity of antisense oligonucleotide may be achieved by designing antisense oligonucleotides which do not comprise a region of more than 3 or more than 4 contiguous DNA nucleosides. This may be achieved by using antisense oligonucleotides or contiguous nucleoside regions thereof with a mixmer design, which comprise sugar modified nucleosides, such as 2′ sugar modified nucleosides, and short regions of DNA nucleosides, such as 1, 2 or 3 DNA nucleosides.
  • nucleosides alternate between 1 LNA and 1 DNA nucleoside, e.g. LDLDLDLDLDLDLDLL, with 5′ and 3′ terminal LNA nucleosides, and every third design, such as LDDLDDLDDLDDLDDL, where every third nucleoside is a LNA nucleoside.
  • the internucleoside nucleosides in mixmers and totalmers may be phosphorothioate, or a majority of nucleoside linkages in mixmers may be phosphorothioate.
  • Mixmers and totalmers may comprise other internucleoside linkages, such as phosphodiester or phosphorodithioate, by way of example.
  • the antisense oligonucleotide progranulin agonist of the invention may in some embodiments comprise or consist of the contiguous nucleotide sequence of the oligonucleotide which is complementary to the target nucleic acid, such as a mixmer or toalmer region, and further 5′ and/or 3′ nucleosides.
  • the further 5′ and/or 3′ nucleosides may or may not be complementary, such as fully complementary, to the target nucleic acid.
  • Such further 5′ and/or 3′ nucleosides may be referred to as region D′ and D′′ herein.
  • region D′ or D′′ may be used for the purpose of joining the contiguous nucleotide sequence, such as the mixmer or totoalmer, to a conjugate moiety or another functional group.
  • region D′ or D′′ When used for joining the contiguous nucleotide sequence with a conjugate moiety is can serve as a biocleavable linker. Alternatively, it may be used to provide exonucleoase protection or for ease of synthesis or manufacture.
  • Region D′ or D′′ may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid.
  • the nucleotide adjacent to the F or F′ region is not a sugar-modified nucleotide, such as a DNA or RNA or base modified versions of these.
  • the D′ or D′ region may serve as a nuclease susceptible biocleavable linker (see definition of linkers).
  • the additional 5′ and/or 3′ end nucleotides are linked with phosphodiester linkages, and are DNA or RNA.
  • Nucleotide based biocleavable linkers suitable for use as region D′ or D′′ are disclosed in WO2014/076195, which include by way of example a phosphodiester linked DNA dinucleotide.
  • the use of biocleavable linkers in poly-oligonucleotide constructs is disclosed in WO2015/113922, where they are used to link multiple antisense constructs within a single oligonucleotide.
  • the antisense oligonucleotide progranulin agonist of the invention comprises a region D′ and/or D′′ in addition to the contiguous nucleotide sequence which constitutes a mixmer or a totalmer.
  • the internucleoside linkage positioned between region D′ or D′′ and the mixmer or totalmer region is a phosphodiester linkage.
  • the invention encompasses an antisense oligonucleotide progranulin agonist covalently attached to at least one conjugate moiety. In some embodiments this may be referred to as a conjugate of the invention.
  • conjugate refers to an antisense oligonucleotide progranulin agonist which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).
  • the conjugate moiety may be covalentaly linked to the antisense oligonucleotide, optionally via a linker group, such as region D′ or D′′.
  • Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S. T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103.
  • the non-nucleotide moiety is selected from the group consisting of carbohydrates (e.g. GalNAc), cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.
  • a linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds.
  • Conjugate moieties can be attached to the antisense oligonucleotide progranulin agonist directly or through a linking moiety (e.g. linker or tether).
  • Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A).
  • the conjugate or antisense oligonucleotide progranulin agonist conjugate of the invention may optionally comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).
  • a linker region second region or region B and/or region Y
  • Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body.
  • Conditions under which physiologically labile linkers undergo chemical transformation include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells.
  • Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases.
  • the biocleavable linker is susceptible to S1 nuclease cleavage.
  • the nuclease susceptible linker comprises between 1 and 5 nucleosides, such as DNA nucleoside(s) comprising at least two consecutive phosphodiester linkages.
  • Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195.
  • Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region).
  • the region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups
  • the antisense oligonucleotide progranulin agonist conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C.
  • the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In some embodiments the linker (region Y) is a C6 amino alkyl group.
  • treatment refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, i.e. prophylaxis. It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.
  • the inventors have identified that the expression level of the progranulin transcript can be effectively enhanced by targeting the progranulin precursor-mRNA (pre-mRNA) transcript or the progranulin mature mRNA sequence with antisense oligonucleotides, particularly antisense oligonucleotides which comprise high affinity sugar modified nucleosides, such as high affinity 2′ sugar modified nucleosides, such as LNA nucleosides or 2′-O-methoxyethyl (MOE) nucleosides.
  • pre-mRNA progranulin precursor-mRNA
  • MOE 2′-O-methoxyethyl
  • Described herein are target sites present on the human progranulin nucleic acid target, such as a progranulin precursor-mRNA (pre-mRNA) or mature mRNA sequence, which can be targeted by antisense oligonucleotide agonists of progranulin.
  • pre-mRNA progranulin precursor-mRNA
  • mature mRNA sequence which can be targeted by antisense oligonucleotide agonists of progranulin.
  • the inventors have surprisingly determined that targeting the 5′ UTR and 3′ UTR of the progranulin mature mRNA can be particularly effective.
  • the 5′ UTR contains upstream start sites (AUG sites), also known as upstream open reading frames (uORFs).
  • AUG sites also known as upstream open reading frames (uORFs).
  • uORFs upstream open reading frames
  • the antisense oligonucleotide progranulin agonists of the invention can increase progranulin production by binding to these regions and affecting, such as reducing, protein translation from these upstream AUG sites. This ensures that protein translation is initiated from the downstream canonical start site (ORF), increasing progranulin production.
  • the 3′ UTR contains binding sites for microRNAs.
  • the antisense oligonucleotide progranulin agonists of the invention may regulate gene expression by binding to these sites in the 3′UTR and preventing microRNA-induced repression of gene expression, leading to increased progranulin production.
  • Oligonucleotides such as RNaseH recruiting single stranded antisense oligonucleotides or siRNAs are used extensively in the art to inhibit target RNAs—i.e. are used as antagonists of their complementary nucleic acid target.
  • the antisense oligonucleotide of the present invention are agonists, i.e. enhance the expression of their complementary target, progranulin nucleic acids, and thereby enhance the expression of progranulin protein.
  • Enhanced progranulin expression is desirable to treat a range of neurological disorders, such as TDP-43 pathologies, or disorders which are characterized by, or caused by progranulin haploinsufficiency.
  • the antisense oligonucleotide progranulin agonists of the present invention may enhance the production of their complementary target, progranulin nucleic acids, by at least about 10%. In other embodiments the antisense oligonucleotide progranulin agonists of the present invention may enhance the production of their complementary target, progranulin nucleic acids, by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% or more, at least about 60% or more, at least about 70% or more, at least about 80% or more, at least about 90% or more, at least about 100% or more, at least about 200% or more, at least about 300% or more, at least about 400% or more, or at least about 500% or more.
  • the antisense oligonucleotide progranulin agonist of the invention or the contiguous nucleotide sequence thereof comprises or consists of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 contiguous nucleotides in length.
  • the entire nucleotide sequence of the antisense oligonucleotide is the contiguous nucleotide sequence.
  • the contiguous nucleotide sequence is complementary to a 5′UTR region of a human progranulin mature mRNA transcript.
  • the contiguous nucleotide sequence may be fully complementary to a 5′UTR region of a human progranulin mature mRNA transcript.
  • targeting the 5′UTR may increase progranulin expression by binding to upstream start sites (AUG sites) and affecting, such as reducing, protein translation from these upstream AUG sites. This ensures that protein translation is initiated from the downstream canonical start site (ORF), increasing progranulin production.
  • the contiguous nucleotide sequence may be complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 343-586.
  • contiguous nucleotide sequence may be complementary to nucleotides 38-246 of SEQ ID NO 1.
  • contiguous nucleotide sequence may be fully complementary to SEQ ID NO 2, or SEQ ID NO 689.
  • the contiguous nucleotide sequence may be fully complementary to a sequence selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584 & SEQ ID NO 586.
  • the contiguous nucleotide sequence may a sequence selected from the group consisting of SEQ ID NO 3-342.
  • the invention also contemplates fragements of these contiguous nucleotide sequences, including fragments of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence may be selected from the group consisting of SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241.
  • the invention also contemplates fragements of these contiguous nucleotide sequences, including fragments of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 contiguous nucleotides thereof.
  • the contiguous nucleotide sequence is complementary to a 3′UTR region of a human progranulin mature mRNA transcript.
  • the contiguous nucleotide sequence may be fully complementary to a 3′UTR region of a human progranulin mature mRNA transcript.
  • the antisense oligonucleotide progranulin agonists of the invention may regulate gene expression by binding to microRNA sites in the 3′UTR and preventing microRNA-induced repression of gene expression, leading to increased progranulin production.
  • the contiguous nucleotide sequence may be complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 587-682.
  • contiguous nucleotide sequence may be complementary to nucleotides 2039-2346 of SEQ ID NO 1.
  • the contiguous nucleotide sequence may be fully complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • the contiguous nucleotide sequence may be fully complementary to a sequence selected from the group consisting of SEQ ID NOs 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of sequences SEQ ID NO 3-342. It will be understood that the sequences shown in SEQ ID NO 3-342 may include modified nucleobases which function as the shown nucleobase in base pairing, for example 5-methyl cytosine may be used in place of methyl cytosine. Inosine may be used as a universal base.
  • the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence comprises or consists of 8 to 30 or 8 to 40 nucleotides in length with at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NO: 3 to 342.
  • the antisense oligonucleotide progranulin agonist may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
  • the antisense oligonucleotide progranulin agonists of the invention which bind to target sites outside the 5′ UTR and 3′ UTR regions of the progranulin mature mRNA may increase progranulin protein expression.
  • This increased progranulin protein expression may occur as a result of effects of the antisense oligonucleotide progranulin agonists on secondary regulatory mRNA structures and/or on binding of RNA binding proteins that would otherwise negatively affect protein translation or progranulin mRNA stability.
  • contiguous nucleobase sequences can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid.
  • oligonucleotide design The pattern in which the modified nucleosides (such as high affinity modified nucleosides) are incorporated into the oligonucleotide sequence is generally termed oligonucleotide design.
  • the antisense oligonucleotide progranulin agonists of the invention are designed with modified nucleosides and DNA nucleosides.
  • modified nucleosides and DNA nucleosides are used.
  • high affinity modified nucleosides are used.
  • the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides.
  • the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides.
  • modified nucleosides such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides.
  • LNA Locked nucleic acids
  • the antisense oligonucleotide progranulin agonist comprises one or more sugar modified nucleosides, such as 2′ sugar modified nucleosides.
  • the antisense oligonucleotide progranulin agonist of the invention comprises one or more 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA (2′oMe), 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (2′MOE), 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides. It is advantageous if one or more of the modified nucleoside(s) is a locked nucleic acid (LNA).
  • LNA locked nucleic acid
  • the antisense oligonucleotide progranulin agonist comprises at least one modified internucleoside linkage. Suitable internucleoside modifications are described in the “Definitions” section under “Modified internucleoside linkage”. It is advantageous if at least 75%, such as all, the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages. In some embodiments all the internucleotide linkages in the contiguous sequence of the oligonucleotide are phosphorothioate linkages.
  • An antisense oligonucleotide progranulin agonist may have the structure:
  • the invention also includes an antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
  • an antisense oligonucleotide progranulin agonist wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are fully complementary to a human progranulin pre-mRNA or mRNA transcript, such as SEQ ID NO 1.
  • antisense oligonucleotide according to any one of paragraphs 1-4, 9, 10, or 11 wherein contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NOs 607, 608, 609, 610, 611, 612, 619, 620, 633, 640, 641, 645, 651, and 652.
  • antisense oligonucleotide of any one of paragraphs 1-14 wherein the antisense oligonucleotide or contiguous nucleotide sequence thereof is 10-20 nucleotides in length.
  • a conjugate comprising the antisense oligonucleotide according to any one of paragraphs 1-16, and at least one conjugate moiety covalently attached to said oligonucleotide.
  • a pharmaceutical composition comprising the antisense oligonucleotide of paragraph 1-16 or the conjugate of paragraph 17 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • An in vivo or in vitro method for enhancing the expression of progranulin in a cell which is expressing progranulin comprising administering an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 in an effective amount to said cell.
  • a method for treating or preventing neurological disease comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 to a subject suffering from or susceptible to neurological disease.
  • an antisense oligonucleotide progranulin agonist wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary to a human progranulin pre-mRNA or mRNA transcript.
  • antisense oligonucleotide progranulin agonist according to embodiment 4, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, or a sequence selected from the group consisting of SEQ ID NO 343-586.
  • the antisense oligonucleotide progranulin agonist according to any one of embodiments 1-5, wherein the contiguous nucleotide sequence is selected from SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241 or at least 8 or at least 10 contiguous nucleotides thereof.
  • antisense oligonucleotide progranulin agonist according to any one of embodiments 1-8, wherein the antisense oligonucleotide progranulin agonist is or comprises an antisense oligonucleotide mixmer or totalmer.
  • An antisense oligonucleotide progranulin agonist having the structure:
  • An antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
  • An in vivo or in vitro method for enhancing the expression of progranulin in a cell which is expressing progranulin comprising administering an antisense oligonucleotide progranulin agonist according to any one of embodiments 1-11 in an effective amount to said cell.
  • the GRN 5′ UTR sequence (SEQ ID #690) was cloned into the psiCHECK2 plasmid (Promega) immediately in front of the renilla luciferase ATG site using the Q5 site-directed mutagenesis kit (New England Biolabs) according to manufactorer's instruction.
  • the GRN 3′ UTR (SEQ ID #2) was cloned into the psiCHECK2 plasmid (Promega) after the renilla luciferase coding sequence using the psiCHECK2 multiple cloning site and the XhoI and NotI restriction sites.
  • 3′ UTR sequence from nucleotide number 2039 to 2346 according to Homo sapiens granulin precursor (GRN), RefSeq NM_002087.3 (SEQ ID NO 1).
  • Double stranded DNA fragment (gBlock, Integrated DNA technologies) containing the GRN 3′ UTR (SEQ ID #2) flanked by XhoI and NotI sites was cut by XhoI and NotI enzymes (New England Biolabs) according to vendors protocol and ligated using T4 Ligase (New England Biolabs) into the previously XhoI/NotI cut psiCHECK2 plasmid.
  • the day before transfection 15000 HeLa cells per well were seeded in 96-well plates (NuncTM F96 MicroWellTM White Polystyrene Plates) in 100 ⁇ L full growth medium. The day at transfection, media is removed and the transfection mixture consisting of 80 ⁇ L Opti-MEM Reduced Serum Medium (ThermoFisher Scientific), 6.25 ⁇ g/mL Lipofectamine 2000 (ThermoFisher Scientific) and 100 ng psiCHECK2 plasmid with 5′ UTR/3′UTR of GRN is added to each well according to manufactorer's instructions (ThermoFisher Scientific).
  • Opti-MEM Reduced Serum Medium with 500 nM of each antisense oligonucleotide is added to each well for a final concentration of 100 nM.
  • Wells with seeded cells not exposed to transfection reagents are included to correct for background luciferase activity.
  • transfection mixture is removed from all wells and replaced with full growth medium. The following day, media is removed and replaced with 75 ⁇ L PBS, and the Firefly luciferase activity is measured using the Dual-GLo luciferase system (Promega) according to vendors protocol and the EnSight Multimode. Plate Reader (Perkin Elmer).
  • Antisense oligonucleotides were designed for the 5′ UTR from position 38 to 241 according to RefSeq NM_002087.3 (SEQ ID NO 1) with one nucleotide basepair shift as shown in table 1, which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • All the antisense oligonucleotides are designed as 16-mers DNA-LNA mixmers with a phosphorothioate backbone, LNA at the very 5′ and 3′ position and e.g. LNA for every 2 nd or 3 rd nucleotide (see Compound table).
  • Antisense oligonucleotides were designed for the 5′ UTR from position 119 to 158 according to RefSeq NM_002087.3 (SEQ ID NO 1) with one nucleotide basepair shift as shown in table 2, which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • antisense oligonucleotide agonism was identified for several compounds targeting the progranulin 5′UTR, particularly compounds with a contiguous nucleotide complementary to nucleotides 1-229 of SEQ ID NO 1, such as compounds complementary to SEQ ID NO 445, SEQ ID NO: 446, SEQ ID NO: 459, SEQ ID NO 465, SEQ ID NO 683, SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584, & SEQ ID NO 586.
  • All the antisense oligonucleotides are designed as 18-mers DNA-LNA mixmers with a phosphorothioate backbone, DNA-LNA mixmers with a phosphorothioate backbone, LNA at the very 5′ and 3′ position and e.g. LNA for every 2 nd or 3 rd nucleotide (see Compound table).
  • Antisense oligonucleotides were designed for the 3′ UTR from position 2044 to 2346 according to RefSeq NM_002807.3 with three nucleotide basepar shift as shown in table 3 which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • progranulin i.e. progranulin agonist activity of the antisense oligonucleotide
  • a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • the data shows antisense oligonucleotide antisense oligonucleotides with progranulin agonist activity that are complementary to the 3′UTR region of a human progranulin mRNA transcript were identified, for example compounds with a contiguous nucleotide sequence which is complementary to a sequence selected from the group consisting of SEQ ID NO 684, 685, 683, 686, 687, and 688, such as compounds with a contiguous nucleotide sequence which is complementary to a sequence selected from the group consisting of 607, 608, 609, 610, 611, 612, 619, 620, 633, 640, 641,645, 651, and 652.
  • All the antisense oligonucleotides are designed as 18-mers DNA-LNA mixmers with a phosphorothioate backbone, DNA-LNA mixmers with a phosphorothioate backbone, LNA at the very 5′ and 3′ position and e.g. LNA for every 2 nd or 3 rd nucleotide (see Compound table).
  • H4 neuroglioma cells were seeded in 96 well plates 5000 pr well, and treated with 10 ⁇ M final concentration of compounds for 5 days in 200 ⁇ L medium.
  • Microglia cells were chosen for analysis because these cells produce high levels of progranulin. Reduction of progranulin in microglia cells alone is sufficient to effect inflammation, lysosomal dysfunction, and hyperproliferation in a cell-autonomous manner. Therefore, targeting microglial dysfunction caused by progranulin insufficiency represents a potential therapeutic strategy to manage neurodegeneration in Frontotemporal dementia.
  • H4 cells ATCC HTB-1478 a commercial available glial cell line derived from a cancer patient have been used for identifying oligonucleotides capable of increasing progranulin production.
  • Microglia that exhibit functional characteristics similar to human microglia, including phagocytosis and cytokine-mediated inflammatory responses, and express relevant microglial markers, hiPSC derived microglia iCell® Microglia from FujiFilm Cellular Dynamics Inc. (Cat. no R1131) have been used for investigating effects of selected oligonucleotides on progranulin production.
  • Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • Compound #105, #106, #110, #113 and #114 induced progranulin secretion more than 150% compared to PBS as shown in FIG. 1 .
  • Compounds #105, #106, #110 and #114 localise on the 5′ UTR of Proganulin transcript, targeting the uORF region as shown in FIG. 2 .
  • H4 cells were seeded in 96 well plates 5000 pr well, and treated with 10 ⁇ M final concentration of compounds for 5 days in 200 ⁇ L medium.
  • Progranulin expression levels were evaluated in cell lysate (RIPA lysis and extraction buffer from Pierce cat. No. 89900) using the WES platform (ProteinSimple) and GRN antibody Invitrogen PA5-27275 diluted 1:25 and HPRT1 antibody ab109021 (Abcam) diluted 1:50.
  • GRN expression was normalized to endogenous housekeeping protein HPRT1.
  • hiPSC derived microglia (iCell Microglia Kit, 01279, Cat. no R1131) were seeded in 48 well plates with 100000 pr well in 500 ⁇ L, and were treated with varying concentrations of Compound #106 for 5 days.
  • Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • H4 neuroglioma cells were seeded in 96 well plates 5000 pr well and treated with 10 ⁇ M final concentration of compounds for 5 days in 200 ⁇ L medium. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • Compound #231 and #241 induced Progranulin secretion compared to PBS as shown in FIG. 6 .
  • Compound ID #106 (SEQ ID NO 106) inducing upregulation of Progranulin in both H4 cells and hiPSC derived Microglia cells, is shown in FIG. 7 .
  • Example 11 Full 2′MOE and 2′oMe Modified Versions of SEQ ID NO: 106
  • SEQ ID NO: 106 (TGGCCAGGGATCAGGG) was tested as both a full 2′MOE modified oligo (Compound #106 full 2′MOE) and a full 2′oMe modified oligo (Compound #106 full 2′oMe).
  • H4 neuroglioma cells seeded in 96 well plates 5000 pr well were treated with 10 ⁇ M final concentration of compounds for 5 days in 200 ⁇ L medium.
  • Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • Compound #106 and Compound #106 full 2′MOE and Compound #106 full 2′oMe induced a ⁇ 2-fold increase in progranulin secretion to the media compared to PBS.
  • H4 neuroglioma cells seeded in 48 well plates 15000 per well were treated with 10 ⁇ M final concentration of compounds for 5 days in 500 ⁇ L medium.
  • mRNA was isolated using the MagNAPure 96 system (Roche) according to manufacturer's protocol. The purified mRNA were sent for gene expression array analysis at Eurofins Genomics, using ClariomTM S Arrays (ThermoFisher Scientific). Expression analysis was conducted using the Qlucore Omics Explorer software, using a two-group comparison and by adjusting the FDR ⁇ 0.1.
  • H4 neuroglioma cells seeded in 96 well plates 5000 pr well were treated with 10 ⁇ M final concentration of compounds for 5 days in 200 ⁇ L full growth medium.
  • Progranulin expression levels were evaluated in the media after dilution 1:8 by ELISA from Abcam (ab252364) according to manufactorer's protocol. Progranulins levels were normalized to PBS treated cells and values above >1 therefore indicates an upregulation of PGRN protein levels.
  • Table 4 list the compounds tested, their sequences and their corresponding target site on the PGRN mRNA as well as the Progranulin protein expression levels.

Abstract

The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.

Description

    REFERENCE TO SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 2, 2023, is named 067211.019US1.xml and is 4 MB in size.
    • FIELD OF INVENTION
  • The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
    • BACKGROUND
  • Progranulin (PGRN) is a highly conserved secreted protein that is expressed in multiple cell types, both in the CNS and in peripheral tissues.
  • Deficiency of the secreted protein progranulin in the central nervous system causes the neurodegenerative disease fronto temporal dementia (FTD). Pathogenic progranulin (GRN) mutations lead to a loss of about 50% in progranulin levels through haploinsufficiency and to intraneuronal aggregation of TDP-43 protein. Progranulin plays a supportive and protective role in numerous processes within the brain, including neurite outgrowth, synapse biology, response to exogenous stressors, lysosomal function, neuroinflammation, and angiogenesis in both cell autonomous and non-autonomous manners.
  • In several neurodegenerative diseases TDP-43 is a common denominator. TDP-43 pathology is associated with cytoplasmic TDP-43 aggregation. For example, more than 95% of ALS patients display pathological mislocalization of TDP-43 and several mutations in its gene cause familial ALS.
  • The presence of cytoplasmic TDP-43 aggregates is associated with a concomitant loss of nuclear TDP-43, and there is evidence of both loss of function and gain of function associated pathophysiologies.
  • Both directly and via its conversion to granulins, progranulin regulates lysosomal function, cell growth, survival, repair, and inflammation. Progranulin has a major role in regulation of lysosomal function associated microglial responses in the CNS. Autosomal dominant mutations of the progranulin (GRN) gene leading to protein haploinsufficiency are linked to familial frontotemporal dementia with neuropathologic frontotemporal lobar degeneration (FTLD) associated with accumulation of TAR-DNA binding protein of 43kDA (TDP-43) inclusions (FTLD-TDP). Homozygous GRN mutations are linked to neuronal ceroid lipofuscinosis (NCL) (Townley, et al., Neurology. 2018 Jun. 12; 90(24): 1127).
  • Mutations in the progranulin gene (GRN) have recently been identified as a cause of about 5% of all FTD, including some sporadic cases. Recent studies using mouse models has defined the expression of PGRN in the brain (Petkau et al., 2010). PGRN is expressed late in neurodevelopment, localizing with markers of mature neurons. PGRN is expressed in neurons in most brain regions, with highest expression in the thalamus, hippocampus, and cortex. Microglia cells also express progranulin, and the level of expression is upregulated by microglial activation. Around 70 different GRN mutations have been identified in FTD and all reduce progranulin levels or result in loss of progranulin function.
  • WO 2020/077165 reports on AAV particle delivery of therapeutic nucleic acids, and lists progranulin as a potential gene of interest.
  • There is therefore an urgent need for therapeutic agents which can increase the expression of progranulin.
    • SUMMARY OF INVENTION
  • The invention provides antisense oligonucleotide agonists of progranulin or antisense oligonucleotide progranulin agonists—i.e. antisense oligonucleotides which are complementary to a progranulin nucleic acid sequence, and which are capable of up-regulating the expression of progranulin. Alternatively stated, the invention provides antisense oligonucleotide positive modulators (i.e. agonists) of progranulin.
  • The antisense oligonucelotides of the invention may therefore be used to restore progranulin expression in cells which exhibit progranulin haploinsufficiency, or to enhance expression of progranulin in cells.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to SEQ ID NO 2 or 689.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-40 nucleotides in length and comprises a contiguous nucleotide sequence of 12-40 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-20 nucleotides in length and comprises a contiguous nucleotide sequence of 12-20 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 14-18 nucleotides in length and comprises a contiguous nucleotide sequence of 14-18 nucleotides in length which are complementary, such as fully complementary, to a to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • The invention provides an antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 12-18 nucleotides in length and comprises a contiguous nucleotide sequence of 12-18 nucleotides in length which are complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 683, 684, 685, 686, 687 and 688.
  • The antisense oligonucleotide progranulin agonist may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length. In some embodiments the antisense oligonucleotide, or contiguous nucleotide sequence thereof, is 8-40, 12-40, 12-20, 14-18, 12-18 or 16-18 nucleotides in length.
  • The contiguous nucleotide sequence may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length. In some embodiments, the contiguous nucleotide sequence is of a length of at least 12 nucleotides in length, such as 12-16 or 12-18 nucleotides in length.
  • In some embodiments, the contiguous nucleotide sequence is the same length as the antisense oligonucleotide progranulin agonist.
  • In some embodiments the antisense oligonucleotide consists of the contiguous nucleotide sequence.
  • In some embodiments the antisense oligonucleotide is the contiguous nucleotide sequence.
  • In some embodiments, the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 343-682.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to the human progranulin mature mRNA (SEQ ID NO: 1).
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to the human progranulin precursor-mRNA (pre-mRNA) (SEQ ID NO: 3949).
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a 5′UTR region of a human progranulin mature mRNA transcript. Herein the 5′ UTR is defined as nucleotides 38 to 241 according to RefSeq NM_002807.3 (SEQ ID NO 1).
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to nucleotides 38-246 of SEQ ID NO 1.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 689.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 2.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to SEQ ID NO 683.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 343-586.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584, & SEQ ID NO 586.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 8 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 9 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 10 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 11 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 12 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 13 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 14 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 15 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 16 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is selected from SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241 or at least 8 or at least 10 contiguous nucleotides thereof.
  • In some embodiments the contiguous nucleotide sequence is SEQ ID NO 106.
  • In some embodiments the contiguous nucleotide sequence is SEQ ID NO 110.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a 3′UTR region of a human progranulin mature mRNA transcript. Herein the 3′ UTR is defined as nucleotides 2044 to 2346 according to RefSeq NM_002807.3 (SEQ ID NO 1).
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to nucleotides 2039-2346 of SEQ ID NO 1.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 587-682.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 8 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 9 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 10 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 11 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 12 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 13 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 14 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 15 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID NO 2040-3386 or at least 16 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2322, SEQ ID 2324, SEQ ID 2328, SEQ ID 2329, SEQ ID 2331, SEQ ID 2334, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2340, SEQ ID 2341, SEQ ID 2342, SEQ ID 2345, SEQ ID 2346, SEQ ID 2347, SEQ ID 2348, SEQ ID 2349, SEQ ID 2350, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2356, SEQ ID 2357, SEQ ID 2358, SEQ ID 2359, SEQ ID 2360, SEQ ID 2361, SEQ ID 2362, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2368, SEQ ID 2369, SEQ ID 2370, SEQ ID 2371, SEQ ID 2372, SEQ ID 2373, SEQ ID 2374, SEQ ID 2375, SEQ ID 2376, SEQ ID 2377, SEQ ID 2378, SEQ ID 2379, SEQ ID 2380, SEQ ID 2381, SEQ ID 2384, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2390, SEQ ID 2392, SEQ ID 2393, SEQ ID 2394, SEQ ID 2395, SEQ ID 2396, SEQ ID 2397, SEQ ID 2398, SEQ ID 2399, SEQ ID 2400, SEQ ID 2401, SEQ ID 2403, SEQ ID 2404, SEQ ID 2405, SEQ ID 2406, SEQ ID 2407, SEQ ID 2408, SEQ ID 2410, SEQ ID 2411, SEQ ID 2413, SEQ ID 2414, SEQ ID 2415, SEQ ID 2416, SEQ ID 2418, SEQ ID 2419, SEQ ID 2421, SEQ ID 2424, SEQ ID 2425, SEQ ID 2426, SEQ ID 2427, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2433, SEQ ID 2434, SEQ ID 2435, SEQ ID 2436, SEQ ID 2437, SEQ ID 2438, SEQ ID 2439, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2443, SEQ ID 2444, SEQ ID 2445, SEQ ID 2446, SEQ ID 2447, SEQ ID 2448, SEQ ID 2449, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2457, SEQ ID 2458, SEQ ID 2459, SEQ ID 2460, SEQ ID 2461, SEQ ID 2462, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2479, SEQ ID 2481, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2490, SEQ ID 2491, SEQ ID 2492, SEQ ID 2493, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2498, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2503, SEQ ID 2504, SEQ ID 2505, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2510, SEQ ID 2511, SEQ ID 2512, SEQ ID 2513, SEQ ID 2514, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2522, SEQ ID 2523, SEQ ID 2524, SEQ ID 2525, SEQ ID 2526, SEQ ID 2527, SEQ ID 2528, SEQ ID 2531, SEQ ID 2533, SEQ ID 2534, SEQ ID 2535, SEQ ID 2536, SEQ ID 2537, SEQ ID 2538, SEQ ID 2540, SEQ ID 2541, SEQ ID 2542, SEQ ID 2544, SEQ ID 2546, SEQ ID 2547, SEQ ID 2549, SEQ ID 2550, SEQ ID 2551, SEQ ID 2553, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2557, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2563, SEQ ID 2565, SEQ ID 2566, SEQ ID 2567, SEQ ID 2572, SEQ ID 2573, SEQ ID 2574, SEQ ID 2575, SEQ ID 2576, SEQ ID 2577, SEQ ID 2578, SEQ ID 2579, SEQ ID 2580, SEQ ID 2581, SEQ ID 2582, SEQ ID 2583, SEQ ID 2584, SEQ ID 2585, SEQ ID 2586, SEQ ID 2588, SEQ ID 2589, SEQ ID 2590, SEQ ID 2591, SEQ ID 2592, SEQ ID 2593, SEQ ID 2594, SEQ ID 2595, SEQ ID 2596, SEQ ID 2597, SEQ ID 2598, SEQ ID 2599, SEQ ID 2601, SEQ ID 2602, SEQ ID 2603, SEQ ID 2604, SEQ ID 2606, SEQ ID 2610, SEQ ID 2613, SEQ ID 2614, SEQ ID 2615, SEQ ID 2619, SEQ ID 2622, SEQ ID 2623, SEQ ID 2624, SEQ ID 2625, SEQ ID 2626, SEQ ID 2627, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2632, SEQ ID 2633, SEQ ID 2634, SEQ ID 2635, SEQ ID 2636, SEQ ID 2637, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2641, SEQ ID 2642, SEQ ID 2643, SEQ ID 2644, SEQ ID 2645, SEQ ID 2646, SEQ ID 2647, SEQ ID 2648, SEQ ID 2649, SEQ ID 2650, SEQ ID 2651, SEQ ID 2652, SEQ ID 2653, SEQ ID 2654, SEQ ID 2655, SEQ ID 2656, SEQ ID 2658, SEQ ID 2659, SEQ ID 2660, SEQ ID 2661, SEQ ID 2662, SEQ ID 2663, SEQ ID 2664, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2668, SEQ ID 2669, SEQ ID 2670, SEQ ID 2671, SEQ ID 2672, SEQ ID 2673, SEQ ID 2674, SEQ ID 2675, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2680, SEQ ID 2681, SEQ ID 2682, SEQ ID 2683, SEQ ID 2684, SEQ ID 2685, SEQ ID 2686, SEQ ID 2687, SEQ ID 2688, SEQ ID 2689, SEQ ID 2690, SEQ ID 2691, SEQ ID 2693, SEQ ID 2694, SEQ ID 2695, SEQ ID 2696, SEQ ID 2697, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2702, SEQ ID 2703, SEQ ID 2704, SEQ ID 2705, SEQ ID 2706, SEQ ID 2707, SEQ ID 2708, SEQ ID 2709, SEQ ID 2710, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2715, SEQ ID 2716, SEQ ID 2717, SEQ ID 2718, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2722, SEQ ID 2723, SEQ ID 2726, SEQ ID 2727, SEQ ID 2728, SEQ ID 2729, SEQ ID 2730, SEQ ID 2733, SEQ ID 2734, SEQ ID 2735, SEQ ID 2736, SEQ ID 2737, SEQ ID 2738, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2759, SEQ ID 2760, SEQ ID 2761, SEQ ID 2762, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2773, SEQ ID 2774, SEQ ID 2775, SEQ ID 2815, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2821, SEQ ID 2822, SEQ ID 2823, SEQ ID 2824, SEQ ID 2825, SEQ ID 2826, SEQ ID 2827, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2838, SEQ ID 2839, SEQ ID 2840, SEQ ID 2841, SEQ ID 2842, SEQ ID 2843, SEQ ID 2844, SEQ ID 2845, SEQ ID 2847, SEQ ID 2848, SEQ ID 2849, SEQ ID 2850, SEQ ID 2851, SEQ ID 2852, SEQ ID 2853, SEQ ID 2854, SEQ ID 2855, SEQ ID 2858, SEQ ID 2859, SEQ ID 2860, SEQ ID 2861, SEQ ID 2862, SEQ ID 2863, SEQ ID 2864, SEQ ID 2865, SEQ ID 2866, SEQ ID 2867, SEQ ID 2868, SEQ ID 2869, SEQ ID 2870, SEQ ID 2871, SEQ ID 2872, SEQ ID 2873, SEQ ID 2874, SEQ ID 2875, SEQ ID 2876, SEQ ID 2878, SEQ ID 2879, SEQ ID 2880, SEQ ID 2881, SEQ ID 2882, SEQ ID 2883, SEQ ID 2884, SEQ ID 2885, SEQ ID 2886, SEQ ID 2887, SEQ ID 2888, SEQ ID 2889, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2893, SEQ ID 2894, SEQ ID 2895, SEQ ID 2896, SEQ ID 2897, SEQ ID 2898, SEQ ID 2899, SEQ ID 2900, SEQ ID 2901, SEQ ID 2902, SEQ ID 2903, SEQ ID 2904, SEQ ID 2905, SEQ ID 2906, SEQ ID 2907, SEQ ID 2908, SEQ ID 2909, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2915, SEQ ID 2916, SEQ ID 2917, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2921, SEQ ID 2922, SEQ ID 2923, SEQ ID 2924, SEQ ID 2925, SEQ ID 2926, SEQ ID 2927, SEQ ID 2928, SEQ ID 2929, SEQ ID 2930, SEQ ID 2931, SEQ ID 2932, SEQ ID 2934, SEQ ID 2935, SEQ ID 2936, SEQ ID 2937, SEQ ID 2938, SEQ ID 2939, SEQ ID 2940, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2944, SEQ ID 2945, SEQ ID 2946, SEQ ID 2947, SEQ ID 2948, SEQ ID 2949, SEQ ID 2950, SEQ ID 2951, SEQ ID 2953, SEQ ID 2954, SEQ ID 2955, SEQ ID 2956, SEQ ID 2957, SEQ ID 2958, SEQ ID 2960, SEQ ID 2961, SEQ ID 2963, SEQ ID 2964, SEQ ID 2965, SEQ ID 2966, SEQ ID 2967, SEQ ID 2969, SEQ ID 2970, SEQ ID 2971, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2978, SEQ ID 2979, SEQ ID 2980, SEQ ID 2981, SEQ ID 2982, SEQ ID 2983, SEQ ID 2984, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3057, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3080, SEQ ID 3081, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3086, SEQ ID 3087, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3093, SEQ ID 3094, SEQ ID 3095, SEQ ID 3097, SEQ ID 3098, SEQ ID 3099, SEQ ID 3100, SEQ ID 3102, SEQ ID 3103, SEQ ID 3104, SEQ ID 3105, SEQ ID 3106, SEQ ID 3107, SEQ ID 3108, SEQ ID 3109, SEQ ID 3110, SEQ ID 3112, SEQ ID 3113, SEQ ID 3115, SEQ ID 3116, SEQ ID 3117, SEQ ID 3119, SEQ ID 3120, SEQ ID 3121, SEQ ID 3122, SEQ ID 3123, SEQ ID 3124, SEQ ID 3125, SEQ ID 3126, SEQ ID 3127, SEQ ID 3128, SEQ ID 3129, SEQ ID 3130, SEQ ID 3131, SEQ ID 3132, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3136, SEQ ID 3137, SEQ ID 3138, SEQ ID 3139, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3144, SEQ ID 3145, SEQ ID 3146, SEQ ID 3147, SEQ ID 3148, SEQ ID 3149, SEQ ID 3150, SEQ ID 3151, SEQ ID 3152, SEQ ID 3153, SEQ ID 3154, SEQ ID 3155, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3171, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3185, SEQ ID 3186, SEQ ID 3187, SEQ ID 3188, SEQ ID 3189, SEQ ID 3190, SEQ ID 3191, SEQ ID 3192, SEQ ID 3193, SEQ ID 3194, SEQ ID 3195, SEQ ID 3196, SEQ ID 3197, SEQ ID 3198, SEQ ID 3199, SEQ ID 3200, SEQ ID 3201, SEQ ID 3202, SEQ ID 3203, SEQ ID 3204, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3208, SEQ ID 3209, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3220, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3225, SEQ ID 3226, SEQ ID 3227, SEQ ID 3228, SEQ ID 3229, SEQ ID 3230, SEQ ID 3231, SEQ ID 3232, SEQ ID 3233, SEQ ID 3234, SEQ ID 3235, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3253, SEQ ID 3254, SEQ ID 3255, SEQ ID 3256, SEQ ID 3257, SEQ ID 3258, SEQ ID 3259, SEQ ID 3260, SEQ ID 3261, SEQ ID 3262, SEQ ID 3263, SEQ ID 3264, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3268, SEQ ID 3269, SEQ ID 3270, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3275, SEQ ID 3276, SEQ ID 3277, SEQ ID 3278, SEQ ID 3279, SEQ ID 3280, SEQ ID 3282, SEQ ID 3284, SEQ ID 3285, SEQ ID 3286, SEQ ID 3287, SEQ ID 3288, SEQ ID 3289, SEQ ID 3291, SEQ ID 3292, SEQ ID 3293, SEQ ID 3294, SEQ ID 3295, SEQ ID 3296, SEQ ID 3297, SEQ ID 3298, SEQ ID 3299, SEQ ID 3300, SEQ ID 3301, SEQ ID 3302, SEQ ID 3303, SEQ ID 3304, SEQ ID 3305, SEQ ID 3306, SEQ ID 3307, SEQ ID 3308, SEQ ID 3309, SEQ ID 3310, SEQ ID 3311, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3315, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3321, SEQ ID 3322, SEQ ID 3323, SEQ ID 3324, SEQ ID 3325, SEQ ID 3326, SEQ ID 3327, SEQ ID 3329, SEQ ID 3331, SEQ ID 3332, SEQ ID 3333, SEQ ID 3334, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3344, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3357, SEQ ID 3358, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3367, SEQ ID 3368, SEQ ID 3369, SEQ ID 3370, SEQ ID 3371, SEQ ID 3390, SEQ ID 3391, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3400, SEQ ID 3401, SEQ ID 3402, SEQ ID 3403, SEQ ID 3404, SEQ ID 3405, SEQ ID 3406, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3416, SEQ ID 3417, SEQ ID 3418, SEQ ID 3419, SEQ ID 3420, SEQ ID 3421, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3425, SEQ ID 3426, SEQ ID 3427, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3431, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3438, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3453, SEQ ID 3454, SEQ ID 3460, SEQ ID 3461, SEQ ID 3464, SEQ ID 3465, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3486, SEQ ID 3487, SEQ ID 3488, SEQ ID 3489, SEQ ID 3490, SEQ ID 3491, SEQ ID 3493, SEQ ID 3494, SEQ ID 3496, SEQ ID 3497, SEQ ID 3501, SEQ ID 3505, SEQ ID 3508, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3518, SEQ ID 3521, SEQ ID 3522, SEQ ID 3523, SEQ ID 3524, SEQ ID 3525, SEQ ID 3526, SEQ ID 3527, SEQ ID 3528, SEQ ID 3530, SEQ ID 3531, SEQ ID 3532, SEQ ID 3534, SEQ ID 3535, SEQ ID 3536, SEQ ID 3538, SEQ ID 3539, SEQ ID 3541, SEQ ID 3542, SEQ ID 3543, SEQ ID 3544, SEQ ID 3546, SEQ ID 3548, SEQ ID 3549, SEQ ID 3550, SEQ ID 3552, SEQ ID 3556, SEQ ID 3557, SEQ ID 3558, SEQ ID 3560, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3573, SEQ ID 3574, SEQ ID 3576, SEQ ID 3577, SEQ ID 3578, SEQ ID 3580, SEQ ID 3581, SEQ ID 3584, SEQ ID 3585, SEQ ID 3586, SEQ ID 3588, SEQ ID 3590, SEQ ID 3592, SEQ ID 3594, SEQ ID 3595, SEQ ID 3598, SEQ ID 3599, SEQ ID 3600, SEQ ID 3601, SEQ ID 3602, SEQ ID 3603, SEQ ID 3605, SEQ ID 3607, SEQ ID 3609, SEQ ID 3610, SEQ ID 3613, SEQ ID 3614, SEQ ID 3615, SEQ ID 3616, SEQ ID 3617, SEQ ID 3621, SEQ ID 3623, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3629, SEQ ID 3630, SEQ ID 3631, SEQ ID 3632, SEQ ID 3633, SEQ ID 3636, SEQ ID 3637, SEQ ID 3638, SEQ ID 3639, SEQ ID 3641, SEQ ID 3642, SEQ ID 3643, SEQ ID 3645, SEQ ID 3647, SEQ ID 3648, SEQ ID 3649, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3663, SEQ ID 3664, SEQ ID 3665, SEQ ID 3666, SEQ ID 3670, SEQ ID 3672, SEQ ID 3676, SEQ ID 3678, SEQ ID 3679, SEQ ID 3680, SEQ ID 3681, SEQ ID 3682, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3690, SEQ ID 3691, SEQ ID 3692, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3697, SEQ ID 3698, SEQ ID 3699, SEQ ID 3700, SEQ ID 3701, SEQ ID 3702, SEQ ID 3703, SEQ ID 3704, SEQ ID 3705, SEQ ID 3706, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3724, SEQ ID 3725, SEQ ID 3726, SEQ ID 3727, SEQ ID 3729, SEQ ID 3730, SEQ ID 3731, SEQ ID 3732, SEQ ID 3733, SEQ ID 3734, SEQ ID 3735, SEQ ID 3736, SEQ ID 3737, SEQ ID 3738, SEQ ID 3739, SEQ ID 3740, SEQ ID 3741, SEQ ID 3742, SEQ ID 3743, SEQ ID 3744, SEQ ID 3745, SEQ ID 3746, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3777, SEQ ID 3778, SEQ ID 3779, SEQ ID 3780, SEQ ID 3781, SEQ ID 3782, SEQ ID 3783, SEQ ID 3784, SEQ ID 3785, SEQ ID 3786, SEQ ID 3787, SEQ ID 3788, SEQ ID 3789, SEQ ID 3790, SEQ ID 3791, SEQ ID 3792, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3806, SEQ ID 3807, SEQ ID 3808, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3816, SEQ ID 3817, SEQ ID 3818, SEQ ID 3819, SEQ ID 3820, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3829, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3833, SEQ ID 3834, SEQ ID 3835, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3848, SEQ ID 3850, SEQ ID 3851, SEQ ID 3852, SEQ ID 3853, SEQ ID 3867, SEQ ID 3868, SEQ ID 3869, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3877, SEQ ID 3878, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3898, SEQ ID 3899, SEQ ID 3900, SEQ ID 3901, SEQ ID 3902, SEQ ID 3903, SEQ ID 3904, SEQ ID 3905, SEQ ID 3906, SEQ ID 3907, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3914, SEQ ID 3915, SEQ ID 3916, SEQ ID 3917, SEQ ID 3918, SEQ ID 3919, SEQ ID 3920, SEQ ID 3921, SEQ ID 3922, SEQ ID 3923, SEQ ID 3924, SEQ ID 3925, SEQ ID 3926, SEQ ID 3927, SEQ ID 3928, SEQ ID 3929, SEQ ID 3930, SEQ ID 3931, SEQ ID 3932, SEQ ID 3933, SEQ ID 3934, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3941, SEQ ID 3942, SEQ ID 3943, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948, or at least 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous nucleotides thereof.
  • In some embodiments, the contiguous nucleotide sequence is complementary, such as fully complementary, to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2348, SEQ ID 2349, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2358, SEQ ID 2360, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2369, SEQ ID 2371, SEQ ID 2373, SEQ ID 2375, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2394, SEQ ID 2403, SEQ ID 2426, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2435, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2444, SEQ ID 2446, SEQ ID 2447, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2458, SEQ ID 2459, SEQ ID 2461, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2504, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2511, SEQ ID 2513, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2523, SEQ ID 2525, SEQ ID 2534, SEQ ID 2537, SEQ ID 2544, SEQ ID 2546, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2595, SEQ ID 2626, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2633, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2649, SEQ ID 2651, SEQ ID 2652, SEQ ID 2655, SEQ ID 2658, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2669, SEQ ID 2670, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2682, SEQ ID 2686, SEQ ID 2688, SEQ ID 2689, SEQ ID 2691, SEQ ID 2694, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2703, SEQ ID 2706, SEQ ID 2709, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2737, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2760, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2774, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2824, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2851, SEQ ID 2852, SEQ ID 2866, SEQ ID 2871, SEQ ID 2872, SEQ ID 2886, SEQ ID 2887, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2895, SEQ ID 2896, SEQ ID 2899, SEQ ID 2904, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2916, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2922, SEQ ID 2925, SEQ ID 2926, SEQ ID 2932, SEQ ID 2939, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2980, SEQ ID 2983, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3095, SEQ ID 3097, SEQ ID 3102, SEQ ID 3106, SEQ ID 3108, SEQ ID 3110, SEQ ID 3116, SEQ ID 3120, SEQ ID 3121, SEQ ID 3125, SEQ ID 3126, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3137, SEQ ID 3138, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3145, SEQ ID 3148, SEQ ID 3152, SEQ ID 3153, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3186, SEQ ID 3188, SEQ ID 3191, SEQ ID 3193, SEQ ID 3196, SEQ ID 3197, SEQ ID 3203, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3227, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3254, SEQ ID 3258, SEQ ID 3259, SEQ ID 3261, SEQ ID 3263, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3276, SEQ ID 3277, SEQ ID 3279, SEQ ID 3286, SEQ ID 3295, SEQ ID 3297, SEQ ID 3305, SEQ ID 3307, SEQ ID 3309, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3332, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3369, SEQ ID 3370, SEQ ID 3390, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3401, SEQ ID 3403, SEQ ID 3404, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3417, SEQ ID 3419, SEQ ID 3420, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3460, SEQ ID 3461, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3490, SEQ ID 3494, SEQ ID 3496, SEQ ID 3501, SEQ ID 3505, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3521, SEQ ID 3522, SEQ ID 3556, SEQ ID 3557, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3576, SEQ ID 3578, SEQ ID 3580, SEQ ID 3584, SEQ ID 3594, SEQ ID 3613, SEQ ID 3614, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3633, SEQ ID 3641, SEQ ID 3643, SEQ ID 3648, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3670, SEQ ID 3676, SEQ ID 3680, SEQ ID 3681, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3691, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3698, SEQ ID 3700, SEQ ID 3701, SEQ ID 3703, SEQ ID 3704, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3725, SEQ ID 3744, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3786, SEQ ID 3788, SEQ ID 3790, SEQ ID 3791, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3834, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3850, SEQ ID 3852, SEQ ID 3867, SEQ ID 3868, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3922, SEQ ID 3923, SEQ ID 3930, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948, or at least 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous nucleotides thereof.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 8 contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 9 contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 10 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 11 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 12 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 13 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 14 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 15 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments the contiguous nucleotide sequence is complementary, such as fully complementary, to at least 16 contiguous nucleotides contiguous nucleotides of any of the target sequences recited herein.
  • In some embodiments, the antisense oligonucleotide progranulin agonist is or comprises an antisense oligonucleotide mixmer or totalmer. In some embodiments, the contiguous nucleotide sequence is a mixmer or a tolalmer.
  • In some embodiments, the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence thereof is 10-20 nucleotides in length.
  • In some embodiments, the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID NOs 3-342.
  • In some embodiments, the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID NOs 693-2039.
  • In some embodiments, the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 694, SEQ ID 696, SEQ ID 700, SEQ ID 701, SEQ ID 703, SEQ ID 706, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 712, SEQ ID 713, SEQ ID 714, SEQ ID 717, SEQ ID 718, SEQ ID 719, SEQ ID 720, SEQ ID 721, SEQ ID 722, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 728, SEQ ID 729, SEQ ID 730, SEQ ID 731, SEQ ID 732, SEQ ID 733, SEQ ID 734, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 740, SEQ ID 741, SEQ ID 742, SEQ ID 743, SEQ ID 744, SEQ ID 745, SEQ ID 746, SEQ ID 747, SEQ ID 748, SEQ ID 749, SEQ ID 750, SEQ ID 751, SEQ ID 752, SEQ ID 753, SEQ ID 756, SEQ ID 758, SEQ ID 759, SEQ ID 760, SEQ ID 761, SEQ ID 762, SEQ ID 764, SEQ ID 765, SEQ ID 766, SEQ ID 767, SEQ ID 768, SEQ ID 769, SEQ ID 770, SEQ ID 771, SEQ ID 772, SEQ ID 773, SEQ ID 775, SEQ ID 776, SEQ ID 777, SEQ ID 778, SEQ ID 779, SEQ ID 780, SEQ ID 782, SEQ ID 783, SEQ ID 785, SEQ ID 786, SEQ ID 787, SEQ ID 788, SEQ ID 790, SEQ ID 791, SEQ ID 793, SEQ ID 796, SEQ ID 797, SEQ ID 798, SEQ ID 799, SEQ ID 800, SEQ ID 801, SEQ ID 802, SEQ ID 803, SEQ ID 804, SEQ ID 805, SEQ ID 806, SEQ ID 807, SEQ ID 808, SEQ ID 809, SEQ ID 810, SEQ ID 811, SEQ ID 812, SEQ ID 813, SEQ ID 814, SEQ ID 815, SEQ ID 816, SEQ ID 817, SEQ ID 818, SEQ ID 819, SEQ ID 820, SEQ ID 821, SEQ ID 822, SEQ ID 823, SEQ ID 824, SEQ ID 825, SEQ ID 826, SEQ ID 827, SEQ ID 828, SEQ ID 829, SEQ ID 830, SEQ ID 831, SEQ ID 832, SEQ ID 833, SEQ ID 834, SEQ ID 835, SEQ ID 836, SEQ ID 837, SEQ ID 838, SEQ ID 839, SEQ ID 840, SEQ ID 841, SEQ ID 842, SEQ ID 843, SEQ ID 844, SEQ ID 845, SEQ ID 846, SEQ ID 847, SEQ ID 848, SEQ ID 849, SEQ ID 850, SEQ ID 851, SEQ ID 853, SEQ ID 854, SEQ ID 855, SEQ ID 856, SEQ ID 857, SEQ ID 859, SEQ ID 861, SEQ ID 862, SEQ ID 863, SEQ ID 864, SEQ ID 865, SEQ ID 866, SEQ ID 867, SEQ ID 868, SEQ ID 869, SEQ ID 870, SEQ ID 871, SEQ ID 873, SEQ ID 874, SEQ ID 875, SEQ ID 876, SEQ ID 877, SEQ ID 878, SEQ ID 879, SEQ ID 880, SEQ ID 881, SEQ ID 882, SEQ ID 883, SEQ ID 884, SEQ ID 885, SEQ ID 886, SEQ ID 887, SEQ ID 888, SEQ ID 890, SEQ ID 891, SEQ ID 892, SEQ ID 893, SEQ ID 894, SEQ ID 895, SEQ ID 896, SEQ ID 897, SEQ ID 898, SEQ ID 899, SEQ ID 900, SEQ ID 903, SEQ ID 905, SEQ ID 906, SEQ ID 907, SEQ ID 908, SEQ ID 909, SEQ ID 910, SEQ ID 912, SEQ ID 913, SEQ ID 914, SEQ ID 916, SEQ ID 918, SEQ ID 919, SEQ ID 921, SEQ ID 922, SEQ ID 923, SEQ ID 925, SEQ ID 926, SEQ ID 927, SEQ ID 928, SEQ ID 929, SEQ ID 932, SEQ ID 933, SEQ ID 934, SEQ ID 935, SEQ ID 937, SEQ ID 938, SEQ ID 939, SEQ ID 944, SEQ ID 945, SEQ ID 946, SEQ ID 947, SEQ ID 948, SEQ ID 949, SEQ ID 950, SEQ ID 951, SEQ ID 952, SEQ ID 953, SEQ ID 954, SEQ ID 955, SEQ ID 956, SEQ ID 957, SEQ ID 958, SEQ ID 960, SEQ ID 961, SEQ ID 962, SEQ ID 963, SEQ ID 964, SEQ ID 965, SEQ ID 966, SEQ ID 967, SEQ ID 968, SEQ ID 969, SEQ ID 970, SEQ ID 971, SEQ ID 973, SEQ ID 974, SEQ ID 975, SEQ ID 976, SEQ ID 978, SEQ ID 982, SEQ ID 985, SEQ ID 986, SEQ ID 987, SEQ ID 991, SEQ ID 994, SEQ ID 995, SEQ ID 996, SEQ ID 997, SEQ ID 998, SEQ ID 999, SEQ ID 1000, SEQ ID 1001, SEQ ID 1002, SEQ ID 1003, SEQ ID 1004, SEQ ID 1005, SEQ ID 1006, SEQ ID 1007, SEQ ID 1008, SEQ ID 1009, SEQ ID 1010, SEQ ID 1011, SEQ ID 1012, SEQ ID 1013, SEQ ID 1014, SEQ ID 1015, SEQ ID 1016, SEQ ID 1017, SEQ ID 1018, SEQ ID 1019, SEQ ID 1020, SEQ ID 1021, SEQ ID 1022, SEQ ID 1023, SEQ ID 1024, SEQ ID 1025, SEQ ID 1026, SEQ ID 1027, SEQ ID 1028, SEQ ID 1030, SEQ ID 1031, SEQ ID 1032, SEQ ID 1033, SEQ ID 1034, SEQ ID 1035, SEQ ID 1036, SEQ ID 1037, SEQ ID 1038, SEQ ID 1039, SEQ ID 1040, SEQ ID 1041, SEQ ID 1042, SEQ ID 1043, SEQ ID 1044, SEQ ID 1045, SEQ ID 1046, SEQ ID 1047, SEQ ID 1048, SEQ ID 1049, SEQ ID 1050, SEQ ID 1051, SEQ ID 1052, SEQ ID 1053, SEQ ID 1054, SEQ ID 1055, SEQ ID 1056, SEQ ID 1057, SEQ ID 1058, SEQ ID 1059, SEQ ID 1060, SEQ ID 1061, SEQ ID 1062, SEQ ID 1063, SEQ ID 1065, SEQ ID 1066, SEQ ID 1067, SEQ ID 1068, SEQ ID 1069, SEQ ID 1070, SEQ ID 1071, SEQ ID 1072, SEQ ID 1073, SEQ ID 1074, SEQ ID 1075, SEQ ID 1076, SEQ ID 1077, SEQ ID 1078, SEQ ID 1079, SEQ ID 1080, SEQ ID 1081, SEQ ID 1082, SEQ ID 1083, SEQ ID 1084, SEQ ID 1085, SEQ ID 1086, SEQ ID 1087, SEQ ID 1088, SEQ ID 1089, SEQ ID 1090, SEQ ID 1091, SEQ ID 1092, SEQ ID 1093, SEQ ID 1094, SEQ ID 1095, SEQ ID 1098, SEQ ID 1099, SEQ ID 1100, SEQ ID 1101, SEQ ID 1102, SEQ ID 1105, SEQ ID 1106, SEQ ID 1107, SEQ ID 1108, SEQ ID 1109, SEQ ID 1110, SEQ ID 1111, SEQ ID 1112, SEQ ID 1113, SEQ ID 1114, SEQ ID 1115, SEQ ID 1116, SEQ ID 1117, SEQ ID 1118, SEQ ID 1119, SEQ ID 1120, SEQ ID 1121, SEQ ID 1122, SEQ ID 1123, SEQ ID 1124, SEQ ID 1125, SEQ ID 1126, SEQ ID 1127, SEQ ID 1128, SEQ ID 1129, SEQ ID 1130, SEQ ID 1131, SEQ ID 1132, SEQ ID 1133, SEQ ID 1134, SEQ ID 1135, SEQ ID 1136, SEQ ID 1137, SEQ ID 1138, SEQ ID 1139, SEQ ID 1140, SEQ ID 1141, SEQ ID 1142, SEQ ID 1143, SEQ ID 1144, SEQ ID 1145, SEQ ID 1146, SEQ ID 1147, SEQ ID 1187, SEQ ID 1188, SEQ ID 1189, SEQ ID 1190, SEQ ID 1191, SEQ ID 1192, SEQ ID 1193, SEQ ID 1194, SEQ ID 1195, SEQ ID 1196, SEQ ID 1197, SEQ ID 1198, SEQ ID 1199, SEQ ID 1200, SEQ ID 1201, SEQ ID 1202, SEQ ID 1203, SEQ ID 1204, SEQ ID 1205, SEQ ID 1206, SEQ ID 1207, SEQ ID 1208, SEQ ID 1209, SEQ ID 1210, SEQ ID 1211, SEQ ID 1212, SEQ ID 1213, SEQ ID 1214, SEQ ID 1215, SEQ ID 1216, SEQ ID 1217, SEQ ID 1219, SEQ ID 1220, SEQ ID 1221, SEQ ID 1222, SEQ ID 1223, SEQ ID 1224, SEQ ID 1225, SEQ ID 1226, SEQ ID 1227, SEQ ID 1230, SEQ ID 1231, SEQ ID 1232, SEQ ID 1233, SEQ ID 1234, SEQ ID 1235, SEQ ID 1236, SEQ ID 1237, SEQ ID 1238, SEQ ID 1239, SEQ ID 1240, SEQ ID 1241, SEQ ID 1242, SEQ ID 1243, SEQ ID 1244, SEQ ID 1245, SEQ ID 1246, SEQ ID 1247, SEQ ID 1248, SEQ ID 1250, SEQ ID 1251, SEQ ID 1252, SEQ ID 1253, SEQ ID 1254, SEQ ID 1255, SEQ ID 1256, SEQ ID 1257, SEQ ID 1258, SEQ ID 1259, SEQ ID 1260, SEQ ID 1261, SEQ ID 1262, SEQ ID 1263, SEQ ID 1264, SEQ ID 1265, SEQ ID 1266, SEQ ID 1267, SEQ ID 1268, SEQ ID 1269, SEQ ID 1270, SEQ ID 1271, SEQ ID 1272, SEQ ID 1273, SEQ ID 1274, SEQ ID 1275, SEQ ID 1276, SEQ ID 1277, SEQ ID 1278, SEQ ID 1279, SEQ ID 1280, SEQ ID 1281, SEQ ID 1282, SEQ ID 1283, SEQ ID 1284, SEQ ID 1285, SEQ ID 1286, SEQ ID 1287, SEQ ID 1288, SEQ ID 1289, SEQ ID 1290, SEQ ID 1291, SEQ ID 1292, SEQ ID 1293, SEQ ID 1294, SEQ ID 1295, SEQ ID 1296, SEQ ID 1297, SEQ ID 1298, SEQ ID 1299, SEQ ID 1300, SEQ ID 1301, SEQ ID 1302, SEQ ID 1303, SEQ ID 1304, SEQ ID 1306, SEQ ID 1307, SEQ ID 1308, SEQ ID 1309, SEQ ID 1310, SEQ ID 1311, SEQ ID 1312, SEQ ID 1313, SEQ ID 1314, SEQ ID 1315, SEQ ID 1316, SEQ ID 1317, SEQ ID 1318, SEQ ID 1319, SEQ ID 1320, SEQ ID 1321, SEQ ID 1322, SEQ ID 1323, SEQ ID 1325, SEQ ID 1326, SEQ ID 1327, SEQ ID 1328, SEQ ID 1329, SEQ ID 1330, SEQ ID 1332, SEQ ID 1333, SEQ ID 1335, SEQ ID 1336, SEQ ID 1337, SEQ ID 1338, SEQ ID 1339, SEQ ID 1341, SEQ ID 1342, SEQ ID 1343, SEQ ID 1344, SEQ ID 1345, SEQ ID 1346, SEQ ID 1347, SEQ ID 1348, SEQ ID 1349, SEQ ID 1350, SEQ ID 1351, SEQ ID 1352, SEQ ID 1353, SEQ ID 1354, SEQ ID 1355, SEQ ID 1356, SEQ ID 1357, SEQ ID 1425, SEQ ID 1426, SEQ ID 1427, SEQ ID 1428, SEQ ID 1429, SEQ ID 1430, SEQ ID 1431, SEQ ID 1432, SEQ ID 1433, SEQ ID 1434, SEQ ID 1435, SEQ ID 1436, SEQ ID 1437, SEQ ID 1438, SEQ ID 1440, SEQ ID 1441, SEQ ID 1442, SEQ ID 1443, SEQ ID 1444, SEQ ID 1445, SEQ ID 1446, SEQ ID 1447, SEQ ID 1448, SEQ ID 1449, SEQ ID 1450, SEQ ID 1451, SEQ ID 1452, SEQ ID 1453, SEQ ID 1454, SEQ ID 1455, SEQ ID 1456, SEQ ID 1457, SEQ ID 1458, SEQ ID 1459, SEQ ID 1460, SEQ ID 1461, SEQ ID 1462, SEQ ID 1463, SEQ ID 1464, SEQ ID 1465, SEQ ID 1466, SEQ ID 1467, SEQ ID 1469, SEQ ID 1470, SEQ ID 1471, SEQ ID 1472, SEQ ID 1474, SEQ ID 1475, SEQ ID 1476, SEQ ID 1477, SEQ ID 1478, SEQ ID 1479, SEQ ID 1480, SEQ ID 1481, SEQ ID 1482, SEQ ID 1484, SEQ ID 1485, SEQ ID 1487, SEQ ID 1488, SEQ ID 1489, SEQ ID 1491, SEQ ID 1492, SEQ ID 1493, SEQ ID 1494, SEQ ID 1495, SEQ ID 1496, SEQ ID 1497, SEQ ID 1498, SEQ ID 1499, SEQ ID 1500, SEQ ID 1501, SEQ ID 1502, SEQ ID 1503, SEQ ID 1504, SEQ ID 1505, SEQ ID 1506, SEQ ID 1507, SEQ ID 1508, SEQ ID 1509, SEQ ID 1510, SEQ ID 1511, SEQ ID 1512, SEQ ID 1513, SEQ ID 1514, SEQ ID 1515, SEQ ID 1516, SEQ ID 1517, SEQ ID 1518, SEQ ID 1519, SEQ ID 1520, SEQ ID 1521, SEQ ID 1522, SEQ ID 1523, SEQ ID 1524, SEQ ID 1525, SEQ ID 1526, SEQ ID 1527, SEQ ID 1528, SEQ ID 1529, SEQ ID 1530, SEQ ID 1531, SEQ ID 1532, SEQ ID 1533, SEQ ID 1534, SEQ ID 1535, SEQ ID 1536, SEQ ID 1537, SEQ ID 1538, SEQ ID 1539, SEQ ID 1540, SEQ ID 1541, SEQ ID 1542, SEQ ID 1543, SEQ ID 1544, SEQ ID 1545, SEQ ID 1546, SEQ ID 1547, SEQ ID 1548, SEQ ID 1549, SEQ ID 1550, SEQ ID 1551, SEQ ID 1552, SEQ ID 1553, SEQ ID 1554, SEQ ID 1555, SEQ ID 1556, SEQ ID 1557, SEQ ID 1558, SEQ ID 1559, SEQ ID 1560, SEQ ID 1561, SEQ ID 1562, SEQ ID 1563, SEQ ID 1564, SEQ ID 1565, SEQ ID 1566, SEQ ID 1567, SEQ ID 1568, SEQ ID 1569, SEQ ID 1570, SEQ ID 1571, SEQ ID 1572, SEQ ID 1573, SEQ ID 1574, SEQ ID 1575, SEQ ID 1576, SEQ ID 1577, SEQ ID 1578, SEQ ID 1579, SEQ ID 1580, SEQ ID 1581, SEQ ID 1582, SEQ ID 1583, SEQ ID 1584, SEQ ID 1585, SEQ ID 1586, SEQ ID 1587, SEQ ID 1588, SEQ ID 1589, SEQ ID 1590, SEQ ID 1591, SEQ ID 1592, SEQ ID 1593, SEQ ID 1594, SEQ ID 1595, SEQ ID 1596, SEQ ID 1597, SEQ ID 1598, SEQ ID 1599, SEQ ID 1600, SEQ ID 1601, SEQ ID 1602, SEQ ID 1603, SEQ ID 1604, SEQ ID 1605, SEQ ID 1606, SEQ ID 1607, SEQ ID 1608, SEQ ID 1609, SEQ ID 1610, SEQ ID 1611, SEQ ID 1612, SEQ ID 1613, SEQ ID 1614, SEQ ID 1615, SEQ ID 1616, SEQ ID 1617, SEQ ID 1618, SEQ ID 1620, SEQ ID 1621, SEQ ID 1622, SEQ ID 1623, SEQ ID 1624, SEQ ID 1625, SEQ ID 1626, SEQ ID 1627, SEQ ID 1628, SEQ ID 1629, SEQ ID 1630, SEQ ID 1631, SEQ ID 1632, SEQ ID 1633, SEQ ID 1634, SEQ ID 1635, SEQ ID 1636, SEQ ID 1637, SEQ ID 1638, SEQ ID 1639, SEQ ID 1640, SEQ ID 1641, SEQ ID 1642, SEQ ID 1643, SEQ ID 1644, SEQ ID 1645, SEQ ID 1647, SEQ ID 1648, SEQ ID 1649, SEQ ID 1650, SEQ ID 1651, SEQ ID 1652, SEQ ID 1654, SEQ ID 1656, SEQ ID 1657, SEQ ID 1658, SEQ ID 1659, SEQ ID 1660, SEQ ID 1661, SEQ ID 1663, SEQ ID 1664, SEQ ID 1665, SEQ ID 1666, SEQ ID 1667, SEQ ID 1668, SEQ ID 1669, SEQ ID 1670, SEQ ID 1671, SEQ ID 1672, SEQ ID 1673, SEQ ID 1674, SEQ ID 1675, SEQ ID 1676, SEQ ID 1677, SEQ ID 1678, SEQ ID 1679, SEQ ID 1680, SEQ ID 1681, SEQ ID 1682, SEQ ID 1683, SEQ ID 1684, SEQ ID 1685, SEQ ID 1686, SEQ ID 1687, SEQ ID 1688, SEQ ID 1689, SEQ ID 1690, SEQ ID 1692, SEQ ID 1693, SEQ ID 1694, SEQ ID 1695, SEQ ID 1696, SEQ ID 1697, SEQ ID 1698, SEQ ID 1699, SEQ ID 1701, SEQ ID 1703, SEQ ID 1704, SEQ ID 1705, SEQ ID 1706, SEQ ID 1707, SEQ ID 1708, SEQ ID 1709, SEQ ID 1710, SEQ ID 1711, SEQ ID 1712, SEQ ID 1714, SEQ ID 1715, SEQ ID 1716, SEQ ID 1717, SEQ ID 1718, SEQ ID 1719, SEQ ID 1720, SEQ ID 1721, SEQ ID 1722, SEQ ID 1723, SEQ ID 1724, SEQ ID 1725, SEQ ID 1726, SEQ ID 1727, SEQ ID 1728, SEQ ID 1729, SEQ ID 1730, SEQ ID 1731, SEQ ID 1732, SEQ ID 1733, SEQ ID 1734, SEQ ID 1735, SEQ ID 1736, SEQ ID 1737, SEQ ID 1738, SEQ ID 1739, SEQ ID 1740, SEQ ID 1741, SEQ ID 1742, SEQ ID 1743, SEQ ID 1762, SEQ ID 1763, SEQ ID 1764, SEQ ID 1765, SEQ ID 1766, SEQ ID 1767, SEQ ID 1768, SEQ ID 1769, SEQ ID 1770, SEQ ID 1771, SEQ ID 1772, SEQ ID 1773, SEQ ID 1774, SEQ ID 1775, SEQ ID 1776, SEQ ID 1777, SEQ ID 1778, SEQ ID 1779, SEQ ID 1780, SEQ ID 1781, SEQ ID 1782, SEQ ID 1783, SEQ ID 1784, SEQ ID 1785, SEQ ID 1786, SEQ ID 1787, SEQ ID 1788, SEQ ID 1789, SEQ ID 1790, SEQ ID 1791, SEQ ID 1792, SEQ ID 1793, SEQ ID 1794, SEQ ID 1795, SEQ ID 1796, SEQ ID 1797, SEQ ID 1798, SEQ ID 1799, SEQ ID 1800, SEQ ID 1801, SEQ ID 1802, SEQ ID 1803, SEQ ID 1804, SEQ ID 1805, SEQ ID 1806, SEQ ID 1807, SEQ ID 1808, SEQ ID 1809, SEQ ID 1810, SEQ ID 1811, SEQ ID 1812, SEQ ID 1813, SEQ ID 1814, SEQ ID 1815, SEQ ID 1816, SEQ ID 1817, SEQ ID 1818, SEQ ID 1819, SEQ ID 1820, SEQ ID 1821, SEQ ID 1822, SEQ ID 1823, SEQ ID 1824, SEQ ID 1825, SEQ ID 1826, SEQ ID 1832, SEQ ID 1833, SEQ ID 1836, SEQ ID 1837, SEQ ID 1838, SEQ ID 1839, SEQ ID 1840, SEQ ID 1858, SEQ ID 1859, SEQ ID 1860, SEQ ID 1861, SEQ ID 1862, SEQ ID 1863, SEQ ID 1865, SEQ ID 1866, SEQ ID 1868, SEQ ID 1869, SEQ ID 1873, SEQ ID 1877, SEQ ID 1880, SEQ ID 1883, SEQ ID 1884, SEQ ID 1888, SEQ ID 1889, SEQ ID 1890, SEQ ID 1893, SEQ ID 1894, SEQ ID 1895, SEQ ID 1896, SEQ ID 1897, SEQ ID 1898, SEQ ID 1899, SEQ ID 1900, SEQ ID 1902, SEQ ID 1903, SEQ ID 1904, SEQ ID 1906, SEQ ID 1907, SEQ ID 1908, SEQ ID 1910, SEQ ID 1911, SEQ ID 1913, SEQ ID 1914, SEQ ID 1915, SEQ ID 1916, SEQ ID 1918, SEQ ID 1920, SEQ ID 1921, SEQ ID 1922, SEQ ID 1924, SEQ ID 1928, SEQ ID 1929, SEQ ID 1930, SEQ ID 1932, SEQ ID 1933, SEQ ID 1938, SEQ ID 1939, SEQ ID 1940, SEQ ID 1941, SEQ ID 1943, SEQ ID 1944, SEQ ID 1945, SEQ ID 1946, SEQ ID 1948, SEQ ID 1949, SEQ ID 1950, SEQ ID 1952, SEQ ID 1953, SEQ ID 1956, SEQ ID 1957, SEQ ID 1958, SEQ ID 1960, SEQ ID 1962, SEQ ID 1964, SEQ ID 1966, SEQ ID 1967, SEQ ID 1970, SEQ ID 1971, SEQ ID 1972, SEQ ID 1973, SEQ ID 1974, SEQ ID 1975, SEQ ID 1977, SEQ ID 1979, SEQ ID 1981, SEQ ID 1982, SEQ ID 1985, SEQ ID 1986, SEQ ID 1987, SEQ ID 1988, SEQ ID 1989, SEQ ID 1993, SEQ ID 1995, SEQ ID 1996, SEQ ID 1997, SEQ ID 1998, SEQ ID 1999, SEQ ID 2000, SEQ ID 2001, SEQ ID 2002, SEQ ID 2003, SEQ ID 2004, SEQ ID 2005, SEQ ID 2008, SEQ ID 2009, SEQ ID 2010, SEQ ID 2011, SEQ ID 2013, SEQ ID 2014, SEQ ID 2015, SEQ ID 2017, SEQ ID 2019, SEQ ID 2020, SEQ ID 2021, SEQ ID 2023, SEQ ID 2026, SEQ ID 2028, SEQ ID 2031, SEQ ID 2032, SEQ ID 2033, SEQ ID 2035, SEQ ID 2036, SEQ ID 2037, SEQ ID 2038, SEQ ID 2042, SEQ ID 2044, SEQ ID 2048, SEQ ID 2050, SEQ ID 2051, SEQ ID 2052, SEQ ID 2053, SEQ ID 2054, SEQ ID 2055, SEQ ID 2056, SEQ ID 2057, SEQ ID 2058, SEQ ID 2059, SEQ ID 2060, SEQ ID 2061, SEQ ID 2062, SEQ ID 2063, SEQ ID 2064, SEQ ID 2065, SEQ ID 2066, SEQ ID 2067, SEQ ID 2068, SEQ ID 2069, SEQ ID 2070, SEQ ID 2071, SEQ ID 2072, SEQ ID 2073, SEQ ID 2074, SEQ ID 2075, SEQ ID 2076, SEQ ID 2077, SEQ ID 2078, SEQ ID 2079, SEQ ID 2080, SEQ ID 2081, SEQ ID 2082, SEQ ID 2083, SEQ ID 2084, SEQ ID 2085, SEQ ID 2086, SEQ ID 2087, SEQ ID 2088, SEQ ID 2089, SEQ ID 2090, SEQ ID 2091, SEQ ID 2092, SEQ ID 2093, SEQ ID 2094, SEQ ID 2095, SEQ ID 2096, SEQ ID 2097, SEQ ID 2098, SEQ ID 2099, SEQ ID 2101, SEQ ID 2102, SEQ ID 2103, SEQ ID 2104, SEQ ID 2105, SEQ ID 2106, SEQ ID 2107, SEQ ID 2108, SEQ ID 2109, SEQ ID 2110, SEQ ID 2111, SEQ ID 2112, SEQ ID 2113, SEQ ID 2114, SEQ ID 2115, SEQ ID 2116, SEQ ID 2117, SEQ ID 2118, SEQ ID 2119, SEQ ID 2120, SEQ ID 2121, SEQ ID 2122, SEQ ID 2123, SEQ ID 2124, SEQ ID 2125, SEQ ID 2126, SEQ ID 2127, SEQ ID 2146, SEQ ID 2147, SEQ ID 2148, SEQ ID 2149, SEQ ID 2150, SEQ ID 2151, SEQ ID 2152, SEQ ID 2153, SEQ ID 2154, SEQ ID 2155, SEQ ID 2156, SEQ ID 2157, SEQ ID 2158, SEQ ID 2159, SEQ ID 2160, SEQ ID 2161, SEQ ID 2162, SEQ ID 2163, SEQ ID 2164, SEQ ID 2165, SEQ ID 2166, SEQ ID 2167, SEQ ID 2168, SEQ ID 2169, SEQ ID 2170, SEQ ID 2171, SEQ ID 2172, SEQ ID 2173, SEQ ID 2174, SEQ ID 2175, SEQ ID 2176, SEQ ID 2177, SEQ ID 2178, SEQ ID 2179, SEQ ID 2180, SEQ ID 2181, SEQ ID 2182, SEQ ID 2183, SEQ ID 2184, SEQ ID 2185, SEQ ID 2186, SEQ ID 2187, SEQ ID 2188, SEQ ID 2189, SEQ ID 2190, SEQ ID 2191, SEQ ID 2192, SEQ ID 2193, SEQ ID 2194, SEQ ID 2195, SEQ ID 2196, SEQ ID 2197, SEQ ID 2198, SEQ ID 2199, SEQ ID 2200, SEQ ID 2201, SEQ ID 2202, SEQ ID 2203, SEQ ID 2204, SEQ ID 2205, SEQ ID 2206, SEQ ID 2207, SEQ ID 2208, SEQ ID 2209, SEQ ID 2210, SEQ ID 2211, SEQ ID 2212, SEQ ID 2213, SEQ ID 2214, SEQ ID 2216, SEQ ID 2220, SEQ ID 2222, SEQ ID 2223, SEQ ID 2224, SEQ ID 2225, SEQ ID 2239, SEQ ID 2240, SEQ ID 2241, SEQ ID 2242, SEQ ID 2243, SEQ ID 2244, SEQ ID 2245, SEQ ID 2246, SEQ ID 2247, SEQ ID 2248, SEQ ID 2249, SEQ ID 2250, SEQ ID 2251, SEQ ID 2252, SEQ ID 2253, SEQ ID 2254, SEQ ID 2255, SEQ ID 2256, SEQ ID 2257, SEQ ID 2258, SEQ ID 2259, SEQ ID 2260, SEQ ID 2261, SEQ ID 2262, SEQ ID 2263, SEQ ID 2264, SEQ ID 2265, SEQ ID 2266, SEQ ID 2267, SEQ ID 2268, SEQ ID 2269, SEQ ID 2270, SEQ ID 2271, SEQ ID 2272, SEQ ID 2273, SEQ ID 2274, SEQ ID 2275, SEQ ID 2276, SEQ ID 2277, SEQ ID 2278, SEQ ID 2279, SEQ ID 2280, SEQ ID 2281, SEQ ID 2282, SEQ ID 2283, SEQ ID 2284, SEQ ID 2285, SEQ ID 2286, SEQ ID 2287, SEQ ID 2288, SEQ ID 2289, SEQ ID 2290, SEQ ID 2291, SEQ ID 2292, SEQ ID 2293, SEQ ID 2294, SEQ ID 2295, SEQ ID 2296, SEQ ID 2297, SEQ ID 2298, SEQ ID 2299, SEQ ID 2300, SEQ ID 2301, SEQ ID 2302, SEQ ID 2303, SEQ ID 2304, SEQ ID 2305, SEQ ID 2306, SEQ ID 2307, SEQ ID 2308, SEQ ID 2309, SEQ ID 2310, SEQ ID 2311, SEQ ID 2312, SEQ ID 2313, SEQ ID 2314, SEQ ID 2315, SEQ ID 2316, SEQ ID 2317, SEQ ID 2318, SEQ ID 2319, and SEQ ID 2320.
  • In some embodiments, the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 720, SEQ ID 721, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 730, SEQ ID 732, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 741, SEQ ID 743, SEQ ID 745, SEQ ID 747, SEQ ID 758, SEQ ID 759, SEQ ID 760, SEQ ID 761, SEQ ID 766, SEQ ID 775, SEQ ID 798, SEQ ID 800, SEQ ID 801, SEQ ID 802, SEQ ID 803, SEQ ID 804, SEQ ID 807, SEQ ID 812, SEQ ID 813, SEQ ID 814, SEQ ID 816, SEQ ID 818, SEQ ID 819, SEQ ID 822, SEQ ID 823, SEQ ID 824, SEQ ID 825, SEQ ID 826, SEQ ID 827, SEQ ID 828, SEQ ID 830, SEQ ID 831, SEQ ID 833, SEQ ID 835, SEQ ID 836, SEQ ID 837, SEQ ID 838, SEQ ID 839, SEQ ID 840, SEQ ID 841, SEQ ID 842, SEQ ID 843, SEQ ID 844, SEQ ID 845, SEQ ID 846, SEQ ID 847, SEQ ID 848, SEQ ID 849, SEQ ID 850, SEQ ID 854, SEQ ID 855, SEQ ID 856, SEQ ID 857, SEQ ID 859, SEQ ID 861, SEQ ID 866, SEQ ID 867, SEQ ID 868, SEQ ID 869, SEQ ID 871, SEQ ID 873, SEQ ID 874, SEQ ID 876, SEQ ID 878, SEQ ID 879, SEQ ID 880, SEQ ID 881, SEQ ID 883, SEQ ID 885, SEQ ID 887, SEQ ID 888, SEQ ID 890, SEQ ID 891, SEQ ID 892, SEQ ID 893, SEQ ID 895, SEQ ID 897, SEQ ID 906, SEQ ID 909, SEQ ID 916, SEQ ID 918, SEQ ID 926, SEQ ID 927, SEQ ID 928, SEQ ID 932, SEQ ID 933, SEQ ID 934, SEQ ID 967, SEQ ID 998, SEQ ID 1000, SEQ ID 1001, SEQ ID 1002, SEQ ID 1003, SEQ ID 1005, SEQ ID 1010, SEQ ID 1011, SEQ ID 1012, SEQ ID 1021, SEQ ID 1023, SEQ ID 1024, SEQ ID 1027, SEQ ID 1030, SEQ ID 1037, SEQ ID 1038, SEQ ID 1039, SEQ ID 1041, SEQ ID 1042, SEQ ID 1048, SEQ ID 1049, SEQ ID 1050, SEQ ID 1051, SEQ ID 1054, SEQ ID 1058, SEQ ID 1060, SEQ ID 1061, SEQ ID 1063, SEQ ID 1066, SEQ ID 1070, SEQ ID 1071, SEQ ID 1072, SEQ ID 1073, SEQ ID 1075, SEQ ID 1078, SEQ ID 1081, SEQ ID 1083, SEQ ID 1084, SEQ ID 1085, SEQ ID 1086, SEQ ID 1091, SEQ ID 1092, SEQ ID 1093, SEQ ID 1109, SEQ ID 1111, SEQ ID 1112, SEQ ID 1113, SEQ ID 1114, SEQ ID 1115, SEQ ID 1116, SEQ ID 1117, SEQ ID 1118, SEQ ID 1119, SEQ ID 1120, SEQ ID 1121, SEQ ID 1122, SEQ ID 1123, SEQ ID 1124, SEQ ID 1125, SEQ ID 1126, SEQ ID 1127, SEQ ID 1128, SEQ ID 1129, SEQ ID 1130, SEQ ID 1132, SEQ ID 1135, SEQ ID 1136, SEQ ID 1137, SEQ ID 1138, SEQ ID 1139, SEQ ID 1140, SEQ ID 1141, SEQ ID 1142, SEQ ID 1143, SEQ ID 1144, SEQ ID 1146, SEQ ID 1188, SEQ ID 1189, SEQ ID 1190, SEQ ID 1191, SEQ ID 1192, SEQ ID 1196, SEQ ID 1200, SEQ ID 1201, SEQ ID 1202, SEQ ID 1203, SEQ ID 1204, SEQ ID 1205, SEQ ID 1206, SEQ ID 1207, SEQ ID 1208, SEQ ID 1209, SEQ ID 1223, SEQ ID 1224, SEQ ID 1238, SEQ ID 1243, SEQ ID 1244, SEQ ID 1258, SEQ ID 1259, SEQ ID 1262, SEQ ID 1263, SEQ ID 1264, SEQ ID 1267, SEQ ID 1268, SEQ ID 1271, SEQ ID 1276, SEQ ID 1282, SEQ ID 1283, SEQ ID 1284, SEQ ID 1285, SEQ ID 1286, SEQ ID 1288, SEQ ID 1290, SEQ ID 1291, SEQ ID 1292, SEQ ID 1294, SEQ ID 1297, SEQ ID 1298, SEQ ID 1304, SEQ ID 1311, SEQ ID 1313, SEQ ID 1314, SEQ ID 1315, SEQ ID 1344, SEQ ID 1345, SEQ ID 1346, SEQ ID 1347, SEQ ID 1348, SEQ ID 1349, SEQ ID 1352, SEQ ID 1355, SEQ ID 1357, SEQ ID 1425, SEQ ID 1426, SEQ ID 1427, SEQ ID 1428, SEQ ID 1430, SEQ ID 1431, SEQ ID 1432, SEQ ID 1433, SEQ ID 1434, SEQ ID 1435, SEQ ID 1436, SEQ ID 1437, SEQ ID 1438, SEQ ID 1440, SEQ ID 1441, SEQ ID 1442, SEQ ID 1443, SEQ ID 1444, SEQ ID 1445, SEQ ID 1446, SEQ ID 1447, SEQ ID 1448, SEQ ID 1449, SEQ ID 1450, SEQ ID 1451, SEQ ID 1454, SEQ ID 1455, SEQ ID 1456, SEQ ID 1457, SEQ ID 1460, SEQ ID 1461, SEQ ID 1462, SEQ ID 1463, SEQ ID 1464, SEQ ID 1467, SEQ ID 1469, SEQ ID 1474, SEQ ID 1478, SEQ ID 1480, SEQ ID 1482, SEQ ID 1488, SEQ ID 1492, SEQ ID 1493, SEQ ID 1497, SEQ ID 1498, SEQ ID 1505, SEQ ID 1506, SEQ ID 1507, SEQ ID 1509, SEQ ID 1510, SEQ ID 1512, SEQ ID 1513, SEQ ID 1514, SEQ ID 1515, SEQ ID 1517, SEQ ID 1520, SEQ ID 1524, SEQ ID 1525, SEQ ID 1528, SEQ ID 1529, SEQ ID 1530, SEQ ID 1531, SEQ ID 1532, SEQ ID 1533, SEQ ID 1534, SEQ ID 1535, SEQ ID 1536, SEQ ID 1537, SEQ ID 1538, SEQ ID 1539, SEQ ID 1540, SEQ ID 1541, SEQ ID 1542, SEQ ID 1544, SEQ ID 1545, SEQ ID 1546, SEQ ID 1547, SEQ ID 1548, SEQ ID 1549, SEQ ID 1550, SEQ ID 1551, SEQ ID 1552, SEQ ID 1553, SEQ ID 1554, SEQ ID 1555, SEQ ID 1556, SEQ ID 1558, SEQ ID 1560, SEQ ID 1563, SEQ ID 1565, SEQ ID 1568, SEQ ID 1569, SEQ ID 1575, SEQ ID 1577, SEQ ID 1578, SEQ ID 1579, SEQ ID 1582, SEQ ID 1583, SEQ ID 1584, SEQ ID 1585, SEQ ID 1586, SEQ ID 1587, SEQ ID 1588, SEQ ID 1589, SEQ ID 1590, SEQ ID 1591, SEQ ID 1593, SEQ ID 1594, SEQ ID 1595, SEQ ID 1596, SEQ ID 1599, SEQ ID 1608, SEQ ID 1609, SEQ ID 1610, SEQ ID 1611, SEQ ID 1612, SEQ ID 1613, SEQ ID 1614, SEQ ID 1615, SEQ ID 1616, SEQ ID 1617, SEQ ID 1618, SEQ ID 1620, SEQ ID 1621, SEQ ID 1622, SEQ ID 1623, SEQ ID 1624, SEQ ID 1626, SEQ ID 1630, SEQ ID 1631, SEQ ID 1633, SEQ ID 1635, SEQ ID 1637, SEQ ID 1638, SEQ ID 1639, SEQ ID 1643, SEQ ID 1644, SEQ ID 1645, SEQ ID 1648, SEQ ID 1649, SEQ ID 1651, SEQ ID 1658, SEQ ID 1667, SEQ ID 1669, SEQ ID 1677, SEQ ID 1679, SEQ ID 1681, SEQ ID 1684, SEQ ID 1685, SEQ ID 1686, SEQ ID 1688, SEQ ID 1689, SEQ ID 1690, SEQ ID 1692, SEQ ID 1704, SEQ ID 1707, SEQ ID 1708, SEQ ID 1709, SEQ ID 1710, SEQ ID 1711, SEQ ID 1712, SEQ ID 1714, SEQ ID 1715, SEQ ID 1717, SEQ ID 1718, SEQ ID 1719, SEQ ID 1720, SEQ ID 1721, SEQ ID 1722, SEQ ID 1723, SEQ ID 1724, SEQ ID 1725, SEQ ID 1726, SEQ ID 1727, SEQ ID 1728, SEQ ID 1731, SEQ ID 1732, SEQ ID 1733, SEQ ID 1734, SEQ ID 1735, SEQ ID 1736, SEQ ID 1737, SEQ ID 1738, SEQ ID 1741, SEQ ID 1742, SEQ ID 1762, SEQ ID 1764, SEQ ID 1765, SEQ ID 1766, SEQ ID 1767, SEQ ID 1768, SEQ ID 1769, SEQ ID 1770, SEQ ID 1771, SEQ ID 1773, SEQ ID 1775, SEQ ID 1776, SEQ ID 1779, SEQ ID 1780, SEQ ID 1781, SEQ ID 1782, SEQ ID 1783, SEQ ID 1784, SEQ ID 1785, SEQ ID 1786, SEQ ID 1787, SEQ ID 1789, SEQ ID 1791, SEQ ID 1792, SEQ ID 1794, SEQ ID 1795, SEQ ID 1796, SEQ ID 1800, SEQ ID 1801, SEQ ID 1802, SEQ ID 1804, SEQ ID 1805, SEQ ID 1806, SEQ ID 1807, SEQ ID 1808, SEQ ID 1809, SEQ ID 1811, SEQ ID 1812, SEQ ID 1813, SEQ ID 1814, SEQ ID 1815, SEQ ID 1816, SEQ ID 1817, SEQ ID 1818, SEQ ID 1819, SEQ ID 1820, SEQ ID 1821, SEQ ID 1822, SEQ ID 1823, SEQ ID 1824, SEQ ID 1832, SEQ ID 1833, SEQ ID 1838, SEQ ID 1839, SEQ ID 1840, SEQ ID 1862, SEQ ID 1866, SEQ ID 1868, SEQ ID 1873, SEQ ID 1877, SEQ ID 1883, SEQ ID 1884, SEQ ID 1888, SEQ ID 1889, SEQ ID 1893, SEQ ID 1894, SEQ ID 1928, SEQ ID 1929, SEQ ID 1933, SEQ ID 1938, SEQ ID 1939, SEQ ID 1940, SEQ ID 1941, SEQ ID 1943, SEQ ID 1944, SEQ ID 1948, SEQ ID 1950, SEQ ID 1952, SEQ ID 1956, SEQ ID 1966, SEQ ID 1985, SEQ ID 1986, SEQ ID 1996, SEQ ID 1997, SEQ ID 1998, SEQ ID 1999, SEQ ID 2000, SEQ ID 2005, SEQ ID 2013, SEQ ID 2015, SEQ ID 2020, SEQ ID 2023, SEQ ID 2026, SEQ ID 2028, SEQ ID 2031, SEQ ID 2032, SEQ ID 2033, SEQ ID 2042, SEQ ID 2048, SEQ ID 2052, SEQ ID 2053, SEQ ID 2055, SEQ ID 2056, SEQ ID 2057, SEQ ID 2058, SEQ ID 2059, SEQ ID 2060, SEQ ID 2061, SEQ ID 2063, SEQ ID 2065, SEQ ID 2066, SEQ ID 2067, SEQ ID 2068, SEQ ID 2070, SEQ ID 2072, SEQ ID 2073, SEQ ID 2075, SEQ ID 2076, SEQ ID 2079, SEQ ID 2080, SEQ ID 2081, SEQ ID 2082, SEQ ID 2083, SEQ ID 2084, SEQ ID 2085, SEQ ID 2086, SEQ ID 2087, SEQ ID 2088, SEQ ID 2089, SEQ ID 2090, SEQ ID 2091, SEQ ID 2092, SEQ ID 2093, SEQ ID 2094, SEQ ID 2095, SEQ ID 2097, SEQ ID 2116, SEQ ID 2119, SEQ ID 2120, SEQ ID 2121, SEQ ID 2122, SEQ ID 2123, SEQ ID 2124, SEQ ID 2125, SEQ ID 2126, SEQ ID 2127, SEQ ID 2146, SEQ ID 2147, SEQ ID 2148, SEQ ID 2158, SEQ ID 2160, SEQ ID 2162, SEQ ID 2163, SEQ ID 2165, SEQ ID 2166, SEQ ID 2167, SEQ ID 2168, SEQ ID 2169, SEQ ID 2170, SEQ ID 2171, SEQ ID 2172, SEQ ID 2173, SEQ ID 2174, SEQ ID 2175, SEQ ID 2176, SEQ ID 2177, SEQ ID 2181, SEQ ID 2182, SEQ ID 2183, SEQ ID 2184, SEQ ID 2185, SEQ ID 2186, SEQ ID 2187, SEQ ID 2193, SEQ ID 2194, SEQ ID 2195, SEQ ID 2196, SEQ ID 2197, SEQ ID 2198, SEQ ID 2199, SEQ ID 2200, SEQ ID 2202, SEQ ID 2203, SEQ ID 2204, SEQ ID 2206, SEQ ID 2208, SEQ ID 2209, SEQ ID 2210, SEQ ID 2211, SEQ ID 2212, SEQ ID 2213, SEQ ID 2214, SEQ ID 2216, SEQ ID 2222, SEQ ID 2224, SEQ ID 2239, SEQ ID 2240, SEQ ID 2242, SEQ ID 2243, SEQ ID 2244, SEQ ID 2245, SEQ ID 2246, SEQ ID 2247, SEQ ID 2248, SEQ ID 2251, SEQ ID 2252, SEQ ID 2253, SEQ ID 2254, SEQ ID 2255, SEQ ID 2256, SEQ ID 2257, SEQ ID 2258, SEQ ID 2259, SEQ ID 2260, SEQ ID 2261, SEQ ID 2262, SEQ ID 2263, SEQ ID 2264, SEQ ID 2265, SEQ ID 2266, SEQ ID 2267, SEQ ID 2268, SEQ ID 2269, SEQ ID 2280, SEQ ID 2281, SEQ ID 2282, SEQ ID 2283, SEQ ID 2284, SEQ ID 2285, SEQ ID 2294, SEQ ID 2295, SEQ ID 2302, SEQ ID 2307, SEQ ID 2308, SEQ ID 2309, SEQ ID 2310, SEQ ID 2311, SEQ ID 2312, SEQ ID 2316, SEQ ID 2317, SEQ ID 2318, SEQ ID 2319, and SEQ ID 2320.
  • The invention provides for a conjugate comprising the antisense oligonucleotide progranulin agonist according to the invention, and at least one conjugate moiety covalently attached to said antisense oligonucleotide progranulin agonist.
  • The invention provides an antisense oligonucleotide progranulin agonist covalently attached to at least one conjugate moiety.
  • The invention provides for a pharmaceutically acceptable salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • The invention provides for an antisense oligonucleotide progranulin agonist according to the invention wherein the antisense oligonucleotide progranulin agonist is in the form of a pharmaceutically acceptable salt. In some embodiments the pharmaceutically acceptable salt may be a sodium salt or a potassium salt.
  • The invention provides for a pharmaceutically acceptable sodium salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • The invention provides for a pharmaceutically acceptable potassium salt of the antisense oligonucleotide progranulin agonist according to the invention, or the conjugate according to the invention.
  • The invention provides for a pharmaceutical composition comprising the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • The invention provides for a pharmaceutical composition comprising the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, and a pharmaceutically acceptable salt. For example, the salt may comprise a metal cation, such as a sodium salt or a potassium salt.
  • The invention provides for a pharmaceutical composition according to the invention, wherein the pharmaceutical composition comprises the antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the pharmaceutically acceptable salt of the invention; and an aqueous diluent or solvent.
  • The invention provides for a solution, such as a phosphate buffered saline solution of the antisense oligonucleotide progranulin agonist of the invention, or the conjugate of the invention, or the pharmaceutically acceptable salt of the invention. Suitably the solution, such as phosphate buffered saline solution, of the invention, is a sterile solution.
  • The invention provides for a method for enhancing the expression of progranulin in a cell which is expressing progranulin, said method comprising administering an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention in an effective amount to said cell. In some embodiments the method is an in vitro method. In some embodiments the method is an in vivo method.
  • In some embodiments, the cell is either a human cell or a mammalian cell.
  • The invention provides for a method for treating or preventing neurological disease, comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention to a subject suffering from or susceptible to neurological disease. In one embodiment the neurological disease may be a TDP-43 pathology.
  • The invention provides for a method for treating progranulin haploinsufficiency disease, comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention to a subject suffering from progranulin haploinsufficiency or a related disorder.
  • The invention provides for an antisense oligonucleotide progranulin agonist, for use as a medicament.
  • The invention provides for an antisense oligonucleotide progranulin agonist, for use in therapy.
  • The invention provides for the antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt of the invention, or the pharmaceutical composition of the invention, for use as a medicament.
  • The invention provides an antisense oligonucleotide progranulin agonist of the invention or the conjugate of the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in therapy.
  • The invention provides for an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in the treatment of a neurological disease. In one embodiment the neurological disease may be a TDP-43 pathology.
  • The invention provides for an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention for use in the treatment of progranulin haploinsufficiency, or a related disorder.
  • The invention provides for the use of an antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention, for the preparation of a medicament for treatment or prevention of a neurological disease In one embodiment the neurological disease may be a TDP-43 pathology.
  • The invention provides for the use of the antisense oligonucleotide progranulin agonist of the invention or the conjugate according to the invention, or the salt according to the invention, or the pharmaceutical composition according to the invention, for the preparation of a medicament for treatment of progranulin haploinsufficiency or a related disorder.
  • In some embodiments the method or use of the invention is for the treatment of fronto temporal dementia (FTD), neuropathologic frontotemporal lobar degeneration or neuroinflammation. In other embodiments the method or use of the invention is for the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Autism, Hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases, spinocerebellar ataxia 3, myopathies or Chronic Traumatic Encephalopathy.
  • In one aspect the invention includes an oligonucleotide progranulin agonist having the structure:
  • Figure US20230287412A1-20230914-C00001
  • The invention also includes an antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
    • BRIEF DESCRIPTION OF FIGURES
  • FIG. 1 shows progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 16-mer oligos targeting the progranulin 5′ UTR uORF region. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 2 shows localization of compounds #105, #106, #110 and #114 to the 5′ UTR of the proganulin mature mRNA transcript, targeting the uORF region.
  • FIGS. 3 and 4 show progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 16-mer oligos targeting 5′ UTR uORF region. Progranulin expression levels were evaluated in cell lysate (RIPA lysis and extraction buffer from Pierce cat. No. 89900) using the WES platform (ProteinSimple) and GRN antibody Invitrogen PA5-27275 diluted 1:25 and HPRT1 antibody ab109021 (Abcam) diluted 1:50.
  • FIG. 5 shows the level of progranulin expression in hiPSC derived micoglia following 5 days of treatment with Compound #106. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 6 shows progranulin expression levels in H4 neuroglioma cells following 5 days of treatment with 18-mer oligos targeting the progranulin 5′ UTR uORF region. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • FIG. 7 shows the structure of Compound ID #106 (SEQ ID NO 106).
  • FIG. 8 shows progranulin expression in H4 neuroglioma cells following treatment with Compound #106, Compound #106 full 2′MOE, and Compound #106 full 2′oMe.
  • FIG. 9 shows heat maps indicating genes upregulated and down regulated relative to PBS control treated cells. Left is compound #106, middle is Compound #106 full 2′oMe and right is Compound #106 full 2′MOE.
  • FIG. 10 is a plot showing the position of oligos within the progranulin precursor-mRNA (pre-mRNA) sequence (SEQ ID NO 3949) relative to the activity of the oligo. Oligos complementary to exon-exon junctions are plotted downstream of the schematic figure of the pre-mRNA
    •  DEFINITIONS
  • Progranulin Agonist
  • The term “progranulin agonist” as used herein refers to a compound which is capable of enhancing the expression of progranulin transcripts and/or protein in a cell which is expressing progranulin.
  • Tdp-43 Pathologies
  • A TDP-43 pathology is a disease which is associated with reduced or aberrant expression of TDP-43, often associated with an increase in cytoplasmic TDP-43, particularly hyper-phosphorylated and ubiquitinated TDP-43.
  • Diseases associated with TDP-43 pathology include amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Alzheimer's disease, Parkinson's disease, Autism, Hippocampal sclerosis dementia, Down syndrome, Huntington's disease, polyglutamine diseases, such as spinocerebellar ataxia 3, myopathies and Chronic Traumatic Encephalopathy.
  • Oligonucleotide
  • The term “oligonucleotide” as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers.
  • Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification and isolation. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides. The oligonucleotides of the invention are man-made, and are chemically synthesized, and are typically purified or isolated. The oligonucleotides of the invention may comprise one or more modified nucleosides such as 2′ sugar modified nucleosides. The oligonucleotides of the invention may comprise one or more modified internucleoside linkages, such as one or more phosphorothioate internucleoside linkages.
  • Antisense Oligonucleotides
  • The term “antisense oligonucleotide” as used herein is defined as an oligonucleotide capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid. Antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs or shRNAs. The antisense oligonucleotides of the present invention may be single stranded. It is understood that single stranded oligonucleotides of the present invention can form hairpins or intermolecular duplex structures (duplex between two molecules of the same oligonucleotide), as long as the degree of intra or inter self-complementarity is less than approximately 50% across of the full length of the oligonucleotide.
  • In some embodiments, the single stranded antisense oligonucleotides of the invention may not contain RNA nucleosides.
  • Advantageously, the antisense oligonucleotides of the invention comprise one or more modified nucleosides or nucleotides, such as 2′ sugar modified nucleosides. Furthermore, in some antisense oligonucleotides of the invention, it may be advantageous that the nucleosides which are not modified are DNA nucleosides.
  • Contiguous Nucleotide Sequence
  • The term “contiguous nucleotide sequence” refers to the region of the oligonucleotide which is complementary to a target nucleic acid, which may be or may comprise an oligonucleotide motif sequence. The term is used interchangeably herein with the term “contiguous nucleobase sequence”. In some embodiments all the nucleosides of the oligonucleotide constitute the contiguous nucleotide sequence. The contiguous nucleotide sequence is the sequence of nucleotides in the oligonucleotide of the invention which are complementary to, and in some instances fully complementary to, the target nucleic acid or target sequence, or target site sequence.
  • In some embodiments the target sequence is SEQ ID NO 2.
  • SEQ ID NO 2:
    TAGCCCTGATCCCTGGCCAATGGAAACTGAGGTAGG
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID NO 343-682.
  • In some embodiments the target sequence is nucleotides 38-246 of SEQ ID NO 1.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584 & SEQ ID NO 586.
  • In some embodiments the target sequence is SEQ ID NO 683.
  • SEQ ID NO 683 =
    TGGCCAATGGAAACTGAGGTAGG
  • In some embodiments the target sequence is SEQ ID NO 684.
  • SEQ ID NO 684 =
    CCCTAGCACCTCCCCCTAACCAAATTCTCCCTG
  • In some embodiments the target sequence is SEQ ID NO 685.
  • SEQ ID NO 685 =
    CCCATTCTGAGCTCCCCATCA
  • In some embodiments the target sequence is SEQ ID NO 686.
  • SEQ ID NO 686 =
    AGGGGGTTGTGGCAAAAGCCA
  • In some embodiments the target sequence is SEQ ID NO 687.
  • SEQ ID NO 687 =
    CCATCCCCTCCCCGTTTCAGT
  • In some embodiments the target sequence is SEQ ID NO 688.
  • SEQ ID NO 688 =
    ATCCACAGGGGTGTTTGT
  • In some embodiments the target sequence is SEQ ID NO 689.
  • SEQ ID NO 689 =
    TAAGTAGCCAATGGGAGCGGGTAGCCCTGATCCCTGGCCAATGGAAACT
    GAGGTAGG
  • SEQ ID NO 689 is in the human progranulin mature mRNA 5′ UTR from position 119 to 158 according to RefSeq NM_002087 (SEQ ID NO 1), as targeted by SEQ ID NOs 207 to 246 and identified herein as an advantageous region to target for progranulin agonist activity.
  • In some embodiments the target sequence is nucleotides 2039-2346 of SEQ ID NO 1.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 683, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID NO 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID NO 2040-3386.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID 2321, SEQ ID 2322, SEQ ID 2324, SEQ ID 2328, SEQ ID 2329, SEQ ID 2331, SEQ ID 2334, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2340, SEQ ID 2341, SEQ ID 2342, SEQ ID 2345, SEQ ID 2346, SEQ ID 2347, SEQ ID 2348, SEQ ID 2349, SEQ ID 2350, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2356, SEQ ID 2357, SEQ ID 2358, SEQ ID 2359, SEQ ID 2360, SEQ ID 2361, SEQ ID 2362, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2368, SEQ ID 2369, SEQ ID 2370, SEQ ID 2371, SEQ ID 2372, SEQ ID 2373, SEQ ID 2374, SEQ ID 2375, SEQ ID 2376, SEQ ID 2377, SEQ ID 2378, SEQ ID 2379, SEQ ID 2380, SEQ ID 2381, SEQ ID 2384, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2390, SEQ ID 2392, SEQ ID 2393, SEQ ID 2394, SEQ ID 2395, SEQ ID 2396, SEQ ID 2397, SEQ ID 2398, SEQ ID 2399, SEQ ID 2400, SEQ ID 2401, SEQ ID 2403, SEQ ID 2404, SEQ ID 2405, SEQ ID 2406, SEQ ID 2407, SEQ ID 2408, SEQ ID 2410, SEQ ID 2411, SEQ ID 2413, SEQ ID 2414, SEQ ID 2415, SEQ ID 2416, SEQ ID 2418, SEQ ID 2419, SEQ ID 2421, SEQ ID 2424, SEQ ID 2425, SEQ ID 2426, SEQ ID 2427, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2433, SEQ ID 2434, SEQ ID 2435, SEQ ID 2436, SEQ ID 2437, SEQ ID 2438, SEQ ID 2439, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2443, SEQ ID 2444, SEQ ID 2445, SEQ ID 2446, SEQ ID 2447, SEQ ID 2448, SEQ ID 2449, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2457, SEQ ID 2458, SEQ ID 2459, SEQ ID 2460, SEQ ID 2461, SEQ ID 2462, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2479, SEQ ID 2481, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2490, SEQ ID 2491, SEQ ID 2492, SEQ ID 2493, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2498, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2503, SEQ ID 2504, SEQ ID 2505, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2510, SEQ ID 2511, SEQ ID 2512, SEQ ID 2513, SEQ ID 2514, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2522, SEQ ID 2523, SEQ ID 2524, SEQ ID 2525, SEQ ID 2526, SEQ ID 2527, SEQ ID 2528, SEQ ID 2531, SEQ ID 2533, SEQ ID 2534, SEQ ID 2535, SEQ ID 2536, SEQ ID 2537, SEQ ID 2538, SEQ ID 2540, SEQ ID 2541, SEQ ID 2542, SEQ ID 2544, SEQ ID 2546, SEQ ID 2547, SEQ ID 2549, SEQ ID 2550, SEQ ID 2551, SEQ ID 2553, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2557, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2563, SEQ ID 2565, SEQ ID 2566, SEQ ID 2567, SEQ ID 2572, SEQ ID 2573, SEQ ID 2574, SEQ ID 2575, SEQ ID 2576, SEQ ID 2577, SEQ ID 2578, SEQ ID 2579, SEQ ID 2580, SEQ ID 2581, SEQ ID 2582, SEQ ID 2583, SEQ ID 2584, SEQ ID 2585, SEQ ID 2586, SEQ ID 2588, SEQ ID 2589, SEQ ID 2590, SEQ ID 2591, SEQ ID 2592, SEQ ID 2593, SEQ ID 2594, SEQ ID 2595, SEQ ID 2596, SEQ ID 2597, SEQ ID 2598, SEQ ID 2599, SEQ ID 2601, SEQ ID 2602, SEQ ID 2603, SEQ ID 2604, SEQ ID 2606, SEQ ID 2610, SEQ ID 2613, SEQ ID 2614, SEQ ID 2615, SEQ ID 2619, SEQ ID 2622, SEQ ID 2623, SEQ ID 2624, SEQ ID 2625, SEQ ID 2626, SEQ ID 2627, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2632, SEQ ID 2633, SEQ ID 2634, SEQ ID 2635, SEQ ID 2636, SEQ ID 2637, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2641, SEQ ID 2642, SEQ ID 2643, SEQ ID 2644, SEQ ID 2645, SEQ ID 2646, SEQ ID 2647, SEQ ID 2648, SEQ ID 2649, SEQ ID 2650, SEQ ID 2651, SEQ ID 2652, SEQ ID 2653, SEQ ID 2654, SEQ ID 2655, SEQ ID 2656, SEQ ID 2658, SEQ ID 2659, SEQ ID 2660, SEQ ID 2661, SEQ ID 2662, SEQ ID 2663, SEQ ID 2664, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2668, SEQ ID 2669, SEQ ID 2670, SEQ ID 2671, SEQ ID 2672, SEQ ID 2673, SEQ ID 2674, SEQ ID 2675, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2680, SEQ ID 2681, SEQ ID 2682, SEQ ID 2683, SEQ ID 2684, SEQ ID 2685, SEQ ID 2686, SEQ ID 2687, SEQ ID 2688, SEQ ID 2689, SEQ ID 2690, SEQ ID 2691, SEQ ID 2693, SEQ ID 2694, SEQ ID 2695, SEQ ID 2696, SEQ ID 2697, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2702, SEQ ID 2703, SEQ ID 2704, SEQ ID 2705, SEQ ID 2706, SEQ ID 2707, SEQ ID 2708, SEQ ID 2709, SEQ ID 2710, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2715, SEQ ID 2716, SEQ ID 2717, SEQ ID 2718, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2722, SEQ ID 2723, SEQ ID 2726, SEQ ID 2727, SEQ ID 2728, SEQ ID 2729, SEQ ID 2730, SEQ ID 2733, SEQ ID 2734, SEQ ID 2735, SEQ ID 2736, SEQ ID 2737, SEQ ID 2738, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2759, SEQ ID 2760, SEQ ID 2761, SEQ ID 2762, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2773, SEQ ID 2774, SEQ ID 2775, SEQ ID 2815, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2821, SEQ ID 2822, SEQ ID 2823, SEQ ID 2824, SEQ ID 2825, SEQ ID 2826, SEQ ID 2827, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2838, SEQ ID 2839, SEQ ID 2840, SEQ ID 2841, SEQ ID 2842, SEQ ID 2843, SEQ ID 2844, SEQ ID 2845, SEQ ID 2847, SEQ ID 2848, SEQ ID 2849, SEQ ID 2850, SEQ ID 2851, SEQ ID 2852, SEQ ID 2853, SEQ ID 2854, SEQ ID 2855, SEQ ID 2858, SEQ ID 2859, SEQ ID 2860, SEQ ID 2861, SEQ ID 2862, SEQ ID 2863, SEQ ID 2864, SEQ ID 2865, SEQ ID 2866, SEQ ID 2867, SEQ ID 2868, SEQ ID 2869, SEQ ID 2870, SEQ ID 2871, SEQ ID 2872, SEQ ID 2873, SEQ ID 2874, SEQ ID 2875, SEQ ID 2876, SEQ ID 2878, SEQ ID 2879, SEQ ID 2880, SEQ ID 2881, SEQ ID 2882, SEQ ID 2883, SEQ ID 2884, SEQ ID 2885, SEQ ID 2886, SEQ ID 2887, SEQ ID 2888, SEQ ID 2889, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2893, SEQ ID 2894, SEQ ID 2895, SEQ ID 2896, SEQ ID 2897, SEQ ID 2898, SEQ ID 2899, SEQ ID 2900, SEQ ID 2901, SEQ ID 2902, SEQ ID 2903, SEQ ID 2904, SEQ ID 2905, SEQ ID 2906, SEQ ID 2907, SEQ ID 2908, SEQ ID 2909, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2915, SEQ ID 2916, SEQ ID 2917, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2921, SEQ ID 2922, SEQ ID 2923, SEQ ID 2924, SEQ ID 2925, SEQ ID 2926, SEQ ID 2927, SEQ ID 2928, SEQ ID 2929, SEQ ID 2930, SEQ ID 2931, SEQ ID 2932, SEQ ID 2934, SEQ ID 2935, SEQ ID 2936, SEQ ID 2937, SEQ ID 2938, SEQ ID 2939, SEQ ID 2940, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2944, SEQ ID 2945, SEQ ID 2946, SEQ ID 2947, SEQ ID 2948, SEQ ID 2949, SEQ ID 2950, SEQ ID 2951, SEQ ID 2953, SEQ ID 2954, SEQ ID 2955, SEQ ID 2956, SEQ ID 2957, SEQ ID 2958, SEQ ID 2960, SEQ ID 2961, SEQ ID 2963, SEQ ID 2964, SEQ ID 2965, SEQ ID 2966, SEQ ID 2967, SEQ ID 2969, SEQ ID 2970, SEQ ID 2971, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2978, SEQ ID 2979, SEQ ID 2980, SEQ ID 2981, SEQ ID 2982, SEQ ID 2983, SEQ ID 2984, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3057, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3080, SEQ ID 3081, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3086, SEQ ID 3087, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3093, SEQ ID 3094, SEQ ID 3095, SEQ ID 3097, SEQ ID 3098, SEQ ID 3099, SEQ ID 3100, SEQ ID 3102, SEQ ID 3103, SEQ ID 3104, SEQ ID 3105, SEQ ID 3106, SEQ ID 3107, SEQ ID 3108, SEQ ID 3109, SEQ ID 3110, SEQ ID 3112, SEQ ID 3113, SEQ ID 3115, SEQ ID 3116, SEQ ID 3117, SEQ ID 3119, SEQ ID 3120, SEQ ID 3121, SEQ ID 3122, SEQ ID 3123, SEQ ID 3124, SEQ ID 3125, SEQ ID 3126, SEQ ID 3127, SEQ ID 3128, SEQ ID 3129, SEQ ID 3130, SEQ ID 3131, SEQ ID 3132, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3136, SEQ ID 3137, SEQ ID 3138, SEQ ID 3139, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3144, SEQ ID 3145, SEQ ID 3146, SEQ ID 3147, SEQ ID 3148, SEQ ID 3149, SEQ ID 3150, SEQ ID 3151, SEQ ID 3152, SEQ ID 3153, SEQ ID 3154, SEQ ID 3155, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3171, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3185, SEQ ID 3186, SEQ ID 3187, SEQ ID 3188, SEQ ID 3189, SEQ ID 3190, SEQ ID 3191, SEQ ID 3192, SEQ ID 3193, SEQ ID 3194, SEQ ID 3195, SEQ ID 3196, SEQ ID 3197, SEQ ID 3198, SEQ ID 3199, SEQ ID 3200, SEQ ID 3201, SEQ ID 3202, SEQ ID 3203, SEQ ID 3204, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3208, SEQ ID 3209, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3220, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3225, SEQ ID 3226, SEQ ID 3227, SEQ ID 3228, SEQ ID 3229, SEQ ID 3230, SEQ ID 3231, SEQ ID 3232, SEQ ID 3233, SEQ ID 3234, SEQ ID 3235, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3253, SEQ ID 3254, SEQ ID 3255, SEQ ID 3256, SEQ ID 3257, SEQ ID 3258, SEQ ID 3259, SEQ ID 3260, SEQ ID 3261, SEQ ID 3262, SEQ ID 3263, SEQ ID 3264, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3268, SEQ ID 3269, SEQ ID 3270, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3275, SEQ ID 3276, SEQ ID 3277, SEQ ID 3278, SEQ ID 3279, SEQ ID 3280, SEQ ID 3282, SEQ ID 3284, SEQ ID 3285, SEQ ID 3286, SEQ ID 3287, SEQ ID 3288, SEQ ID 3289, SEQ ID 3291, SEQ ID 3292, SEQ ID 3293, SEQ ID 3294, SEQ ID 3295, SEQ ID 3296, SEQ ID 3297, SEQ ID 3298, SEQ ID 3299, SEQ ID 3300, SEQ ID 3301, SEQ ID 3302, SEQ ID 3303, SEQ ID 3304, SEQ ID 3305, SEQ ID 3306, SEQ ID 3307, SEQ ID 3308, SEQ ID 3309, SEQ ID 3310, SEQ ID 3311, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3315, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3321, SEQ ID 3322, SEQ ID 3323, SEQ ID 3324, SEQ ID 3325, SEQ ID 3326, SEQ ID 3327, SEQ ID 3329, SEQ ID 3331, SEQ ID 3332, SEQ ID 3333, SEQ ID 3334, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3344, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3357, SEQ ID 3358, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3367, SEQ ID 3368, SEQ ID 3369, SEQ ID 3370, SEQ ID 3371, SEQ ID 3390, SEQ ID 3391, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3400, SEQ ID 3401, SEQ ID 3402, SEQ ID 3403, SEQ ID 3404, SEQ ID 3405, SEQ ID 3406, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3416, SEQ ID 3417, SEQ ID 3418, SEQ ID 3419, SEQ ID 3420, SEQ ID 3421, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3425, SEQ ID 3426, SEQ ID 3427, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3431, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3438, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3453, SEQ ID 3454, SEQ ID 3460, SEQ ID 3461, SEQ ID 3464, SEQ ID 3465, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3486, SEQ ID 3487, SEQ ID 3488, SEQ ID 3489, SEQ ID 3490, SEQ ID 3491, SEQ ID 3493, SEQ ID 3494, SEQ ID 3496, SEQ ID 3497, SEQ ID 3501, SEQ ID 3505, SEQ ID 3508, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3518, SEQ ID 3521, SEQ ID 3522, SEQ ID 3523, SEQ ID 3524, SEQ ID 3525, SEQ ID 3526, SEQ ID 3527, SEQ ID 3528, SEQ ID 3530, SEQ ID 3531, SEQ ID 3532, SEQ ID 3534, SEQ ID 3535, SEQ ID 3536, SEQ ID 3538, SEQ ID 3539, SEQ ID 3541, SEQ ID 3542, SEQ ID 3543, SEQ ID 3544, SEQ ID 3546, SEQ ID 3548, SEQ ID 3549, SEQ ID 3550, SEQ ID 3552, SEQ ID 3556, SEQ ID 3557, SEQ ID 3558, SEQ ID 3560, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3573, SEQ ID 3574, SEQ ID 3576, SEQ ID 3577, SEQ ID 3578, SEQ ID 3580, SEQ ID 3581, SEQ ID 3584, SEQ ID 3585, SEQ ID 3586, SEQ ID 3588, SEQ ID 3590, SEQ ID 3592, SEQ ID 3594, SEQ ID 3595, SEQ ID 3598, SEQ ID 3599, SEQ ID 3600, SEQ ID 3601, SEQ ID 3602, SEQ ID 3603, SEQ ID 3605, SEQ ID 3607, SEQ ID 3609, SEQ ID 3610, SEQ ID 3613, SEQ ID 3614, SEQ ID 3615, SEQ ID 3616, SEQ ID 3617, SEQ ID 3621, SEQ ID 3623, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3629, SEQ ID 3630, SEQ ID 3631, SEQ ID 3632, SEQ ID 3633, SEQ ID 3636, SEQ ID 3637, SEQ ID 3638, SEQ ID 3639, SEQ ID 3641, SEQ ID 3642, SEQ ID 3643, SEQ ID 3645, SEQ ID 3647, SEQ ID 3648, SEQ ID 3649, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3663, SEQ ID 3664, SEQ ID 3665, SEQ ID 3666, SEQ ID 3670, SEQ ID 3672, SEQ ID 3676, SEQ ID 3678, SEQ ID 3679, SEQ ID 3680, SEQ ID 3681, SEQ ID 3682, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3690, SEQ ID 3691, SEQ ID 3692, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3697, SEQ ID 3698, SEQ ID 3699, SEQ ID 3700, SEQ ID 3701, SEQ ID 3702, SEQ ID 3703, SEQ ID 3704, SEQ ID 3705, SEQ ID 3706, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3724, SEQ ID 3725, SEQ ID 3726, SEQ ID 3727, SEQ ID 3729, SEQ ID 3730, SEQ ID 3731, SEQ ID 3732, SEQ ID 3733, SEQ ID 3734, SEQ ID 3735, SEQ ID 3736, SEQ ID 3737, SEQ ID 3738, SEQ ID 3739, SEQ ID 3740, SEQ ID 3741, SEQ ID 3742, SEQ ID 3743, SEQ ID 3744, SEQ ID 3745, SEQ ID 3746, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3777, SEQ ID 3778, SEQ ID 3779, SEQ ID 3780, SEQ ID 3781, SEQ ID 3782, SEQ ID 3783, SEQ ID 3784, SEQ ID 3785, SEQ ID 3786, SEQ ID 3787, SEQ ID 3788, SEQ ID 3789, SEQ ID 3790, SEQ ID 3791, SEQ ID 3792, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3806, SEQ ID 3807, SEQ ID 3808, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3816, SEQ ID 3817, SEQ ID 3818, SEQ ID 3819, SEQ ID 3820, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3829, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3833, SEQ ID 3834, SEQ ID 3835, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3848, SEQ ID 3850, SEQ ID 3851, SEQ ID 3852, SEQ ID 3853, SEQ ID 3867, SEQ ID 3868, SEQ ID 3869, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3877, SEQ ID 3878, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3898, SEQ ID 3899, SEQ ID 3900, SEQ ID 3901, SEQ ID 3902, SEQ ID 3903, SEQ ID 3904, SEQ ID 3905, SEQ ID 3906, SEQ ID 3907, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3914, SEQ ID 3915, SEQ ID 3916, SEQ ID 3917, SEQ ID 3918, SEQ ID 3919, SEQ ID 3920, SEQ ID 3921, SEQ ID 3922, SEQ ID 3923, SEQ ID 3924, SEQ ID 3925, SEQ ID 3926, SEQ ID 3927, SEQ ID 3928, SEQ ID 3929, SEQ ID 3930, SEQ ID 3931, SEQ ID 3932, SEQ ID 3933, SEQ ID 3934, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3941, SEQ ID 3942, SEQ ID 3943, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948.
  • In some embodiments the target sequence is selected from the group consisting of SEQ ID 2321, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2348, SEQ ID 2349, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2358, SEQ ID 2360, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2369, SEQ ID 2371, SEQ ID 2373, SEQ ID 2375, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2394, SEQ ID 2403, SEQ ID 2426, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2435, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2444, SEQ ID 2446, SEQ ID 2447, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2458, SEQ ID 2459, SEQ ID 2461, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2504, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2511, SEQ ID 2513, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2523, SEQ ID 2525, SEQ ID 2534, SEQ ID 2537, SEQ ID 2544, SEQ ID 2546, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2595, SEQ ID 2626, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2633, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2649, SEQ ID 2651, SEQ ID 2652, SEQ ID 2655, SEQ ID 2658, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2669, SEQ ID 2670, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2682, SEQ ID 2686, SEQ ID 2688, SEQ ID 2689, SEQ ID 2691, SEQ ID 2694, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2703, SEQ ID 2706, SEQ ID 2709, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2737, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2760, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2774, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2824, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2851, SEQ ID 2852, SEQ ID 2866, SEQ ID 2871, SEQ ID 2872, SEQ ID 2886, SEQ ID 2887, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2895, SEQ ID 2896, SEQ ID 2899, SEQ ID 2904, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2916, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2922, SEQ ID 2925, SEQ ID 2926, SEQ ID 2932, SEQ ID 2939, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2980, SEQ ID 2983, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3095, SEQ ID 3097, SEQ ID 3102, SEQ ID 3106, SEQ ID 3108, SEQ ID 3110, SEQ ID 3116, SEQ ID 3120, SEQ ID 3121, SEQ ID 3125, SEQ ID 3126, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3137, SEQ ID 3138, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3145, SEQ ID 3148, SEQ ID 3152, SEQ ID 3153, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3186, SEQ ID 3188, SEQ ID 3191, SEQ ID 3193, SEQ ID 3196, SEQ ID 3197, SEQ ID 3203, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3227, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3254, SEQ ID 3258, SEQ ID 3259, SEQ ID 3261, SEQ ID 3263, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3276, SEQ ID 3277, SEQ ID 3279, SEQ ID 3286, SEQ ID 3295, SEQ ID 3297, SEQ ID 3305, SEQ ID 3307, SEQ ID 3309, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3332, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3369, SEQ ID 3370, SEQ ID 3390, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3401, SEQ ID 3403, SEQ ID 3404, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3417, SEQ ID 3419, SEQ ID 3420, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3460, SEQ ID 3461, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3490, SEQ ID 3494, SEQ ID 3496, SEQ ID 3501, SEQ ID 3505, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3521, SEQ ID 3522, SEQ ID 3556, SEQ ID 3557, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3576, SEQ ID 3578, SEQ ID 3580, SEQ ID 3584, SEQ ID 3594, SEQ ID 3613, SEQ ID 3614, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3633, SEQ ID 3641, SEQ ID 3643, SEQ ID 3648, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3670, SEQ ID 3676, SEQ ID 3680, SEQ ID 3681, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3691, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3698, SEQ ID 3700, SEQ ID 3701, SEQ ID 3703, SEQ ID 3704, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3725, SEQ ID 3744, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3786, SEQ ID 3788, SEQ ID 3790, SEQ ID 3791, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3834, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3850, SEQ ID 3852, SEQ ID 3867, SEQ ID 3868, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3922, SEQ ID 3923, SEQ ID 3930, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948.
  • In some embodiments the oligonucleotide comprises the contiguous nucleotide sequence, and may optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group (e.g. a conjugate group) to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid. It is understood that the contiguous nucleotide sequence of the oligonucleotide cannot be longer than the oligonucleotide as such and that the oligonucleotide cannot be shorter than the contiguous nucleotide sequence.
  • Nucleotides and Nucleosides
  • Nucleotides and nucleosides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides and nucleosides. In nature, nucleotides, such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides). Nucleosides and nucleotides may also interchangeably be referred to as “units” or “monomers”.
  • Modified Nucleoside
  • Advantageously, the antisense oligonucleotide progranulin agonist of the invention may comprise one or more modified nucleoside.
  • The term “modified nucleoside” or “nucleoside modification” as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety. Advantageously, one or more of the modified nucleosides of the antisense oligonucleotides of the invention may comprise a modified sugar moiety. The term modified nucleoside may also be used herein interchangeably with the term “nucleoside analogue” or modified “units” or modified “monomers”. Nucleosides with an unmodified DNA or RNA sugar moiety are termed DNA or RNA nucleosides herein. Nucleosides with modifications in the base region of the DNA or RNA nucleoside are still generally termed DNA or RNA if they allow Watson Crick base pairing. Exemplary modified nucleosides which may be used in the antisense oligonucleotide progranulin agonists of the invention include LNA, 2′-O-MOE, 2′oMe and morpholino nucleoside analogues.
  • Modified Internucleoside Linkage
  • Advantageously, the antisense oligonucleotide progranulin agonist of the invention comprises one or more modified internucleoside linkage.
  • The term “modified internucleoside linkage” is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couple two nucleosides together. The antisense oligonucleotide progranulin agonists of the invention may therefore comprise one or more modified internucleoside linkages such as one or more phosphorothioate internucleoside linkage.
  • In some embodiments at least 50% of the internucleoside linkages in the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof, are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90% or more of the internucleoside linkages in the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the antisense oligonucleotide progranulin agonist, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • Advantageously, all the internucleoside linkages of the contiguous nucleotide sequence of the antisense oligonucleotide progranulin agonist may be phosphorothioate, or all the internucleoside linkages of the antisense oligonucleotide progranulin agonist may be phosphorothioate linkages.
  • Nucleobase
  • The term nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention the term nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but which are functional during nucleic acid hybridization. In this context “nucleobase” refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.
  • In some embodiments the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2′thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.
  • The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine. Optionally, for LNA gapmers, 5-methyl cytosine LNA nucleosides may be used.
  • Modified Oligonucleotide
  • The antisense oligonucleotide progranulin agonist of the invention may be a modified oligonucleotide.
  • The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages. The term “chimeric oligonucleotide” is a term that has been used in the literature to describe oligonucleotides comprising sugar modified nucleosides and DNA nucleosides. In some embodiments, it may be advantageous for the antisense oligonucleotide progranulin agonist of the invention to be a chimeric oligonucleotide.
  • Complementarity
  • The term “complementarity” describes the capacity for Watson-Crick base-pairing of nucleosides/nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U).
  • It will be understood that oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-paring between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).
  • The term “% complementary” as used herein, refers to the proportion of nucleotides (in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are complementary to a reference sequence (e.g. a target sequence or sequence motif). The percentage of complementarity is thus calculated by counting the number of aligned nucleobases that are complementary (from Watson Crick base pairs) between the two sequences (when aligned with the target sequence 5′-3′ and the oligonucleotide sequence from 3′-5′), dividing that number by the total number of nucleotides in the oligonucleotide and multiplying by 100. In such a comparison a nucleobase/nucleotide which does not align (form a base pair) is termed a mismatch. Insertions and deletions are not allowed in the calculation of complementarity of a contiguous nucleotide sequence. It will be understood that in determining complementarity, chemical modifications of the nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5′-methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • Within the present invention the term “complementary” requires the antisense oligonucleotide progranulin agonist to be at least about 80% complementary, or at least about 90% complementary, to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript. In some embodiments the antisense oligonucleotide progranulin agonist may be at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% complementary to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript. Put another way, for some embodiments, an antisense oligonucleotide progranulin agonist of the invention may include one, two, three or more mis-matches, wherein a mis-match is a nucleotide within the antisense oligonucleotide progranulin agonist of the invention which does not base pair with its target.
  • The term “fully complementary”, refers to 100% complementarity.
  • The antisense oligonucleotide progranulin agonists of the invention are advantageously complementary to the human progranulin precursor mRNA (pre-mRNA) or the human prograulin mature mRNA sequence. The human progranulin mature mRNA sequence is exemplified herein as SEQ ID NO 1. The human progranulin precursor-mRNA (pre-mRNA) sequence is exemplified herein as SEQ ID NO 3949. SEQ ID NO 1 and SEQ ID NO 3949 are provided herein as reference sequences and it will be understood that the target progranulin nucleic acid may be an allelic variant of SEQ ID NO 1 or SEQ ID NO 3949, such as an allelic variant which comprises one or more polymorphism in the human progranulin nucleic acid sequence.
  • Identity
  • The term “identity” as used herein, refers to the proportion of nucleotides (expressed in percent) of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which across the contiguous nucleotide sequence, are identical to a reference sequence (e.g. a sequence motif).
  • The percentage of identity is thus calculated by counting the number of aligned nucleobases that are identical (a Match) between two sequences (in the contiguous nucleotide sequence of the compound of the invention and in the reference sequence), dividing that number by the total number of nucleotides in the oligonucleotide and multiplying by 100. Therefore, Percentage of Identity=(Matches×100)/Length of aligned region (e.g. the contiguous nucleotide sequence). Insertions and deletions are not allowed in the calculation the percentage of identity of a contiguous nucleotide sequence. It will be understood that in determining identity, chemical modifications of the nucleobases are disregarded as long as the functional capacity of the nucleobase to form Watson Crick base pairing is retained (e.g. 5-methyl cytosine is considered identical to a cytosine for the purpose of calculating % identity).
  • Hybridization
  • The terms “hybridizing” or “hybridizes” as used herein are to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex. The affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (Tm) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions Tm is not strictly proportional to the affinity (Mergny and Lacroix, 2003, Oligonucleotides 13:515-537). The standard state Gibbs free energy ΔG° is a more accurate representation of binding affinity and is related to the dissociation constant (Kd) of the reaction by ΔG°=−RTln(Kd), where R is the gas constant and T is the absolute temperature. Therefore, a very low ΔG° of the reaction between an oligonucleotide and the target nucleic acid reflects a strong hybridization between the oligonucleotide and target nucleic acid. ΔG° is the energy associated with a reaction where aqueous concentrations are 1M, the pH is 7, and the temperature is 37° C. The hybridization of oligonucleotides to a target nucleic acid is a spontaneous reaction and for spontaneous reactions ΔG° is less than zero. ΔG° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965, Chem. Comm. 36-38 and Holdgate et al., 2005, Drug Discov Today. The skilled person will know that commercial equipment is available for ΔG° measurements. ΔG° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998, Proc Natl Acad Sci USA. 95: 1460-1465 using appropriately derived thermodynamic parameters described by Sugimoto et al., 1995, Biochemistry 34:11211-11216 and McTigue et al., 2004, Biochemistry 43:5388-5405.
  • In some embodiments, antisense oligonucleotide progranulin agonists of the present invention hybridize to a target nucleic acid with estimated ΔG° values below −10 kcal for oligonucleotides that are 10-30 nucleotides in length.
  • In some embodiments the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. The oligonucleotides may hybridize to a target nucleic acid with estimated ΔG° values below the range of −10 kcal, such as below −15 kcal, such as below −20 kcal and such as below −25 kcal for oligonucleotides that are 8-30 nucleotides in length. In some embodiments the oligonucleotides hybridize to a target nucleic acid with an estimated ΔG° value of −10 to −60 kcal, such as −12 to −40, such as from −15 to −30 kcal, or −16 to −27 kcal such as −18 to −25 kcal.
  • High Affinity Modified Nucleosides
  • A high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (Tm). A high affinity modified nucleoside of the present invention preferably results in an increase in melting temperature between +0.5 to +12° C., more preferably between +1.5 to +10° C. and most preferably between +3 to +8° C. per modified nucleoside. Numerous high affinity modified nucleosides are known in the art and include for example, many 2′ substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).
  • Sugar Modifications
  • The antisense oligonucleotide progranulin agonist of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.
  • Numerous nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.
  • Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.
  • Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2′-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2′, 3′, 4′ or 5′ positions.
  • 2′ Sugar Modified Nucleosides
  • A 2′ sugar modified nucleoside is a nucleoside which has a substituent other than H or —OH at the 2′ position (2′ substituted nucleoside) or comprises a 2′ linked biradicle capable of forming a bridge between the 2′ carbon and a second carbon in the ribose ring, such as LNA (2′-4′ biradicle bridged) nucleosides.
  • Indeed, much focus has been spent on developing 2′ sugar substituted nucleosides, and numerous 2′ substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides. For example, the 2′ modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide. Examples of 2′ substituted modified nucleosides are 2′-O-alkyl-RNA, 2′-O-methyl-RNA (2′oMe), 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-F-ANA nucleoside. For further examples, please see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2′ substituted modified nucleosides.
  • Figure US20230287412A1-20230914-C00002
  • In relation to the present invention 2′ substituted sugar modified nucleosides does not include 2′ bridged nucleosides like LNA.
  • Locked Nucleic Acid Nucleosides (LNA Nucleoside)
  • A “LNA nucleoside” is a 2′-modified nucleoside which comprises a biradical linking the C2′ and C4′ of the ribose sugar ring of said nucleoside (also referred to as a “2′-4′ bridge”), which restricts or locks the conformation of the ribose ring. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature. The locking of the conformation of the ribose is associated with an enhanced affinity of hybridization (duplex stabilization) when the LNA is incorporated into an oligonucleotide for a complementary RNA or DNA molecule. This can be routinely determined by measuring the melting temperature of the oligonucleotide/complement duplex.
  • Non limiting, exemplary LNA nucleosides are disclosed in WO 99/014226, WO 00/66604, WO 98/039352, WO 2004/046160, WO 00/047599, WO 2007/134181, WO 2010/077578, WO 2010/036698, WO 2007/090071, WO 2009/006478, WO 2011/156202, WO 2008/154401, WO 2009/067647, WO 2008/150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol 75(5) pp. 1569-81, and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, and Wan and Seth, J. Medical Chemistry 2016, 59, 9645-9667.
  • Further non limiting, exemplary LNA nucleosides are disclosed in Scheme 1.
  • Figure US20230287412A1-20230914-C00003
  • Particular LNA nucleosides are beta-D-oxy-LNA, 6′-methyl-beta-D-oxy LNA such as (S)-6′-methyl-beta-D-oxy-LNA (ScET) and ENA.
  • A particularly advantageous LNA is beta-D-oxy-LNA.
  • Morpholino Oligonucleotides
  • In some embodiments, the antisense oligonucleotide progranulin agonist of the invention comprises or consists of morpholino nucleosides (i.e. is a Morpholino oligomer and as a phosphorodiamidate Morpholino oligomer (PMO)). Splice modulating morpholino oligonucleotides have been approved for clinical use—see for example eteplirsen, a 30nt morpholino oligonucleotide targeting a frame shift mutation in DMD, used to treat Duchenne muscular dystrophy. Morpholino oligonucleotides have nucleobases attached to six membered morpholine rings rather ribose, such as methylenemorpholine rings linked through phosphorodiamidate groups, for example as illustrated by the following illustration of 4 consecutive morpholino nucleotides:
  • Figure US20230287412A1-20230914-C00004
  • In some embodiments, morpholino oligonucleotides of the invention may be, for example 20-40 morpholino nucleotides in length, such as morpholino 25-35 nucleotides in length.
  • RNase H Activity and Recruitment
  • The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule. WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. Typically an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10%, at least 20% or more than 20%, of the initial rate determined when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Examples 91-95 of WO01/23613 (hereby incorporated by reference). For use in determining RHase H activity, recombinant RNase H1 is available from Lubio Science GmbH, Lucerne, Switzerland.
  • DNA oligonucleotides are known to effectively recruit RNaseH, as are gapmer oligonucleotides which comprise a region of DNA nucleosides (typically at least 5 or 6 contiguous DNA nucleosides), flanked 5′ and 3′ by regions comprising 2′ sugar modified nucleosides, typically high affinity 2′ sugar modified nucleosides, such as 2-O-MOE and/or LNA. For effective modulation of splicing, degradation of the pre-mRNA is not desirable, and as such it is preferable to avoid the RNaseH degradation of the target. Therefore, the antisense oligonucleotide progranulin agonists of the invention are not RNaseH recruiting gapmer oligonucleotide.
  • RNaseH recruitment may be avoided by limiting the number of contiguous DNA nucleotides in the oligonucleotide—therefore mimxes and totalmer designs may be used. Advanateously the antisense oligonucleotide progranulin agonistd of the invention, or the contiguous nucleotide sequence thereof, do not comprise more than 3 contiguous DNA nucleosides. Further, advanateously the antisense oligonucleotide progranulin agonists of the invention, or the contiguous nucleotide sequence thereof, do not comprise more than 4 contiguous DNA nucleosides. Further advantageously, the progranulin agonist antisense oligonucleotide agonists of the invention, or contiguous nucleotide sequence thereof, do not comprise more than 2 contiguous DNA nucleosides.
  • Mixmers and Totalmers
  • For splice modulation it is often advantageous to use antisense oligonucleotides which do not recruit RNAaseH. As RNaseH activity requires a contiguous sequence of DNA nucleotides, RNaseH activity of antisense oligonucleotide may be achieved by designing antisense oligonucleotides which do not comprise a region of more than 3 or more than 4 contiguous DNA nucleosides. This may be achieved by using antisense oligonucleotides or contiguous nucleoside regions thereof with a mixmer design, which comprise sugar modified nucleosides, such as 2′ sugar modified nucleosides, and short regions of DNA nucleosides, such as 1, 2 or 3 DNA nucleosides. Mixmers are exemplified herein by every second design, wherein the nucleosides alternate between 1 LNA and 1 DNA nucleoside, e.g. LDLDLDLDLDLDLDLL, with 5′ and 3′ terminal LNA nucleosides, and every third design, such as LDDLDDLDDLDDLDDL, where every third nucleoside is a LNA nucleoside.
  • A totalmer is an antisense oligonucleotide or a contiguous nucleotide sequence thereof which does not comprise DNA or RNA nucleosides, and may for example comprise only 2′-O-MOE nucleosides, such as a fully MOE phosphorothioate, e.g. MMMMMMMMMMMMMMMMMMMM, where M=2′-O-MOE, or may for example comprise only 2′oMe nucleosides, which are reported to be effective splice modulators for therapeutic use.
  • Alternatively, a mixmer may comprise a mixture of modified nucleosides, such as MLMLMLMLMLMLMLMLMLML, wherein L=LNA and M=2′-O-MOE nucleosides. Advantageously, the internucleoside nucleosides in mixmers and totalmers may be phosphorothioate, or a majority of nucleoside linkages in mixmers may be phosphorothioate. Mixmers and totalmers may comprise other internucleoside linkages, such as phosphodiester or phosphorodithioate, by way of example.
  • Region D′ or D″ in an Oligonucleotide
  • The antisense oligonucleotide progranulin agonist of the invention may in some embodiments comprise or consist of the contiguous nucleotide sequence of the oligonucleotide which is complementary to the target nucleic acid, such as a mixmer or toalmer region, and further 5′ and/or 3′ nucleosides. The further 5′ and/or 3′ nucleosides may or may not be complementary, such as fully complementary, to the target nucleic acid. Such further 5′ and/or 3′ nucleosides may be referred to as region D′ and D″ herein.
  • The addition of region D′ or D″ may be used for the purpose of joining the contiguous nucleotide sequence, such as the mixmer or totoalmer, to a conjugate moiety or another functional group. When used for joining the contiguous nucleotide sequence with a conjugate moiety is can serve as a biocleavable linker. Alternatively, it may be used to provide exonucleoase protection or for ease of synthesis or manufacture.
  • Region D′ or D″ may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. The nucleotide adjacent to the F or F′ region is not a sugar-modified nucleotide, such as a DNA or RNA or base modified versions of these. The D′ or D′ region may serve as a nuclease susceptible biocleavable linker (see definition of linkers). In some embodiments the additional 5′ and/or 3′ end nucleotides are linked with phosphodiester linkages, and are DNA or RNA. Nucleotide based biocleavable linkers suitable for use as region D′ or D″ are disclosed in WO2014/076195, which include by way of example a phosphodiester linked DNA dinucleotide. The use of biocleavable linkers in poly-oligonucleotide constructs is disclosed in WO2015/113922, where they are used to link multiple antisense constructs within a single oligonucleotide.
  • In one embodiment the antisense oligonucleotide progranulin agonist of the invention comprises a region D′ and/or D″ in addition to the contiguous nucleotide sequence which constitutes a mixmer or a totalmer.
  • In some embodiments the internucleoside linkage positioned between region D′ or D″ and the mixmer or totalmer region is a phosphodiester linkage.
  • Conjugate
  • The invention encompasses an antisense oligonucleotide progranulin agonist covalently attached to at least one conjugate moiety. In some embodiments this may be referred to as a conjugate of the invention.
  • The term “conjugate” as used herein refers to an antisense oligonucleotide progranulin agonist which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region). The conjugate moiety may be covalentaly linked to the antisense oligonucleotide, optionally via a linker group, such as region D′ or D″.
  • Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S. T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103.
  • In some embodiments, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates (e.g. GalNAc), cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.
  • Linkers
  • A linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds. Conjugate moieties can be attached to the antisense oligonucleotide progranulin agonist directly or through a linking moiety (e.g. linker or tether). Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A).
  • In some embodiments of the invention the conjugate or antisense oligonucleotide progranulin agonist conjugate of the invention may optionally comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).
  • Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body. Conditions under which physiologically labile linkers undergo chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells. Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases. In one embodiment the biocleavable linker is susceptible to S1 nuclease cleavage. In some embodiments the nuclease susceptible linker comprises between 1 and 5 nucleosides, such as DNA nucleoside(s) comprising at least two consecutive phosphodiester linkages. Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195.
  • Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region). The region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups The antisense oligonucleotide progranulin agonist conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C. In some embodiments the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In some embodiments the linker (region Y) is a C6 amino alkyl group.
  • Treatment
  • The term ‘treatment’ as used herein refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, i.e. prophylaxis. It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The inventors have identified that the expression level of the progranulin transcript can be effectively enhanced by targeting the progranulin precursor-mRNA (pre-mRNA) transcript or the progranulin mature mRNA sequence with antisense oligonucleotides, particularly antisense oligonucleotides which comprise high affinity sugar modified nucleosides, such as high affinity 2′ sugar modified nucleosides, such as LNA nucleosides or 2′-O-methoxyethyl (MOE) nucleosides.
  • Described herein are target sites present on the human progranulin nucleic acid target, such as a progranulin precursor-mRNA (pre-mRNA) or mature mRNA sequence, which can be targeted by antisense oligonucleotide agonists of progranulin.
  • The inventors have surprisingly determined that targeting the 5′ UTR and 3′ UTR of the progranulin mature mRNA can be particularly effective.
  • The 5′ UTR contains upstream start sites (AUG sites), also known as upstream open reading frames (uORFs). Without wishing to be bound by theory, it is considered that the antisense oligonucleotide progranulin agonists of the invention can increase progranulin production by binding to these regions and affecting, such as reducing, protein translation from these upstream AUG sites. This ensures that protein translation is initiated from the downstream canonical start site (ORF), increasing progranulin production.
  • The 3′ UTR contains binding sites for microRNAs. Without wishing to be bound by theory, it is considered that the antisense oligonucleotide progranulin agonists of the invention may regulate gene expression by binding to these sites in the 3′UTR and preventing microRNA-induced repression of gene expression, leading to increased progranulin production.
  • Oligonucleotides, such as RNaseH recruiting single stranded antisense oligonucleotides or siRNAs are used extensively in the art to inhibit target RNAs—i.e. are used as antagonists of their complementary nucleic acid target.
  • The antisense oligonucleotide of the present invention are agonists, i.e. enhance the expression of their complementary target, progranulin nucleic acids, and thereby enhance the expression of progranulin protein. Enhanced progranulin expression is desirable to treat a range of neurological disorders, such as TDP-43 pathologies, or disorders which are characterized by, or caused by progranulin haploinsufficiency.
  • In certain embodiments the antisense oligonucleotide progranulin agonists of the present invention may enhance the production of their complementary target, progranulin nucleic acids, by at least about 10%. In other embodiments the antisense oligonucleotide progranulin agonists of the present invention may enhance the production of their complementary target, progranulin nucleic acids, by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50% or more, at least about 60% or more, at least about 70% or more, at least about 80% or more, at least about 90% or more, at least about 100% or more, at least about 200% or more, at least about 300% or more, at least about 400% or more, or at least about 500% or more.
  • In some embodiments, the antisense oligonucleotide progranulin agonist of the invention or the contiguous nucleotide sequence thereof comprises or consists of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 contiguous nucleotides in length.
  • In some embodiments, the entire nucleotide sequence of the antisense oligonucleotide is the contiguous nucleotide sequence.
  • In some embodiments the contiguous nucleotide sequence is complementary to a 5′UTR region of a human progranulin mature mRNA transcript. The contiguous nucleotide sequence may be fully complementary to a 5′UTR region of a human progranulin mature mRNA transcript. As indicated above, and without wishing to be bound by theory, targeting the 5′UTR may increase progranulin expression by binding to upstream start sites (AUG sites) and affecting, such as reducing, protein translation from these upstream AUG sites. This ensures that protein translation is initiated from the downstream canonical start site (ORF), increasing progranulin production.
  • In some embodiments the contiguous nucleotide sequence may be complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 343-586.
  • In another embodiment the contiguous nucleotide sequence may be complementary to nucleotides 38-246 of SEQ ID NO 1.
  • In another embodiment the contiguous nucleotide sequence may be fully complementary to SEQ ID NO 2, or SEQ ID NO 689.
  • In another embodiment the contiguous nucleotide sequence may be fully complementary to a sequence selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584 & SEQ ID NO 586.
  • In one embodiment the contiguous nucleotide sequence may a sequence selected from the group consisting of SEQ ID NO 3-342. The invention also contemplates fragements of these contiguous nucleotide sequences, including fragments of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 contiguous nucleotides thereof.
  • In certain embodiments the contiguous nucleotide sequence may be selected from the group consisting of SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241. The invention also contemplates fragements of these contiguous nucleotide sequences, including fragments of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 contiguous nucleotides thereof.
  • In some embodiments the contiguous nucleotide sequence is complementary to a 3′UTR region of a human progranulin mature mRNA transcript. The contiguous nucleotide sequence may be fully complementary to a 3′UTR region of a human progranulin mature mRNA transcript. As indicated above, and without wishing to be bound by theory, the antisense oligonucleotide progranulin agonists of the invention may regulate gene expression by binding to microRNA sites in the 3′UTR and preventing microRNA-induced repression of gene expression, leading to increased progranulin production.
  • In some embodiments the contiguous nucleotide sequence may be complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 587-682.
  • In another embodiment the contiguous nucleotide sequence may be complementary to nucleotides 2039-2346 of SEQ ID NO 1.
  • In another embodiment the contiguous nucleotide sequence may be fully complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
  • In another embodiment the contiguous nucleotide sequence may be fully complementary to a sequence selected from the group consisting of SEQ ID NOs 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
  • In some embodiments, the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of sequences SEQ ID NO 3-342. It will be understood that the sequences shown in SEQ ID NO 3-342 may include modified nucleobases which function as the shown nucleobase in base pairing, for example 5-methyl cytosine may be used in place of methyl cytosine. Inosine may be used as a universal base.
  • In some embodiments, the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence comprises or consists of 8 to 30 or 8 to 40 nucleotides in length with at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NO: 3 to 342. In some embodiments the antisense oligonucleotide progranulin agonist may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
  • Without wishing to be bound by theory, it is considered that the antisense oligonucleotide progranulin agonists of the invention which bind to target sites outside the 5′ UTR and 3′ UTR regions of the progranulin mature mRNA may increase progranulin protein expression. This increased progranulin protein expression may occur as a result of effects of the antisense oligonucleotide progranulin agonists on secondary regulatory mRNA structures and/or on binding of RNA binding proteins that would otherwise negatively affect protein translation or progranulin mRNA stability.
  • It is understood that the contiguous nucleobase sequences (motif sequence) can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid.
  • The pattern in which the modified nucleosides (such as high affinity modified nucleosides) are incorporated into the oligonucleotide sequence is generally termed oligonucleotide design.
  • The antisense oligonucleotide progranulin agonists of the invention are designed with modified nucleosides and DNA nucleosides. Advantageously, high affinity modified nucleosides are used.
  • In an embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides.
  • In an embodiment the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides. Suitable modifications are described in the “Definitions” section under “modified nucleoside”, “high affinity modified nucleosides”, “sugar modifications”, “2′ sugar modifications” and Locked nucleic acids (LNA)”.
  • In an embodiment, the antisense oligonucleotide progranulin agonist comprises one or more sugar modified nucleosides, such as 2′ sugar modified nucleosides. Preferably the antisense oligonucleotide progranulin agonist of the invention comprises one or more 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA (2′oMe), 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (2′MOE), 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides. It is advantageous if one or more of the modified nucleoside(s) is a locked nucleic acid (LNA).
  • In a further embodiment the antisense oligonucleotide progranulin agonist comprises at least one modified internucleoside linkage. Suitable internucleoside modifications are described in the “Definitions” section under “Modified internucleoside linkage”. It is advantageous if at least 75%, such as all, the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages. In some embodiments all the internucleotide linkages in the contiguous sequence of the oligonucleotide are phosphorothioate linkages.
  • An antisense oligonucleotide progranulin agonist may have the structure:
  • Figure US20230287412A1-20230914-C00005
  • The invention also includes an antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
  • Numbered Paragraphs of the Invention
  • Aspects of the present invention will now be described by way of numbered paragraphs.
  • 1. An antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are fully complementary to a human progranulin pre-mRNA or mRNA transcript, such as SEQ ID NO 1.
  • 2. The antisense oligonucleotide according to paragraph 1, wherein the contiguous nucleotide sequence is of a length of at least 12 nucleotides in length, such as 12-16 or 12-18 nucleotides in length.
  • 3. The antisense oligonucleotide according to paragraph 1 or 2, wherein the contiguous nucleotide sequence is the same length as the antisense oligonucleotide.
  • 4. The antisense oligonucleotide according to any one of paragraphs 1-3, wherein contiguous nucleotide sequence is fully complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 343-682.
  • 5. The antisense oligonucleotide according to any one of paragraphs 1-4, wherein contiguous nucleotide sequence is fully complementary to a 5′UTR region of a human progranulin mRNA transcript.
  • 6. The antisense oligonucleotide according to any one of paragraphs 1-5, wherein contiguous nucleotide sequence is fully complementary to nucleotides 38-246 of SEQ ID NO 1.
  • 7. The antisense oligonucleotide according to any one of paragraphs 1-6, wherein contiguous nucleotide sequence is fully complementary to SEQ ID NO 2, or SEQ ID NO 689.
  • 8. The antisense oligonucleotide according to any one of paragraphs 1-7, wherein the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 568, 571, 575, 576, 577, 578, 584 & 586.
  • 9. The antisense oligonucleotide according to any one of paragraphs 1-4, wherein contiguous nucleotide sequence is fully complementary to a 3′UTR region of a human progranulin mRNA transcript.
  • 10. The antisense oligonucleotide according to any one of paragraphs 1-4 or 9, wherein contiguous nucleotide sequence is fully complementary to nucleotides 2039-2346 of SEQ ID NO 1.
  • 11. The antisense oligonucleotide according to any one of paragraphs 1-4, 9 or 10 wherein contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 684, 685, 683, 686, 687, and 688.
  • 12. The antisense oligonucleotide according to any one of paragraphs 1-4, 9, 10, or 11 wherein contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NOs 607, 608, 609, 610, 611, 612, 619, 620, 633, 640, 641, 645, 651, and 652.
  • 13. The antisense oligonucleotide according to any one of paragraphs 1-12, wherein contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 8 or at least 10 contiguous nucleotides thereof.
  • 14. The antisense oligonucleotide according to any one of paragraphs 1-13, wherein the oligonucleotide is or comprises an antisense oligonucleotide mixmer or totalmer.
  • 15. The antisense oligonucleotide of any one of paragraphs 1-14, wherein the antisense oligonucleotide or contiguous nucleotide sequence thereof is 10-20 nucleotides in length.
  • 16. The antisense oligonucleotide according to paragraph 1, wherein the antisense oligonucleotide is selected from the group consisting of COMP ID NOs 3-342.
  • 17. A conjugate comprising the antisense oligonucleotide according to any one of paragraphs 1-16, and at least one conjugate moiety covalently attached to said oligonucleotide.
  • 18. A pharmaceutically acceptable salt of the antisense oligonucleotide according to any one of paragraphs 1-16, or the conjugate according to paragraph 17.
  • 19. The pharmaceutically acceptable salt of paragraph 18, wherein the salt is a sodium salt or a potassium salt.
  • 20. A pharmaceutical composition comprising the antisense oligonucleotide of paragraph 1-16 or the conjugate of paragraph 17 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • 21. A pharmaceutical composition according to paragraph 20, wherein the pharmaceutical composition comprises the antisense oligonucleotide of paragraph 1-16 or the conjugate of paragraph 17, or the pharmaceutically acceptable salt of paragraph 18 or 19 and an aqueous diluent or solvent, such as phosphate buffered saline.
  • 22. An in vivo or in vitro method for enhancing the expression of progranulin in a cell which is expressing progranulin, said method comprising administering an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 in an effective amount to said cell.
  • 23. The method according to paragraph 22, wherein the cell is either a human cell or a mammalian cell.
  • 24. A method for treating or preventing neurological disease comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 to a subject suffering from or susceptible to neurological disease.
  • 25. The antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 for use as a medicament.
  • 26. The an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 for use in the treatment of a neurological disease, such as a TDP-43 pathology.
  • 27. The an antisense oligonucleotide of any one of paragraphs 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 for use in the treatment of progranulin haploinsufficiency.
  • 28. Use of the antisense oligonucleotide of paragraph 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21 for the preparation of a medicament for treatment or prevention of a neurological disease, such as a TDP-43 pathology.
  • 29. Use of the antisense oligonucleotide of paragraph 1-16 or the conjugate according to paragraph 17, or the salt according to paragraph 18 or 19, or the pharmaceutical composition according to paragraph 20 or 21, for the preparation of a medicament for treatment of progranulin haploinsufficiency.
  • 30. The method or use according to any one of paragraphs 22-29, wherein the method or use is for the treatment of fronto temporal dementia (FTD), neuropathologic frontotemporal lobar degeneration or neuroinflammation.
    • NUMBERED EMBODIMENTS OF THE INVENTION
  • Numbered embodiments of the present invention will now be described.
  • 1. An antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary to a human progranulin pre-mRNA or mRNA transcript.
  • 2. The antisense oligonucleotide progranulin agonist according to embodiment 1, wherein the contiguous nucleotide sequence is of a length of at least 12 nucleotides in length.
  • 3. The antisense oligonucleotide progranulin agonist according to embodiment 1 or embodiment 2, wherein the contiguous nucleotide sequence is the same length as the antisense oligonucleotide.
  • 4. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-3, wherein the contiguous nucleotide sequence is complementary to a 5′UTR region of a human progranulin mRNA transcript.
  • 5. The antisense oligonucleotide progranulin agonist according to embodiment 4, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, or a sequence selected from the group consisting of SEQ ID NO 343-586.
  • 6. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-5, wherein the contiguous nucleotide sequence is selected from SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241 or at least 8 or at least 10 contiguous nucleotides thereof.
  • 7. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-3, wherein contiguous nucleotide sequence is complementary to a 3′UTR region of a human progranulin mRNA transcript.
  • 8. The antisense oligonucleotide progranulin agonist according to embodiment 7, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 587-682.
  • 9. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-8, wherein the antisense oligonucleotide progranulin agonist is or comprises an antisense oligonucleotide mixmer or totalmer.
  • 10. An antisense oligonucleotide progranulin agonist having the structure:
  • Figure US20230287412A1-20230914-C00006
  • 11. An antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
  • 12. An in vivo or in vitro method for enhancing the expression of progranulin in a cell which is expressing progranulin, said method comprising administering an antisense oligonucleotide progranulin agonist according to any one of embodiments 1-11 in an effective amount to said cell.
  • 13. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-11, for use in the treatment of a neurological disease.
  • 14. The antisense oligonucleotide progranulin agonist or pharmaceutical composition for use in the treatment of a neurological disease according to embodiment 13, wherein the neurological disease is a TDP-43 pathology.
  • 15. The antisense oligonucleotide progranulin agonist according to any one of embodiments 1-11 for use in the treatment of progranulin haploinsufficiency.
    • EXAMPLES Example 1
  • GRN 5′ UTR Luciferase Reporter Constructs
  • The GRN 5′ UTR sequence (SEQ ID #690) was cloned into the psiCHECK2 plasmid (Promega) immediately in front of the renilla luciferase ATG site using the Q5 site-directed mutagenesis kit (New England Biolabs) according to manufactorer's instruction.
  • 5′ UTR sequence from nucleotide number 38 to 256 according to Homo sapiens granulin precursor (GRN), RefSeq NM_002087.3 (SEQ ID NO 1):
  • SEQ 690
    ID#GGCGAGAGGAAGCAGGGAGGAGAGTGATTTGAGTAGAAAAGAAACA
    CAGCATTCCAGGCTGGCCCCACCTCTATATTGATAAGTAGCCAATGGGA
    GCGGGTAGCCCTGATCCCTGGCCAATGGAAACTGAGGTAGGCGGGTCAT
    CGCGCTGGGGTCTGTAGTCTGAGCGCTACCCGGTTGCTGCTGCCCAAGG
    ACCGCGGAGTCGGACGCAGGCAGACC
  • For the site-directed mutagenesis and insertion of the GRN 5′ UTR the following primers were used:
  • Forward primer
    SEQ ID NO 691
    5′-ATGGAAACTGAGGTAGGCGGGTCATCGCGCTGGGGTCTGTAGTCTG
    AGCGCTACCCGGTTGCTGCTGCCCAAGGACCGCGGAGTCGGACGCAGGC
    AGACCATGGCTTCCAAGGTGTACGACCCCGAGC-3′
    and
    reverse primer
    SEQ ID NO 692
    5′-TGGCCAGGGATCAGGGCTACCCGCTCCCATTGGCTACTTATCAATA
    TAGAGGTGGGGCCAGCCTGGAATGCTGTGTTTCTTTTCTACTCAAATCA
    CTCTCCTCCCTGCTTCCTCTCGCCGGCTAGCCTATAGTGAGTCGTATTA
    AGTAC
  • After transformation of chemical competent bacteria (One Shot TOP10 Chemically Competent E. coli, Thermofisher) and overnight growth on LB agar plates containing ampicillin (imMedia Growth Medium, agar, ampicillin, Thermofisher), single colonies were selected and further grown overnight with constant shaking at 37 Degrees Celcius in LB broth medium containing ampicillin (50 μg/mL) (Thermofisher). Final mini- and midi-prep plasmid purifications were done according to vendors instruction (Qiagen). The inserted 5′ UTR GRN sequences were verified using Sanger sequencing (Eurofins Genomics, Ebersberg, Germany).
    • Example 2
  • GRN 3′ UTR Luciferase Reporter Constructs
  • The GRN 3′ UTR (SEQ ID #2) was cloned into the psiCHECK2 plasmid (Promega) after the renilla luciferase coding sequence using the psiCHECK2 multiple cloning site and the XhoI and NotI restriction sites.
  • 3′ UTR sequence from nucleotide number 2039 to 2346 according to Homo sapiens granulin precursor (GRN), RefSeq NM_002087.3 (SEQ ID NO 1).
  • SEQ ID#2:
    GGGACAGTACTGAAGACTCTGCAGCCCTCGGGACCCCACTCGGAGGGTG
    CCCTCTGCTCAGGCCTCCCTAGCACCTCCCCCTAACCAAATTCTCCCTG
    GACCCCATTCTGAGCTCCCCATCACCATGGGAGGTGGGGCCTCAATCTA
    AGGCCTTCCCTGTCAGAAGGGGGTTGTGGCAAAAGCCACATTACAAGCT
    GCCATCCCCTCCCCGTTTCAGTGGACCCTGTGGCCAGGTGCTTTTCCCT
    ATCCACAGGGGTGTTTGTGTGTGTGCGCGTGTGCGTTTCAATAAAGTTT
    GTACACTTTCTTAA
  • Double stranded DNA fragment (gBlock, Integrated DNA technologies) containing the GRN 3′ UTR (SEQ ID #2) flanked by XhoI and NotI sites was cut by XhoI and NotI enzymes (New England Biolabs) according to vendors protocol and ligated using T4 Ligase (New England Biolabs) into the previously XhoI/NotI cut psiCHECK2 plasmid.
  • After transformation of chemical competent bacteria (One Shot® TOP10 Chemically Competent E. coli, Thermofisher) and overnight growth on LB agar plates containing ampicillin (imMedia Growth Medium, agar, ampicilin, Thermofisher), single colonies were selected and further grown overnight with constant shaking at 37 Degrees Celcius in LB broth medium containing ampicillin (50 μg/mL) (Thermofisher). Final mini- and midiprep plasmid purifications were done according to vendors instruction (Qiagen). The inserted 3′ UTR GRN sequence was verified using Sanger sequencing (Eurofins Genomics, Ebersberg, Germany).
    • Example 3 Luciferase Reporter Assays
  • The day before transfection, 15000 HeLa cells per well were seeded in 96-well plates (Nunc™ F96 MicroWell™ White Polystyrene Plates) in 100 μL full growth medium. The day at transfection, media is removed and the transfection mixture consisting of 80 μL Opti-MEM Reduced Serum Medium (ThermoFisher Scientific), 6.25 μg/mL Lipofectamine 2000 (ThermoFisher Scientific) and 100 ng psiCHECK2 plasmid with 5′ UTR/3′UTR of GRN is added to each well according to manufactorer's instructions (ThermoFisher Scientific). Shortly after, 20 μL of Opti-MEM Reduced Serum Medium with 500 nM of each antisense oligonucleotide is added to each well for a final concentration of 100 nM. Wells with seeded cells not exposed to transfection reagents are included to correct for background luciferase activity. After 6 hours incubation, transfection mixture is removed from all wells and replaced with full growth medium. The following day, media is removed and replaced with 75 μL PBS, and the Firefly luciferase activity is measured using the Dual-GLo luciferase system (Promega) according to vendors protocol and the EnSight Multimode. Plate Reader (Perkin Elmer). Measurement of The firefly luciferase activity is followed by measurement of the renilla luciferase activity. After correction of the background luciferase activity for each well, the relative luciferase activity is calculated by dividing the Renilla luciferase activity by the firefly luciferase activity for each well to correct for transfection efficiency. Finally, for each antisense oligonucleotides the relative luciferase activity is normalized to PBS transfected cells (PBS=1) and values >1 reflects that the respective antisense oligonucleotides have increased the activity/expression of the renilla luciferase activity.
    • Example 4
  • Antisense oligonucleotides were designed for the 5′ UTR from position 38 to 241 according to RefSeq NM_002087.3 (SEQ ID NO 1) with one nucleotide basepair shift as shown in table 1, which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • TABLE 1
    All the antisense oligonucleotides are designed as 16-mers DNA-LNA mixmers with a phosphorothioate
    backbone, LNA at the very 5′ and 3′ position and e.g. LNA for every 2nd or 3rd nucleotide (see
    Compound table).
    RefSeq Relative
    Oligonucleotide NM_002087.3 Target luciferase
    Compound ID Sequence Motif (SEQ ID NO 1) Site activity
    (See Compound (nucleobase Start End Sequence Target (Relative
    SEQ ID Table) Sequence) Position Position ID Site Sequence to PBS)
    SEQ ID 3 COMP ID 3 CCTGCTTCCTCTCGCC 38 53 SEQ ID GGCGAGAGGAAGCAGG 0,47
    343
    SEQ ID 4 COMP ID 4 CCCTGCTTCCTCTCGC 39 54 SEQ ID GCGAGAGGAAGCAGGG 0,60
    344
    SEQ ID 5 COMP ID 5 TCCCTGCTTCCTCTCG 40 55 SEQ ID CGAGAGGAAGCAGGGA 0,62
    345
    SEQ ID 6 COMP ID 6 CTCCCTGCTTCCTCTC 41 56 SEQ ID GAGAGGAAGCAGGGAG 0,65
    346
    SEQ ID 7 COMP ID 7 CCTCCCTGCTTCCTCT 42 57 SEQ ID AGAGGAAGCAGGGAGG 0,85
    347
    SEQ ID 8 COMP ID 8 TCCTCCCTGCTTCCTC 43 58 SEQ ID GAGGAAGCAGGGAGGA 0,81
    348
    SEQ ID 9 COMP ID 9 CTCCTCCCTGCTTCCT 44 59 SEQ ID AGGAAGCAGGGAGGAG 0,53
    349
    SEQ ID 10 COMP ID 10 TCTCCTCCCTGCTTCC 45 60 SEQ ID GGAAGCAGGGAGGAGA 0,80
    350
    SEQ ID 11 COMP ID 11 CTCTCCTCCCTGCTTC 46 61 SEQ ID GAAGCAGGGAGGAGAG 0,78
    351
    SEQ ID 12 COMP ID 12 ACTCTCCTCCCTGCTT 47 62 SEQ ID AAGCAGGGAGGAGAGT 0,78
    352
    SEQ ID 13 COMP ID 13 CACTCTCCTCCCTGCT 48 63 SEQ ID AGCAGGGAGGAGAGTG 0,53
    353
    SEQ ID 14 COMP ID 14 TCACTCTCCTCCCTGC 49 64 SEQ ID GCAGGGAGGAGAGTGA 0,66
    354
    SEQ ID 15 COMP ID 15 ATCACTCTCCTCCCTG 50 65 SEQ ID CAGGGAGGAGAGTGAT n.d.
    355
    SEQ ID 16 COMP ID 16 AATCACTCTCCTCCCT 51 66 SEQ ID AGGGAGGAGAGTGATT n.d.
    356
    SEQ ID 17 COMP ID 17 AAATCACTCTCCTCCC 52 67 SEQ ID GGGAGGAGAGTGATTT n.d.
    357
    SEQ ID 18 COMP ID 18 CAAATCACTCTCCTCC 53 68 SEQ ID GGAGGAGAGTGATTTG n.d.
    358
    SEQ ID 19 COMP ID 19 TCAAATCACTCTCCTC 54 69 SEQ ID GAGGAGAGTGATTTGA 0,56
    359
    SEQ ID 20 COMP ID 20 CTCAAATCACTCTCCT 55 70 SEQ ID AGGAGAGTGATTTGAG 0,58
    360
    SEQ ID 21 COMP ID 21 ACTCAAATCACTCTCC 56 71 SEQ ID GGAGAGTGATTTGAGT 0,50
    361
    SEQ ID 22 COMP ID 22 TACTCAAATCACTCTC 57 72 SEQ ID GAGAGTGATTTGAGTA 0,44
    362
    SEQ ID 23 COMP ID 23 CTACTCAAATCACTCT 58 73 SEQ ID AGAGTGATTTGAGTAG 0,61
    363
    SEQ ID 24 COMP ID 24 TCTACTCAAATCACTC 59 74 SEQ ID GAGTGATTTGAGTAGA 0,44
    364
    SEQ ID 25 COMP ID 25 TTCTACTCAAATCACT 60 75 SEQ ID AGTGATTTGAGTAGAA 0,47
    365
    SEQ ID 26 COMP ID 26 TTTCTACTCAAATCAC 61 76 SEQ ID GTGATTTGAGTAGAAA 0,57
    366
    SEQ ID 27 COMP ID 27 TTTTCTACTCAAATCA 62 77 SEQ ID TGATTTGAGTAGAAAA 0,49
    367
    SEQ ID 28 COMP ID 28 CTTTTCTACTCAAATC 63 78 SEQ ID GATTTGAGTAGAAAAG 0,54
    368
    SEQ ID 29 COMP ID 29 TCTTTTCTACTCAAAT 64 79 SEQ ID ATTTGAGTAGAAAAGA 0,49
    369
    SEQ ID 30 COMP ID 30 TTCTTTTCTACTCAAA 65 80 SEQ ID TTTGAGTAGAAAAGAA 0,38
    370
    SEQ ID 31 COMP ID 31 TTTCTTTTCTACTCAA 66 81 SEQ ID TTGAGTAGAAAAGAAA 0,59
    371
    SEQ ID 32 COMP ID 32 GTTTCTTTTCTACTCA 67 82 SEQ ID TGAGTAGAAAAGAAAC 0,44
    372
    SEQ ID 33 COMP ID 33 TGTTTCTTTTCTACTC 68 83 SEQ ID GAGTAGAAAAGAAACA 0,61
    373
    SEQ ID 34 COMP ID 34 GTGTTTCTTTTCTACT 69 84 SEQ ID AGTAGAAAAGAAACAC 0,56
    374
    SEQ ID 35 COMP ID 35 TGTGTTTCTTTTCTAC 70 85 SEQ ID GTAGAAAAGAAACACA 0,47
    375
    SEQ ID 36 COMP ID 36 CTGTGTTTCTTTTCTA 71 86 SEQ ID TAGAAAAGAAACACAG 0,36
    376
    SEQ ID 37 COMP ID 37 GCTGTGTTTCTTTTCT 72 87 SEQ ID AGAAAAGAAACACAGC 0,45
    377
    SEQ ID 38 COMP ID 38 TGCTGTGTTTCTTTTC 73 88 SEQ ID GAAAAGAAACACAGCA 0,58
    378
    SEQ ID 39 COMP ID 39 ATGCTGTGTTTCTTTT 74 89 SEQ ID AAAAGAAACACAGCAT 0,77
    379
    SEQ ID 40 COMP ID 40 AATGCTGTGTTTCTTT 75 90 SEQ ID AAAGAAACACAGCATT 0,53
    380
    SEQ ID 41 COMP ID 41 GAATGCTGTGTTTCTT 76 91 SEQ ID AAGAAACACAGCATTC 0,73
    381
    SEQ ID 42 COMP ID 42 GGAATGCTGTGTTTCT 77 92 SEQ ID AGAAACACAGCATTCC 0,77
    382
    SEQ ID 43 COMP ID 43 TGGAATGCTGTGTTTC 78 93 SEQ ID GAAACACAGCATTCCA 0,69
    383
    SEQ ID 44 COMP ID 44 CTGGAATGCTGTGTTT 79 94 SEQ ID AAACACAGCATTCCAG 0,63
    384
    SEQ ID 45 COMP ID 45 CCTGGAATGCTGTGTT 80 95 SEQ ID AACACAGCATTCCAGG 0,58
    385
    SEQ ID 46 COMP ID 46 GCCTGGAATGCTGTGT 81 96 SEQ ID ACACAGCATTCCAGGC 0,57
    386
    SEQ ID 47 COMP ID 47 AGCCTGGAATGCTGTG 82 97 SEQ ID CACAGCATTCCAGGCT 0,48
    387
    SEQ ID 48 COMP ID 48 CAGCCTGGAATGCTGT 83 98 SEQ ID ACAGCATTCCAGGCTG 0,62
    388
    SEQ ID 49 COMP ID 49 CCAGCCTGGAATGCTG 84 99 SEQ ID CAGCATTCCAGGCTGG 0,40
    389
    SEQ ID 50 COMP ID 50 GCCAGCCTGGAATGCT 85 100 SEQ ID AGCATTCCAGGCTGGC 0,32
    390
    SEQ ID 51 COMP ID 51 GGCCAGCCTGGAATGC 86 101 SEQ ID GCATTCCAGGCTGGCC 0,24
    391
    SEQ ID 52 COMP ID 52 GGGCCAGCCTGGAATG 87 102 SEQ ID CATTCCAGGCTGGCCC 0,15
    392
    SEQ ID 53 COMP ID 53 GGGGCCAGCCTGGAAT 88 103 SEQ ID ATTCCAGGCTGGCCCC 0,20
    393
    SEQ ID 54 COMP ID 54 TGGGGCCAGCCTGGAA 104 SEQ ID TTCCAGGCTGGCCCCA 0,62
    394
    SEQ ID 55 COMP ID 55 GTGGGGCCAGCCTGGA 90 105 SEQ ID TCCAGGCTGGCCCCAC 0,54
    395
    SEQ ID 56 COMP ID 56 GGTGGGGCCAGCCTGG 91 106 SEQ ID CCAGGCTGGCCCCACC 0,62
    396
    SEQ ID 57 COMP ID 57 AGGTGGGGCCAGCCTG 92 107 SEQ ID CAGGCTGGCCCCACCT 0,38
    397
    SEQ ID 58 COMP ID 58 GAGGTGGGGCCAGCCT 93 108 SEQ ID AGGCTGGCCCCACCTC 0,46
    398
    SEQ ID 59 COMP ID 59 AGAGGTGGGGCCAGCC 94 109 SEQ ID GGCTGGCCCCACCTCT 0,32
    399
    SEQ ID 60 COMP ID 60 TAGAGGTGGGGCCAGC 95 110 SEQ ID GCTGGCCCCACCTCTA 0,53
    400
    SEQ ID 61 COMP ID 61 ATAGAGGTGGGGCCAG 96 111 SEQ ID CTGGCCCCACCTCTAT 0,37
    401
    SEQ ID 62 COMP ID 62 TATAGAGGTGGGGCCA 97 112 SEQ ID TGGCCCCACCTCTATA 0,68
    402
    SEQ ID 63 COMP ID 63 ATATAGAGGTGGGGCC 98 113 SEQ ID GGCCCCACCTCTATAT 0,65
    403
    SEQ ID 64 COMP ID 64 AATATAGAGGTGGGGC 99 114 SEQ ID GCCCCACCTCTATATT 0,61
    404
    SEQ ID 65 COMP ID 65 CAATATAGAGGTGGGG 100 115 SEQ ID CCCCACCTCTATATTG 0,79
    405
    SEQ ID 66 COMP ID 66 TCAATATAGAGGTGGG 101 116 SEQ ID CCCACCTCTATATTGA 0,86
    406
    SEQ ID 67 COMP ID 67 ATCAATATAGAGGTGG 102 117 SEQ ID CCACCTCTATATTGAT 0,80
    407
    SEQ ID 68 COMP ID 68 TATCAATATAGAGGTG 103 118 SEQ ID CACCTCTATATTGATA 0,65
    408
    SEQ ID 69 COMP ID 69 TTATCAATATAGAGGT 104 119 SEQ ID ACCTCTATATTGATAA 0,49
    409
    SEQ ID 70 COMP ID 70 CTTATCAATATAGAGG 105 120 SEQ ID CCTCTATATTGATAAG 0,93
    410
    SEQ ID 71 COMP ID 71 ACTTATCAATATAGAG 106 121 SEQ ID CTCTATATTGATAAGT 0,73
    411
    SEQ ID 72 COMP ID 72 TACTTATCAATATAGA 107 122 SEQ ID TCTATATTGATAAGTA 0,87
    412
    SEQ ID 73 COMP ID 73 CTACTTATCAATATAG 108 123 SEQ ID CTATATTGATAAGTAG 0,83
    413
    SEQ ID 74 COMP ID 74 GCTACTTATCAATATA 109 124 SEQ ID TATATTGATAAGTAGC 0,64
    414
    SEQ ID 75 COMP ID 75 GGCTACTTATCAATAT 110 125 SEQ ID ATATTGATAAGTAGCC 0,71
    415
    SEQ ID 76 COMP ID 76 TGGCTACTTATCAATA 111 126 SEQ ID TATTGATAAGTAGCCA 0,81
    416
    SEQ ID 77 COMP ID 77 TTGGCTACTTATCAAT 112 127 SEQ ID ATTGATAAGTAGCCAA 0,48
    417
    SEQ ID 78 COMP ID 78 ATTGGCTACTTATCAA 113 128 SEQ ID TTGATAAGTAGCCAAT 0,88
    418
    SEQ ID 79 COMP ID 79 CATTGGCTACTTATCA 114 129 SEQ ID TGATAAGTAGCCAATG 0,72
    419
    SEQ ID 80 COMP ID 80 CCATTGGCTACTTATC 115 130 SEQ ID GATAAGTAGCCAATGG 0,53
    420
    SEQ ID 81 COMP ID 81 CCCATTGGCTACTTAT 116 131 SEQ ID ATAAGTAGCCAATGGG 0,63
    421
    SEQ ID 82 COMP ID 82 TCCCATTGGCTACTTA 117 132 SEQ ID TAAGTAGCCAATGGGA 0,53
    422
    SEQ ID 83 COMP ID 83 CTCCCATTGGCTACTT 118 133 SEQ ID AAGTAGCCAATGGGAG 0,57
    423
    SEQ ID 84 COMP ID 84 GCTCCCATTGGCTACT 119 134 SEQ ID AGTAGCCAATGGGAGC 0,52
    424
    SEQ ID 85 COMP ID 85 CGCTCCCATTGGCTAC 120 135 SEQ ID GTAGCCAATGGGAGCG 0,25
    425
    SEQ ID 86 COMP ID 86 CCGCTCCCATTGGCTA 121 136 SEQ ID TAGCCAATGGGAGCGG 0,37
    426
    SEQ ID 87 COMP ID 87 CCCGCTCCCATTGGCT 122 137 SEQ ID AGCCAATGGGAGCGGG 0,28
    427
    SEQ ID 88 COMP ID 88 ACCCGCTCCCATTGGC 123 138 SEQ ID GCCAATGGGAGCGGGT 0,30
    428
    SEQ ID 89 COMP ID 89 TACCCGCTCCCATTGG 124 139 SEQ ID CCAATGGGAGCGGGTA 0,43
    429
    SEQ ID 90 COMP ID 90 CTACCCGCTCCCATTG 125 140 SEQ ID CAATGGGAGCGGGTAG 0,38
    430
    SEQ ID 91 COMP ID 91 GCTACCCGCTCCCATT 126 141 SEQ ID AATGGGAGCGGGTAGC 0,65
    431
    SEQ ID 92 COMP ID 92 GGCTACCCGCTCCCAT 127 142 SEQ ID ATGGGAGCGGGTAGCC 0,51
    432
    SEQ ID 93 COMP ID 93 GGGCTACCCGCTCCCA 128 143 SEQ ID TGGGAGCGGGTAGCCC 0,38
    433
    SEQ ID 94 COMP ID 94 AGGGCTACCCGCTCCC 129 144 SEQ ID GGGAGCGGGTAGCCCT 0,50
    434
    SEQ ID 95 COMP ID 95 CAGGGCTACCCGCTCC 130 145 SEQ ID GGAGCGGGTAGCCCTG 0,45
    435
    SEQ ID 96 COMP ID 96 TCAGGGCTACCCGCTC 131 146 SEQ ID GAGCGGGTAGCCCTGA 0,50
    436
    SEQ ID 97 COMP ID 97 ATCAGGGCTACCCGCT 132 147 SEQ ID AGCGGGTAGCCCTGAT 0,39
    437
    SEQ ID 98 COMP ID 98 GATCAGGGCTACCCGC 133 148 SEQ ID GCGGGTAGCCCTGATC 0,31
    438
    SEQ ID 99 COMP ID 99 GGATCAGGGCTACCCG 134 149 SEQ ID CGGGTAGCCCTGATCC 0,32
    439
    SEQ ID 100 COMP ID 100 GGGATCAGGGCTACCC 135 150 SEQ ID GGGTAGCCCTGATCCC 0,56
    440
    SEQ ID 101 COMP ID 101 AGGGATCAGGGCTACC 136 151 SEQ ID GGTAGCCCTGATCCCT 0,41
    441
    SEQ ID 102 COMP ID 102 CAGGGATCAGGGCTAC 137 152 SEQ ID GTAGCCCTGATCCCTG 0,86
    442
    SEQ ID 103 COMP ID 103 CCAGGGATCAGGGCTA 138 153 SEQ ID TAGCCCTGATCCCTGG 0,65
    443
    SEQ ID 104 COMP ID 104 GCCAGGGATCAGGGCT 139 154 SEQ ID AGCCCTGATCCCTGGC 0,65
    444
    SEQ ID 105 COMP ID 105 GGCCAGGGATCAGGGC 140 155 SEQ ID GCCCTGATCCCTGGCC 1,00
    445
    SEQ ID 106 COMP ID 106 TGGCCAGGGATCAGGG 141 156 SEQ ID CCCTGATCCCTGGCCA 1,07
    446
    SEQ ID 107 COMP ID 107 TTGGCCAGGGATCAGG 142 157 SEQ ID CCTGATCCCTGGCCAA 0,52
    447
    SEQ ID 108 COMP ID 108 ATTGGCCAGGGATCAG 143 158 SEQ ID CTGATCCCTGGCCAAT 0,86
    448
    SEQ ID 109 COMP ID 109 CATTGGCCAGGGATCA 144 159 SEQ ID TGATCCCTGGCCAATG 0,67
    449
    SEQ ID 110 COMP ID 110 CCATTGGCCAGGGATC 145 160 SEQ ID GATCCCTGGCCAATGG 0,54
    450
    SEQ ID 111 COMP ID 111 TCCATTGGCCAGGGAT 146 161 SEQ ID ATCCCTGGCCAATGGA n.d.
    451
    SEQ ID 112 COMP ID 112 TTCCATTGGCCAGGGA 147 162 SEQ ID TCCCTGGCCAATGGAA n.d.
    452
    SEQ ID 113 COMP ID 113 TTTCCATTGGCCAGGG 148 163 SEQ ID CCCTGGCCAATGGAAA n.d.
    453
    SEQ ID 114 COMP ID 114 GTTTCCATTGGCCAGG 149 164 SEQ ID CCTGGCCAATGGAAAC n.d.
    454
    SEQ ID 115 COMP ID 115 AGTTTCCATTGGCCAG 150 165 SEQ ID CTGGCCAATGGAAACT 0,43
    455
    SEQ ID 116 COMP ID 116 CAGTTTCCATTGGCCA 151 166 SEQ ID TGGCCAATGGAAACTG 0,56
    456
    SEQ ID 117 COMP ID 117 TCAGTTTCCATTGGCC 152 167 SEQ ID GGCCAATGGAAACTGA 0,61
    457
    SEQ ID 118 COMP ID 118 CTCAGTTTCCATTGGC 153 168 SEQ ID GCCAATGGAAACTGAG 0,71
    458
    SEQ ID 119 COMP ID 119 CCTCAGTTTCCATTGG 154 169 SEQ ID CCAATGGAAACTGAGG 1,03
    459
    SEQ ID 120 COMP ID 120 ACCTCAGTTTCCATTG 155 170 SEQ ID CAATGGAAACTGAGGT 0,90
    460
    SEQ ID 121 COMP ID 121 TACCTCAGTTTCCATT 156 171 SEQ ID AATGGAAACTGAGGTA 0,95
    461
    SEQ ID 122 COMP ID 122 CTACCTCAGTTTCCAT 157 172 SEQ ID ATGGAAACTGAGGTAG 0,63
    462
    SEQ ID 123 COMP ID 123 CCTACCTCAGTTTCCA 158 173 SEQ ID TGGAAACTGAGGTAGG 0,62
    463
    SEQ ID 124 COMP ID 124 GCCTACCTCAGTTTCC 159 174 SEQ ID GGAAACTGAGGTAGGC 0,49
    464
    SEQ ID 125 COMP ID 125 CGCCTACCTCAGTTTC 160 175 SEQ ID GAAACTGAGGTAGGCG 1,18
    465
    SEQ ID 126 COMP ID 126 CCGCCTACCTCAGTTT 161 176 SEQ ID AAACTGAGGTAGGCGG 0,55
    466
    SEQ ID 127 COMP ID 127 CCCGCCTACCTCAGTT 162 177 SEQ ID AACTGAGGTAGGCGGG 0,72
    467
    SEQ ID 128 COMP ID 128 ACCCGCCTACCTCAGT 163 178 SEQ ID ACTGAGGTAGGCGGGT 0,44
    468
    SEQ ID 129 COMP ID 129 GACCCGCCTACCTCAG 164 179 SEQ ID CTGAGGTAGGCGGGTC 0,42
    469
    SEQ ID 130 COMP ID 130 TGACCCGCCTACCTCA 165 180 SEQ ID TGAGGTAGGCGGGTCA 0,28
    470
    SEQ ID 131 COMP ID 131 ATGACCCGCCTACCTC 166 181 SEQ ID GAGGTAGGCGGGTCAT 0,19
    471
    SEQ ID 132 COMP ID 132 GATGACCCGCCTACCT 167 182 SEQ ID AGGTAGGCGGGTCATC 0,18
    472
    SEQ ID 133 COMP ID 133 CGATGACCCGCCTACC 168 183 SEQ ID GGTAGGCGGGTCATCG 0,34
    473
    SEQ ID 134 COMP ID 134 GCGATGACCCGCCTAC 169 184 SEQ ID GTAGGCGGGTCATCGC 0,73
    474
    SEQ ID 135 COMP ID 135 CGCGATGACCCGCCTA 170 185 SEQ ID TAGGCGGGTCATCGCG 0,66
    475
    SEQ ID 136 COMP ID 136 GCGCGATGACCCGCCT 171 186 SEQ ID AGGCGGGTCATCGCGC 0,46
    476
    SEQ ID 137 COMP ID 137 AGCGCGATGACCCGCC 172 187 SEQ ID GGCGGGTCATCGCGCT 0,46
    477
    SEQ ID 138 COMP ID 138 CAGCGCGATGACCCGC 173 188 SEQ ID GCGGGTCATCGCGCTG 0,53
    478
    SEQ ID 139 COMP ID 139 CCAGCGCGATGACCCG 174 189 SEQ ID CGGGTCATCGCGCTGG 0,23
    479
    SEQ ID 140 COMP ID 140 CCCAGCGCGATGACCC 175 190 SEQ ID GGGTCATCGCGCTGGG 0,23
    480
    SEQ ID 141 COMP ID 141 CCCCAGCGCGATGACC 176 191 SEQ ID GGTCATCGCGCTGGGG 0,42
    481
    SEQ ID 142 COMP ID 142 ACCCCAGCGCGATGAC 177 192 SEQ ID GTCATCGCGCTGGGGT 0,30
    482
    SEQ ID 143 COMP ID 143 GACCCCAGCGCGATGA 178 193 SEQ ID TCATCGCGCTGGGGTC 0,63
    483
    SEQ ID 144 COMP ID 144 AGACCCCAGCGCGATG 179 194 SEQ ID CATCGCGCTGGGGTCT 0,57
    484
    SEQ ID 145 COMP ID 145 CAGACCCCAGCGCGAT 180 195 SEQ ID ATCGCGCTGGGGTCTG 0,31
    485
    SEQ ID 146 COMP ID 146 ACAGACCCCAGCGCGA 181 196 SEQ ID TCGCGCTGGGGTCTGT 0,29
    486
    SEQ ID 147 COMP ID 147 TACAGACCCCAGCGCG 182 197 SEQ ID CGCGCTGGGGTCTGTA 0,34
    487
    SEQ ID 148 COMP ID 148 CTACAGACCCCAGCGC 183 198 SEQ ID GCGCTGGGGTCTGTAG 0,32
    488
    SEQ ID 149 COMP ID 149 ACTACAGACCCCAGCG 184 199 SEQ ID CGCTGGGGTCTGTAGT 0,34
    489
    SEQ ID 150 COMP ID 150 GACTACAGACCCCAGC 185 200 SEQ ID GCTGGGGTCTGTAGTC 0,64
    490
    SEQ ID 151 COMP ID 151 AGACTACAGACCCCAG 186 201 SEQ ID CTGGGGTCTGTAGTCT 0,95
    491
    SEQ ID 152 COMP ID 152 CAGACTACAGACCCCA 187 202 SEQ ID TGGGGTCTGTAGTCTG 0,52
    492
    SEQ ID 153 COMP ID 153 TCAGACTACAGACCCC 188 203 SEQ ID GGGGTCTGTAGTCTGA 0,53
    493
    SEQ ID 154 COMP ID 154 CTCAGACTACAGACCC 189 204 SEQ ID GGGTCTGTAGTCTGAG 0,43
    494
    SEQ ID 155 COMP ID 155 GCTCAGACTACAGACC 190 205 SEQ ID GGTCTGTAGTCTGAGC 0,33
    495
    SEQ ID 156 COMP ID 156 CGCTCAGACTACAGAC 191 206 SEQ ID GTCTGTAGTCTGAGCG 0,43
    496
    SEQ ID 157 COMP ID 157 GCGCTCAGACTACAGA 192 207 SEQ ID TCTGTAGTCTGAGCGC 0,46
    497
    SEQ ID 158 COMP ID 158 AGCGCTCAGACTACAG 193 208 SEQ ID CTGTAGTCTGAGCGCT 0,80
    498
    SEQ ID 159 COMP ID 159 TAGCGCTCAGACTACA 194 209 SEQ ID TGTAGTCTGAGCGCTA 0,47
    499
    SEQ ID 160 COMP ID 160 GTAGCGCTCAGACTAC 195 210 SEQ ID GTAGTCTGAGCGCTAC 0,67
    500
    SEQ ID 161 COMP ID 161 GGTAGCGCTCAGACTA 196 211 SEQ ID TAGTCTGAGCGCTACC 0,74
    501
    SEQ ID 162 COMP ID 162 GGGTAGCGCTCAGACT 197 212 SEQ ID AGTCTGAGCGCTACCC 0,62
    502
    SEQ ID 163 COMP ID 163 CGGGTAGCGCTCAGAC 198 213 SEQ ID GTCTGAGCGCTACCCG 0,43
    503
    SEQ ID 164 COMP ID 164 CCGGGTAGCGCTCAGA 199 214 SEQ ID TCTGAGCGCTACCCGG 0,38
    504
    SEQ ID 165 COMP ID 165 ACCGGGTAGCGCTCAG 200 215 SEQ ID CTGAGCGCTACCCGGT 0,45
    505
    SEQ ID 166 COMP ID 166 AACCGGGTAGCGCTCA 201 216 SEQ ID TGAGCGCTACCCGGTT 0,61
    506
    SEQ ID 167 COMP ID 167 CAACCGGGTAGCGCTC 202 217 SEQ ID GAGCGCTACCCGGTTG 0,56
    507
    SEQ ID 168 COMP ID 168 GCAACCGGGTAGCGCT 203 218 SEQ ID AGCGCTACCCGGTTGC 0,50
    508
    SEQ ID 169 COMP ID 169 AGCAACCGGGTAGCGC 204 219 SEQ ID GCGCTACCCGGTTGCT 0,35
    509
    SEQ ID 170 COMP ID 170 CAGCAACCGGGTAGCG 205 220 SEQ ID CGCTACCCGGTTGCTG 0,21
    510
    SEQ ID 171 COMP ID 171 GCAGCAACCGGGTAGC 206 221 SEQ ID GCTACCCGGTTGCTGC 0,19
    511
    SEQ ID 172 COMP ID 172 AGCAGCAACCGGGTAG 207 222 SEQ ID CTACCCGGTTGCTGCT 0,26
    512
    SEQ ID 173 COMP ID 173 CAGCAGCAACCGGGTA 208 223 SEQ ID TACCCGGTTGCTGCTG 0,22
    513
    SEQ ID 174 COMP ID 174 GCAGCAGCAACCGGGT 209 224 SEQ ID ACCCGGTTGCTGCTGC 0,42
    514
    SEQ ID 175 COMP ID 175 GGCAGCAGCAACCGGG 210 225 SEQ ID CCCGGTTGCTGCTGCC 0,41
    515
    SEQ ID 176 COMP ID 176 GGGCAGCAGCAACCGG 211 226 SEQ ID CCGGTTGCTGCTGCCC 0,44
    516
    SEQ ID 177 COMP ID 177 TGGGCAGCAGCAACCG 212 227 SEQ ID CGGTTGCTGCTGCCCA 0,42
    517
    SEQ ID 178 COMP ID 178 TTGGGCAGCAGCAACC 213 228 SEQ ID GGTTGCTGCTGCCCAA 0,36
    518
    SEQ ID 179 COMP ID 179 CTTGGGCAGCAGCAAC 214 229 SEQ ID GTTGCTGCTGCCCAAG 0,28
    519
    SEQ ID 180 COMP ID 180 CCTTGGGCAGCAGCAA 215 230 SEQ ID TTGCTGCTGCCCAAGG 0,31
    520
    SEQ ID 181 COMP ID 181 TCCTTGGGCAGCAGCA 216 231 SEQ ID TGCTGCTGCCCAAGGA 0,26
    521
    SEQ ID 182 COMP ID 182 GTCCTTGGGCAGCAGC 217 232 SEQ ID GCTGCTGCCCAAGGAC 0,60
    522
    SEQ ID 183 COMP ID 183 GGTCCTTGGGCAGCAG 218 233 SEQ ID CTGCTGCCCAAGGACC 0,39
    523
    SEQ ID 184 COMP ID 184 CGGTCCTTGGGCAGCA 219 234 SEQ ID TGCTGCCCAAGGACCG 0,30
    524
    SEQ ID 185 COMP ID 185 GCGGTCCTTGGGCAGC 220 235 SEQ ID GCTGCCCAAGGACCGC 0,44
    525
    SEQ ID 186 COMP ID 186 CGCGGTCCTTGGGCAG 221 236 SEQ ID CTGCCCAAGGACCGCG 0,21
    526
    SEQ ID 187 COMP ID 187 CCGCGGTCCTTGGGCA 222 237 SEQ ID TGCCCAAGGACCGCGG 0,25
    527
    SEQ ID 188 COMP ID 188 TCCGCGGTCCTTGGGC 223 238 SEQ ID GCCCAAGGACCGCGGA 0,21
    528
    SEQ ID 189 COMP ID 189 CTCCGCGGTCCTTGGG 224 239 SEQ ID CCCAAGGACCGCGGAG 0,25
    529
    SEQ ID 190 COMP ID 190 ACTCCGCGGTCCTTGG 225 240 SEQ ID CCAAGGACCGCGGAGT 0,55
    530
    SEQ ID 191 COMP ID 191 GACTCCGCGGTCCTTG 226 241 SEQ ID CAAGGACCGCGGAGTC 0,33
    531
    SEQ ID 192 COMP ID 192 CGACTCCGCGGTCCTT 227 242 SEQ ID AAGGACCGCGGAGTCG 0,49
    532
    SEQ ID 193 COMP ID 193 CCGACTCCGCGGTCCT 228 243 SEQ ID AGGACCGCGGAGTCGG 0,23
    533
    SEQ ID 194 COMP ID 194 TCCGACTCCGCGGTCC 229 244 SEQ ID GGACCGCGGAGTCGGA 0,20
    534
    SEQ ID 195 COMP ID 195 GTCCGACTCCGCGGTC 230 245 SEQ ID GACCGCGGAGTCGGAC 0,25
    535
    SEQ ID 196 COMP ID 196 CGTCCGACTCCGCGGT 231 246 SEQ ID ACCGCGGAGTCGGACG 0,55
    536
    SEQ ID 197 COMP ID 197 GCGTCCGACTCCGCGG 232 247 SEQ ID CCGCGGAGTCGGACGC 0,41
    537
    SEQ ID 198 COMP ID 198 TGCGTCCGACTCCGCG 233 248 SEQ ID CGCGGAGTCGGACGCA 0,33
    538
    SEQ ID 199 COMP ID 199 CTGCGTCCGACTCCGC 234 249 SEQ ID GCGGAGTCGGACGCAG 0,180,47
    539
    SEQ ID 200 COMP ID 200 CCTGCGTCCGACTCCG 235 250 SEQ ID CGGAGTCGGACGCAGG 0,140,60
    540
    SEQ ID 201 COMP ID 201 GCCTGCGTCCGACTCC 236 251 SEQ ID GGAGTCGGACGCAGGC 0,150,62
    541
    SEQ ID 202 COMP ID 202 TGCCTGCGTCCGACTC 237 252 SEQ ID GAGTCGGACGCAGGCA 0,230,65
    542
    SEQ ID 203 COMP ID 203 CTGCCTGCGTCCGACT 238 253 SEQ ID AGTCGGACGCAGGCAG 0,270,85
    543
    SEQ ID 204 COMP ID 204 TCTGCCTGCGTCCGAC 239 254 SEQ ID GTCGGACGCAGGCAGA 0,270,81
    544
    SEQ ID 205 COMP ID 205 GTCTGCCTGCGTCCGA 240 255 SEQ ID TCGGACGCAGGCAGAC 0,220,53
    545
    SEQ ID 206 COMP ID 206 GGTCTGCCTGCGTCCG 241 256 SEQ ID CGGACGCAGGCAGACC 0,330,80
    546
    • Example 5
  • Antisense oligonucleotides were designed for the 5′ UTR from position 119 to 158 according to RefSeq NM_002087.3 (SEQ ID NO 1) with one nucleotide basepair shift as shown in table 2, which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • The results from example 4 and 5 show that antisense oligonucleotide agonism was identified for several compounds targeting the progranulin 5′UTR, particularly compounds with a contiguous nucleotide complementary to nucleotides 1-229 of SEQ ID NO 1, such as compounds complementary to SEQ ID NO 445, SEQ ID NO: 446, SEQ ID NO: 459, SEQ ID NO 465, SEQ ID NO 683, SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584, & SEQ ID NO 586.
  • Compounds 105, 106, 119, 125, 117, 228, 231, 235-8, 244 and 246 were identified as having progranulin agonist activity in the luciferase assay.
  • TABLE 2
    All the antisense oligonucleotides are designed as 18-mers DNA-LNA mixmers with a phosphorothioate
    backbone, DNA-LNA mixmers with a phosphorothioate backbone, LNA at the very 5′ and 3′ position and
    e.g. LNA for every 2nd or 3rd nucleotide (see Compound table).
    Compound RefSeq Relative
    ID Number- NM_002087.3 Target luciferase
    See Oligonucleotide (SEQ ID NO 1) Site activity
    Compound Sequence Motif Start End Sequence Target Relative 
    SEQ ID Table (nucleobase Sequence) Position Position ID Site Sequence to PBS)
    SEQ COMP ID GCTCCCATTGGCTACTTA 119 136 SEQ ID TAAGTAGCCAATGGGAGC 0,32
    ID#207 207 547
    SEQ COMP ID CGCTCCCATTGGCTACTT 120 137 SEQ ID AAGTAGCCAATGGGAGCG 0,22
    ID#208 208 548
    SEQ COMP ID CCGCTCCCATTGGCTACT 121 138 SEQ ID AGTAGCCAATGGGAGCGG 0,19
    ID#209 209 549
    SEQ COMP ID CCCGCTCCCATTGGCTAC 122 139 SEQ ID GTAGCCAATGGGAGCGGG 0,24
    ID#210 210 550
    SEQ COMP ID ACCCGCTCCCATTGGCTA 123 140 SEQ ID TAGCCAATGGGAGCGGGT 0,37
    ID#211 211 551
    SEQ COMP ID TACCCGCTCCCATTGGCT 124 141 SEQ ID AGCCAATGGGAGCGGGTA 0,38
    ID#212 212 552
    SEQ COMP ID CTACCCGCTCCCATTGGC 125 142 SEQ ID GCCAATGGGAGCGGGTAG 0,39
    ID#213 213 553
    SEQ COMP ID GCTACCCGCTCCCATTGG 126 143 SEQ ID CCAATGGGAGCGGGTAGC 0,47
    ID#214 214 554
    SEQ COMP ID GGCTACCCGCTCCCATTG 127 144 SEQ ID CAATGGGAGCGGGTAGCC 0,55
    ID#215 215 555
    SEQ COMP ID GGGCTACCCGCTCCCATT 128 145 SEQ ID AATGGGAGCGGGTAGCCC 0,53
    ID#216 216 556
    SEQ COMP ID AGGGCTACCCGCTCCCAT 129 146 SEQ ID ATGGGAGCGGGTAGCCCT 0,56
    ID#217 217 557
    SEQ COMP ID CAGGGCTACCCGCTCCCA 130 147 SEQ ID TGGGAGCGGGTAGCCCTG 0,49
    ID#218 218 558
    SEQ COMP ID TCAGGGCTACCCGCTCCC 131 148 SEQ ID GGGAGCGGGTAGCCCTGA 0,58
    ID#219 219 559
    SEQ COMP ID ATCAGGGCTACCCGCTCC 132 149 SEQ ID GGAGCGGGTAGCCCTGAT 0,48
    ID#220 220 560
    SEQ COMP ID GATCAGGGCTACCCGCTC 133 150 SEQ ID GAGCGGGTAGCCCTGATC 0,49
    ID#221 221 561
    SEQ COMP ID GGATCAGGGCTACCCGCT 134 151 SEQ ID AGCGGGTAGCCCTGATCC 0,38
    ID#222 222 562
    SEQ COMP ID GGGATCAGGGCTACCCGC 135 152 SEQ ID GCGGGTAGCCCTGATCCC 0,33
    ID#223 223 563
    SEQ COMP ID AGGGATCAGGGCTACCCG 136 153 SEQ ID CGGGTAGCCCTGATCCCT 0,36
    ID#224 224 564
    SEQ COMP ID CAGGGATCAGGGCTACCC 137 154 SEQ ID GGGTAGCCCTGATCCCTG 0,48
    ID#225 225 565
    SEQ COMP ID CCAGGGATCAGGGCTACC 138 155 SEQ ID GGTAGCCCTGATCCCTGG 0,69
    ID#226 226 566
    SEQ COMP ID GCCAGGGATCAGGGCTAC 139 156 SEQ ID GTAGCCCTGATCCCTGGC 0,94
    ID#227 227 567
    SEQ COMP ID GGCCAGGGATCAGGGCTA 140 157 SEQ ID TAGCCCTGATCCCTGGCC 1,15
    ID#228 228 568
    SEQ COMP ID TGGCCAGGGATCAGGGCT 141 158 SEQ ID AGCCCTGATCCCTGGCCA 0,92
    ID#229 229 569
    SEQ COMP ID TTGGCCAGGGATCAGGGC 142 159 SEQ ID GCCCTGATCCCTGGCCAA 0,85
    ID#230 230 570
    SEQ COMP ID ATTGGCCAGGGATCAGGG 143 160 SEQ ID CCCTGATCCCTGGCCAAT 1,12
    ID#231 231 571
    SEQ COMP ID CATTGGCCAGGGATCAGG 144 161 SEQ ID CCTGATCCCTGGCCAATG 0,72
    ID#232 232 572
    SEQ COMP ID CCATTGGCCAGGGATCAG 145 162 SEQ ID CTGATCCCTGGCCAATGG 0,75
    ID#233 233 573
    SEQ COMP ID TCCATTGGCCAGGGATCA 146 163 SEQ ID TGATCCCTGGCCAATGGA 0,97
    ID#234 234 574
    SEQ COMP ID TTCCATTGGCCAGGGATC 147 164 SEQ ID GATCCCTGGCCAATGGAA 1,22
    ID#235 235 575
    SEQ COMP ID TTTCCATTGGCCAGGGAT 148 165 SEQ ID ATCCCTGGCCAATGGAAA 1,13
    ID#236 236 576
    SEQ COMP ID GTTTCCATTGGCCAGGGA 149 166 SEQ ID TCCCTGGCCAATGGAAAC 1,01
    ID#237 237 577
    SEQ COMP ID AGTTTCCATTGGCCAGGG 150 167 SEQ ID CCCTGGCCAATGGAAACT 1,09
    ID#238 238 578
    SEQ COMP ID CAGTTTCCATTGGCCAGG 151 168 SEQ ID CCTGGCCAATGGAAACTG 0,79
    ID#239 239 579
    SEQ COMP ID TCAGTTTCCATTGGCCAG 152 169 SEQ ID CTGGCCAATGGAAACTGA 0,69
    ID#240 240 580
    SEQ COMP ID CTCAGTTTCCATTGGCCA 153 170 SEQ ID TGGCCAATGGAAACTGAG 0,59
    ID#241 241 581
    SEQ COMP ID CCTCAGTTTCCATTGGCC 154 171 SEQ ID GGCCAATGGAAACTGAGG 0,39
    ID#242 242 582
    SEQ COMP ID ACCTCAGTTTCCATTGGC 155 172 SEQ ID GCCAATGGAAACTGAGGT 0,95
    ID#243 243 583
    SEQ COMP ID TACCTCAGTTTCCATTGG 156 173 SEQ ID CCAATGGAAACTGAGGTA 1,12
    ID#244 244 584
    SEQ COMP ID CTACCTCAGTTTCCATTG 157 174 SEQ ID CAATGGAAACTGAGGTAG 1,00
    ID#245 245 585
    SEQ COMP ID CCTACCTCAGTTTCCATT 158 175 SEQ ID AATGGAAACTGAGGTAGG 1,26
    ID#246 246 586
    • Example 6
  • Antisense oligonucleotides were designed for the 3′ UTR from position 2044 to 2346 according to RefSeq NM_002807.3 with three nucleotide basepar shift as shown in table 3 which also provides the data from the luciferase assay, were a value of greater than 1 indicates an increased expression of progranulin (i.e. progranulin agonist activity of the antisense oligonucleotide), and a value lower than 1 indicates a decreased expression of progranulin (i.e. an inhibition or antagonistic effect, on progranulin expression).
  • The data shows antisense oligonucleotide antisense oligonucleotides with progranulin agonist activity that are complementary to the 3′UTR region of a human progranulin mRNA transcript were identified, for example compounds with a contiguous nucleotide sequence which is complementary to a sequence selected from the group consisting of SEQ ID NO 684, 685, 683, 686, 687, and 688, such as compounds with a contiguous nucleotide sequence which is complementary to a sequence selected from the group consisting of 607, 608, 609, 610, 611, 612, 619, 620, 633, 640, 641,645, 651, and 652.
  • Compounds 263, 267, 269-272, 279, 280, 293, 300, 301, 305, 311, 312 and 327 were identified as exhibiting progranulin agonist activity in the luciferase assay system used.
  • TABLE 3
    All the antisense oligonucleotides are designed as 18-mers DNA-LNA mixmers with a phosphorothioate
    backbone, DNA-LNA mixmers with a phosphorothioate backbone, LNA at the very 5′ and 3′ position and
    e.g. LNA for every 2nd or 3rd nucleotide (see Compound table).
    RefSeq Relative
    NM_002087.3 Target luciferase
    Compound Oligonucleotide (SEQ ID NO 1) Site activity
    SEQ ID # (see Sequence Motif Start End Sequence Target Relative
    ID Compound (nucleobase Sequence) Position Position ID Site Sequence to PBS)
    SEQ COMP ID 5′-TGCAGAGTCTTCAGTACT-3′ 2044 2061 SEQ ID AGTACTGAAGACTCTGCA 0,46
    ID 247 587
    #247
    SEQ COMP ID 5′-GGCTGCAGAGTCTTCAGT-3′ 2047 2064 SEQ ID ACTGAAGACTCTGCAGCC 0,25
    ID 248 588
    #248
    SEQ COMP ID 5′-GAGGGCTGCAGAGTCTTC-3′ 2050 2067 SEQ ID GAAGACTCTGCAGCCCTC 0,35
    ID 249 589
    #249
    SEQ COMP ID 5′-CCCGAGGGCTGCAGAGTC-3′ 2053 2070 SEQ ID GACTCTGCAGCCCTCGGG 0,65
    ID 250 590
    #250
    SEQ COMP ID 5′-GGTCCCGAGGGCTGCAGA-3′ 2056 2073 SEQ ID TCTGCAGCCCTCGGGACC 0,69
    ID 251 591
    #251
    SEQ COMP ID 5′-TGGGGTCCCGAGGGCTGC-3′ 2059 2076 SEQ ID GCAGCCCTCGGGACCCCA 0,37
    ID 252 592
    #252
    SEQ COMP ID 5′-GAGTGGGGTCCCGAGGGC-3′ 2062 2079 SEQ ID GCCCTCGGGACCCCACTC 0,77
    ID 253 593
    #253
    SEQ COMP ID 5′-TCCGAGTGGGGTCCCGAG-3′ 2065 2082 SEQ ID CTCGGGACCCCACTCGGA 0,75
    ID 254 594
    #254
    SEQ COMP ID 5′-CCCTCCGAGTGGGGTCCC-3′ 2068 2085 SEQ ID GGGACCCCACTCGGAGGG 0,67
    ID 255 595
    #255
    SEQ COMP ID 5′-GCACCCTCCGAGTGGGGT-3′ 2071 2088 SEQ ID ACCCCACTCGGAGGGTGC 0,57
    ID 256 596
    #256
    SEQ COMP ID 5′-AGGGCACCCTCCGAGTGG-3′ 2074 2091 SEQ ID CCACTCGGAGGGTGCCCT 0,78
    ID 257 597
    #257
    SEQ COMP ID 5′-CAGAGGGCACCCTCCGAG-3′ 2077 2094 SEQ ID CTCGGAGGGTGCCCTCTG 0,92
    ID 258 598
    #258
    SEQ COMP ID 5′-GAGCAGAGGGCACCCTCC-3′ 2080 2097 SEQ ID GGAGGGTGCCCTCTGCTC 0,29
    ID 259 599
    #259
    SEQ COMP ID 5′-CCTGAGCAGAGGGCACCC-3′ 2083 2100 SEQ ID GGGTGCCCTCTGCTCAGG 0,63
    ID 260 600
    #260
    SEQ COMP ID 5′-AGGCCTGAGCAGAGGGCA-3′ 2086 2103 SEQ ID TGCCCTCTGCTCAGGCCT 0,56
    ID 261 601
    #261
    SEQ COMP ID 5′-GGGAGGCCTGAGCAGAGG-3′ 2089 2106 SEQ ID CCTCTGCTCAGGCCTCCC 0,74
    ID 262 602
    #262
    SEQ COMP ID 5′-CTAGGGAGGCCTGAGCAG-3′ 2092 2109 SEQ ID CTGCTCAGGCCTCCCTAG 1,13
    ID 263 603
    #263
    SEQ COMP ID 5′-GTGCTAGGGAGGCCTGAG-3′ 2095 2112 SEQ ID CTCAGGCCTCCCTAGCAC 0,99
    ID 264 604
    #264
    SEQ COMP ID 5′-GAGGTGCTAGGGAGGCCT-3′ 2098 2115 SEQ ID AGGCCTCCCTAGCACCTC 0,83
    ID 265 605
    #265
    SEQ COMP ID 5′-GGGGAGGTGCTAGGGAGG-3′ 2101 2118 SEQ ID CCTCCCTAGCACCTCCCC 0,89
    ID 266 606
    #266
    SEQ COMP ID 5′-TAGGGGGAGGTGCTAGGG-3′ 2104 2121 SEQ ID CCCTAGCACCTCCCCCTA 1,27
    ID 267 607
    #267
    SEQ COMP ID 5′-GGTTAGGGGGAGGTGCTA-3′ 2107 2124 SEQ ID TAGCACCTCCCCCTAACC 0,58
    ID 268 608
    #268
    SEQ COMP ID 5′-TTTGGTTAGGGGGAGGTG-3′ 2110 2127 SEQ ID CACCTCCCCCTAACCAAA 1,09
    ID 269 609
    #269
    SEQ COMP ID 5′-GAATTTGGTTAGGGGGAG-3′ 2113 2130 SEQ ID CTCCCCCTAACCAAATTC 1,24
    ID 270 610
    #270
    SEQ COMP ID 5′-GGAGAATTTGGTTAGGGG-3′ 2116 2133 SEQ ID CCCCTAACCAAATTCTCC 1,05
    ID 271 611
    #271
    SEQ COMP ID 5′-CAGGGAGAATTTGGTTAG-3′ 2119 2136 SEQ ID CTAACCAAATTCTCCCTG 1,04
    ID 272 612
    #272
    SEQ COMP ID 5′-GTCCAGGGAGAATTTGGT-3′ 2122 2139 SEQ ID ACCAAATTCTCCCTGGAC 0,94
    ID 273 613
    #273
    SEQ COMP ID 5′-GGGGTCCAGGGAGAATTT-3′ 2125 2142 SEQ ID AAATTCTCCCTGGACCCC 0,89
    ID 274 614
    #274
    SEQ COMP ID 5′-AATGGGGTCCAGGGAGAA-3′ 2128 2145 SEQ ID TTCTCCCTGGACCCCATT 0,99
    ID 275 615
    #275
    SEQ COMP ID 5′-CAGAATGGGGTCCAGGGA-3′ 2131 2148 SEQ ID TCCCTGGACCCCATTCTG 0,60
    ID 276 616
    #276
    SEQ COMP ID 5′-GCTCAGAATGGGGTCCAG-3′ 2134 2151 SEQ ID CTGGACCCCATTCTGAGC 0,52
    ID 277 617
    #277
    SEQ COMP ID 5′-GGAGCTCAGAATGGGGTC-3′ 2137 2154 SEQ ID GACCCCATTCTGAGCTCC 0,91
    ID 278 618
    #278
    SEQ COMP ID 5′-TGGGGAGCTCAGAATGGG-3′ 2140 2157 SEQ ID CCCATTCTGAGCTCCCCA 1,14
    ID 279 619
    #279
    SEQ COMP ID 5′-TGATGGGGAGCTCAGAAT-3′ 2143 2160 SEQ ID ATTCTGAGCTCCCCATCA 1,11
    ID 280 620
    #280
    SEQ COMP ID 5′-TGGTGATGGGGAGCTCAG-3′ 2146 2163 SEQ ID CTGAGCTCCCCATCACCA 0,97
    ID 281 621
    #281
    SEQ COMP ID 5′-CCATGGTGATGGGGAGCT-3′ 2149 2166 SEQ ID AGCTCCCCATCACCATGG 0,97
    ID 282 622
    #282
    SEQ COMP ID 5′-CTCCCATGGTGATGGGGA-3′ 2152 2169 SEQ ID TCCCCATCACCATGGGAG 0,81
    ID 283 623
    #283
    SEQ COMP ID 5′-CACCTCCCATGGTGATGG-3′ 2155 2172 SEQ ID CCATCACCATGGGAGGTG 0,69
    ID 284 624
    #284
    SEQ COMP ID 5′-CCCCACCTCCCATGGTGA-3′ 2158 2175 SEQ ID TCACCATGGGAGGTGGGG 0,69
    ID 285 625
    #285
    SEQ COMP ID 5′-AGGCCCCACCTCCCATGG-3′ 2161 2178 SEQ ID CCATGGGAGGTGGGGCCT 0,58
    ID 286 626
    #286
    SEQ COMP ID 5′-TTGAGGCCCCACCTCCCA-3′ 2164 2181 SEQ ID TGGGAGGTGGGGCCTCAA 0,47
    ID 287 627
    #287
    SEQ COMP ID 5′-AGATTGAGGCCCCACCTC-3′ 2167 2184 SEQ ID GAGGTGGGGCCTCAATCT 0,59
    ID 288 628
    #288
    SEQ COMP ID 5′-CTTAGATTGAGGCCCCAC-3′ 2170 2187 SEQ ID GTGGGGCCTCAATCTAAG 0,38
    ID 289 629
    #289
    SEQ COMP ID 5′-GGCCTTAGATTGAGGCCC-3′ 2173 2190 SEQ ID GGGCCTCAATCTAAGGCC 0,43
    ID 290 630
    #290
    SEQ COMP ID 5′-GAAGGCCTTAGATTGAGG-3′ 2176 2193 SEQ ID CCTCAATCTAAGGCCTTC 0,76
    ID 291 631
    #291
    SEQ COMP ID 5′-AGGGAAGGCCTTAGATTG-3′ 2179 2196 SEQ ID CAATCTAAGGCCTTCCCT 0,86
    ID 292 632
    #292
    SEQ COMP ID 5′-GACAGGGAAGGCCTTAGA-3′ 2182 2199 SEQ ID TCTAAGGCCTTCCCTGTC 1,04
    ID 293 633
    #293
    SEQ COMP ID 5′-TCTGACAGGGAAGGCCTT-3′ 2185 2202 SEQ ID AAGGCCTTCCCTGTCAGA 0,81
    ID 294 634
    #294
    SEQ COMP ID 5′-CCTTCTGACAGGGAAGGC-3′ 2188 2205 SEQ ID GCCTTCCCTGTCAGAAGG 0,89
    ID 295 635
    #295
    SEQ COMP ID 5′-CCCCCTTCTGACAGGGAA-3′ 2191 2208 SEQ ID TTCCCTGTCAGAAGGGGG 0,71
    ID 296 636
    #296
    SEQ COMP ID 5′-CAACCCCCTTCTGACAGG-3′ 2194 2211 SEQ ID CCTGTCAGAAGGGGGTTG 0,89
    ID 297 637
    #297
    SEQ COMP ID 5′-CCACAACCCCCTTCTGAC-3′ 2197 2214 SEQ ID GTCAGAAGGGGGTTGTGG 0,42
    ID 298 638
    #298
    SEQ COMP ID 5′-TTGCCACAACCCCCTTCT-3′ 2200 2217 SEQ ID AGAAGGGGGTTGTGGCAA 0,88
    ID 299 639
    #299
    SEQ COMP ID 5′-CTTTTGCCACAACCCCCT-3′ 2203 2220 SEQ ID AGGGGGTTGTGGCAAAAG 1,16
    ID 300 640
    #300
    SEQ COMP ID 5′-TGGCTTTTGCCACAACCC-3′ 2206 2223 SEQ ID GGGTTGTGGCAAAAGCCA 1,08
    ID 301 641
    #301
    SEQ COMP ID 5′-ATGTGGCTTTTGCCACAA-3′ 2209 2226 SEQ ID TTGTGGCAAAAGCCACAT 1,01
    ID 302 642
    #302
    SEQ COMP ID 5′-GTAATGTGGCTTTTGCCA-3′ 2212 2229 SEQ ID TGGCAAAAGCCACATTAC 0,55
    ID 303 643
    #303
    SEQ COMP ID 5′-CTTGTAATGTGGCTTTTG-3′ 2215 2232 SEQ ID CAAAAGCCACATTACAAG 1,01
    ID 304 644
    #304
    SEQ COMP ID 5′-CAGCTTGTAATGTGGCTT-3′ 2218 2235 SEQ ID AAGCCACATTACAAGCTG 1,50
    ID 305 645
    #305
    SEQ COMP ID 5′-TGGCAGCTTGTAATGTGG-3′ 2221 2238 SEQ ID CCACATTACAAGCTGCCA 0,96
    ID 306 646
    #306
    SEQ COMP ID 5′-GGATGGCAGCTTGTAATG-3′ 2224 2241 SEQ ID CATTACAAGCTGCCATCC 0,74
    ID 307 647
    #307
    SEQ COMP ID 5′-AGGGGATGGCAGCTTGTA-3′ 2227 2244 SEQ ID TACAAGCTGCCATCCCCT 0,84
    ID 308 648
    #308
    SEQ COMP ID 5′-GGGAGGGGATGGCAGOTT-3′ 2230 2247 SEQ ID AAGCTGCCATCCCCTCCC 0,63
    ID 309 649
    #309
    SEQ COMP ID 5′-ACGGGGAGGGGATGGCAG-3 2233 2250 SEQ ID CTGCCATCCCCTCCCCGT 0,71
    ID 310 650
    #310
    SEQ COMP ID 5′-GAAACGGGGAGGGGATGG-3′ 2236 2253 SEQ ID CCATCCCCTCCCCGTTTC 1,06
    ID 311 651
    #311
    SEQ COMP ID 5′-ACTGAAACGGGGAGGGGA-3′ 2239 2256 SEQ ID TCCCCTCCCCGTTTCAGT 1,08
    ID 312 652
    #312
    SEQ COMP ID 5′-TCCACTGAAACGGGGAGG-3′ 2242 2259 SEQ ID CCTCCCCGTTTCAGTGGA 0,53
    ID 313 653
    #313
    SEQ COMP ID 5′-GGGTCCACTGAAACGGGG-3′ 2245 2262 SEQ ID CCCCGTTTCAGTGGACCC 0,93
    ID 314 654
    #314
    SEQ COMP ID 5′-ACAGGGTCCACTGAAACG-3′ 2248 2265 SEQ ID CGTTTCAGTGGACCCTGT 0,49
    ID 315 655
    #315
    SEQ COMP ID 5′-GCCACAGGGTCCACTGAA-3′ 2251 2268 SEQ ID TTCAGTGGACCCTGTGGC 0,57
    ID 316 656
    #316
    SEQ COMP ID 5′-CTGGCCACAGGGTCCACT-3′ 2254 2271 SEQ ID AGTGGACCCTGTGGCCAG 0,51
    ID 317 657
    #317
    SEQ COMP ID 5′-CACCTGGCCACAGGGTCC-3′ 2257 2274 SEQ ID GGACCCTGTGGCCAGGTG 0,73
    ID 318 658
    #318
    SEQ COMP ID 5′-AAGCACCTGGCCACAGGG-3′ 2260 2277 SEQ ID CCCTGTGGCCAGGTGCTT 0,43
    ID 319 659
    #319
    SEQ COMP ID 5′-GAAAAGCACCTGGCCACA-3′ 2263 2280 SEQ ID TGTGGCCAGGTGCTTTTC 0,33
    ID 320 660
    #320
    SEQ COMP ID 5′-AGGGAAAAGCACCTGGCC-3′ 2266 2283 SEQ ID GGCCAGGTGCTTTTCCCT 0,16
    ID 321 661
    #321
    SEQ COMP ID 5′-GATAGGGAAAAGCACCTG-3′ 2269 2286 SEQ ID CAGGTGCTTTTCCCTATC 0,65
    ID 322 662
    #322
    SEQ COMP ID 5′-GTGGATAGGGAAAAGCAC-3′ 2272 2289 SEQ ID GTGCTTTTCCCTATCCAC 0,54
    ID 323 663
    #323
    SEQ COMP ID 5′-CCTGTGGATAGGGAAAAG-3′ 2275 2292 SEQ ID CTTTTCCCTATCCACAGG 0,63
    ID 324 664
    #324
    SEQ COMP ID 5′-ACCCCTGTGGATAGGGAA-3′ 2278 2295 SEQ ID TTCCCTATCCACAGGGGT 0,29
    ID 325 665
    #325
    SEQ COMP ID 5′-AACACCCCTGTGGATAGG-3′ 2281 2298 SEQ ID CCTATCCACAGGGGTGTT 0,62
    ID 326 666
    #326
    SEQ COMP ID 5′-ACAAACACCCCTGTGGAT-3′ 2284 2301 SEQ ID ATCCACAGGGGTGTTTGT 1,08
    ID 327 667
    #327
    SEQ COMP ID 5′-CACACAAACACCCCTGTG-3′ 2287 2304 SEQ ID CACAGGGGTGTTTGTGTG 0,81
    ID 328 668
    #328
    SEQ COMP ID 5′-ACACACACAAACACCCCT-3′ 2290 2307 SEQ ID AGGGGTGTTTGTGTGTGT 0,88
    ID 329 669
    #329
    SEQ COMP ID 5′-CGCACACACACAAACACC-3′ 2293 2310 SEQ ID GGTGTTTGTGTGTGTGCG 0,60
    ID 330 670
    #330
    SEQ COMP ID 5′-ACGCGCACACACACAAAC-3′ 2296 2313 SEQ ID GTTTGTGTGTGTGCGCGT 0,68
    ID 331 671
    #331
    SEQ COMP ID 5′-CACACGCGCACACACACA-3′ 2299 2316 SEQ ID TGTGTGTGTGCGCGTGTG 0,51
    ID 332 672
    #332
    SEQ COMP ID 5′-ACGCACACGCGCACACAC-3′ 2302 2319 SEQ ID GTGTGTGCGCGTGTGCGT 0,25
    ID 333 673
    #333
    SEQ COMP ID 5′-GAAACGCACACGCGCACA-3′ 2305 2322 SEQ ID TGTGCGCGTGTGCGTTTC 0,66
    ID 334 674
    #334
    SEQ COMP ID 5′-ATTGAAACGCACACGCGC-3′ 2308 2325 SEQ ID GCGCGTGTGCGTTTCAAT 0,82
    ID 335 675
    #335
    SEQ COMP ID 5′-TTTATTGAAACGCACACG-3′ 2311 2328 SEQ ID CGTGTGCGTTTCAATAAA 0,76
    ID 336 676
    #336
    SEQ COMP ID 5′-AACTTTATTGAAACGCAC-3′ 2314 2331 SEQ ID GTGCGTTTCAATAAAGTT 0,73
    ID 337 677
    #337
    SEQ COMP ID 5′-ACAAACTTTATTGAAACG-3′ 2317 2334 SEQ ID CGTTTCAATAAAGTTTGT 0,84
    ID 338 678
    #338
    SEQ COMP ID 5′-TGTACAAACTTTATTGAA-3′ 2320 2337 SEQ ID TTCAATAAAGTTTGTACA 0,98
    ID 339 679
    #339
    SEQ COMP ID 5′-AAGTGTACAAACTTTATT-3′ 2323 2340 SEQ ID AATAAAGTTTGTACACTT 0,87
    ID 340 680
    #340
    SEQ COMP ID 5′-AGAAAGTGTACAAACTTT-3′ 2326 2343 SEQ ID AAAGTTTGTACACTTTCT 0,72
    ID 341 681
    #341
    SEQ COMP ID 5′-TTAAGAAAGTGTACAAAC-3′ 2329 2346 SEQ ID GTTTGTACACTTTCTTAA 0,87
    ID 342 682
    #342
    • Example 7: 16-Mer Oligos Targeting the 5′ UTR
  • 16-mer Oligos targeting 5′ UTR uORF region (SEQ ID Nos 95-136) were selected, prepared and profiled for effects on Progranulin protein expression.
  • H4 neuroglioma cells were seeded in 96 well plates 5000 pr well, and treated with 10 μM final concentration of compounds for 5 days in 200 μL medium.
  • Microglia cells were chosen for analysis because these cells produce high levels of progranulin. Reduction of progranulin in microglia cells alone is sufficient to effect inflammation, lysosomal dysfunction, and hyperproliferation in a cell-autonomous manner. Therefore, targeting microglial dysfunction caused by progranulin insufficiency represents a potential therapeutic strategy to manage neurodegeneration in Frontotemporal dementia. To study effects on Progranulin in cellular systems, H4 cells (ATCC HTB-148) a commercial available glial cell line derived from a cancer patient have been used for identifying oligonucleotides capable of increasing progranulin production.
  • To further use Microglia that exhibit functional characteristics similar to human microglia, including phagocytosis and cytokine-mediated inflammatory responses, and express relevant microglial markers, hiPSC derived microglia iCell® Microglia from FujiFilm Cellular Dynamics Inc. (Cat. no R1131) have been used for investigating effects of selected oligonucleotides on progranulin production.
  • Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364). Compound #105, #106, #110, #113 and #114 induced progranulin secretion more than 150% compared to PBS as shown in FIG. 1 .
  • Compounds #105, #106, #110 and #114 localise on the 5′ UTR of Proganulin transcript, targeting the uORF region as shown in FIG. 2 .
  • H4 cells were seeded in 96 well plates 5000 pr well, and treated with 10 μM final concentration of compounds for 5 days in 200 μL medium. Progranulin expression levels were evaluated in cell lysate (RIPA lysis and extraction buffer from Pierce cat. No. 89900) using the WES platform (ProteinSimple) and GRN antibody Invitrogen PA5-27275 diluted 1:25 and HPRT1 antibody ab109021 (Abcam) diluted 1:50. GRN expression was normalized to endogenous housekeeping protein HPRT1.
  • Compounds #106, #110, and #114 induced Progranulin in cell lysate compared to PBS as shown in FIGS. 3 and 4 .
    • Example 8: Compound #106
  • hiPSC derived microglia (iCell Microglia Kit, 01279, Cat. no R1131) were seeded in 48 well plates with 100000 pr well in 500 μL, and were treated with varying concentrations of Compound #106 for 5 days.
  • Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • Compound #106 (n=3) dose-dependently induced Progranulin secretion compared to PBS as shown in FIG. 5 .
    • Example 9: 18-Mer Oligos Targeting 5′ UTR
  • 18-mer Oligos targeting 5′ UTR uORF region (SEQ ID NOs: 207-245) were selected, prepared and profiled for effects on Progranulin protein expression.
  • H4 neuroglioma cells were seeded in 96 well plates 5000 pr well and treated with 10 μM final concentration of compounds for 5 days in 200 μL medium. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364).
  • Compound #231 and #241 induced Progranulin secretion compared to PBS as shown in FIG. 6 .
    • Example 10: Compound #106
  • The structure of Compound ID #106 (SEQ ID NO 106) inducing upregulation of Progranulin in both H4 cells and hiPSC derived Microglia cells, is shown in FIG. 7 .
    • Example 11: Full 2′MOE and 2′oMe Modified Versions of SEQ ID NO: 106
  • SEQ ID NO: 106 (TGGCCAGGGATCAGGG) was tested as both a full 2′MOE modified oligo (Compound #106 full 2′MOE) and a full 2′oMe modified oligo (Compound #106 full 2′oMe).
  • H4 neuroglioma cells seeded in 96 well plates 5000 pr well were treated with 10 μM final concentration of compounds for 5 days in 200 μL medium. Progranulin expression levels were evaluated in media after dilution 1:8 by ELISA from Abcam (ab252364). Compound #106 and Compound #106 full 2′MOE and Compound #106 full 2′oMe induced a ˜2-fold increase in progranulin secretion to the media compared to PBS.
    • Example 12: Gene Transcript Regulation by Compound #106, Compound #106 Full 2′MOE and Compound #106 Full 2′oMe
  • To understand the number of gene transcripts regulated by compound #106, Compound #106 full 2′MOE and Compound #106 full 2′oMe, H4 neuroglioma cells seeded in 48 well plates 15000 per well were treated with 10 μM final concentration of compounds for 5 days in 500 μL medium. mRNA was isolated using the MagNAPure 96 system (Roche) according to manufacturer's protocol. The purified mRNA were sent for gene expression array analysis at Eurofins Genomics, using Clariom™ S Arrays (ThermoFisher Scientific). Expression analysis was conducted using the Qlucore Omics Explorer software, using a two-group comparison and by adjusting the FDR<0.1. The number of genes regulated more than 2-fold either up and down compared to PBS were identified. Compound #106 showed 1207 genes regulated more than 2-fold, Compound #106 full 2′oMe showed 782 genes regulated more than 2-fold, whereas Compound #106 full 2′MOE only showed 43 transcripts regulated. FIG. 9 shows that Compound #106 full 2′MOE has less off-targets compared to compound #106 and Compound #106 full 2′oMe.
  • The genes regulated more than 2-fold with a FDR<0.1 are shown below.
  • Genes regulated more than 2-fold with a FDR<0.1 following treatment with Compound #106: AATF, ABCA1, ABCC2, ABCC3, ABCG1, ABLIM3, ACAT2, ACKR3, ACSL5, ACSS3, ACTA2, ACVR1B, ADAM9, ADAMTS16, ADAMTS19, ADAMTS3, ADAMTSL4, ADGRA3, ADGRB3, ADI1, ADRBK1, ADRM1, ADSL, AFAP1, AGT, AHCY, AHI1, AHNAK2, AHR, AJAP1, AKAP6, ALCAM, ALDH1L2, ALDH3A1, ALDOA, ALDOC, ALG8, ALKBHS, ALPK2, ALYREF, AMMECR1, AMMECR1L, AMPD2, AMTN, ANGPT1, ANK3, ANKRD18A, ANKRD44, ANLN, ANO7, ANPEP, ANTXR2, ANXA1, AOAH, APCDD1, APEX1, APH1A, APOBEC3B, APOL2, APOL3, APRT, AQP1, AQP3, ARAF, ARCN1, ARHGAP11B, ARHGAP35, ARHGAP8, ARHGEF2, ARL4A, ARMC6, ARPC4, ARPC4-TTLL3, ARRDC3, ARRDC4, ARSG, ASNA1, ASNS, ASPM, ASS1, ATAD2, ATN1, ATP6AP1L, ATP6V0A1, ATP8B3, ATXN2, ATXN2L, AVEN, B4GALT5, BCAM, BCL6, BDNF, BEX1, BHLHE40, BIRC5, BLID, BLM, BMP5, BNC2, BNIP3, BNIP3L, BSG, BTAF1, BUB1B, C10orf10, C10orf107, C12orf76, C17orf89, C1RL, C1orf174, C1orf21, C1orf52, C1orf53, C20orf24, C7orf26, C7orf73, C8orf4, C8orf48, C8orf58, CA12, CA5B, CA9, CACNG4, CACYBP, CALCOCO1, CALR, CAMK4, CAPNS1, CAPZB, CASC5, CASK, CBLB, CCBL1, CCDC102B, CCDC150, CCDC163P, CCDC34, CCNA2, CCNB1, CCNB2, CCND1, CCNE2, CCPG1, CCT2, CD151, CD24, CD55, CD96, CD99, CD99, CDC20, CDC42SE1, CDC45, CDC6, CDCA5, CDCA8, CDH6, CDH8, CDK1, CDKN1A, CDKN3, CDT1, CENPA, CENPF, CENPH, CENPI, CENPM, CENPN, CENPU, CENPW, CEP128, CEP19, CEP55, CEP78, CFC1, CFH, CFI, CFL1, CHAC1, CHAC2, CHAF1B, CHMP1B, CHP1, CHST15, CKAP2, CKS2, CLEC2D, CLIC4, CLIP4, CLK2, CLMN, CLSPN, CLSTN2, CLTA, CLTB, CMTM7, CNTNAP1, CNTNAP3, CNTNAP3B, CNTNAP3B, CNTNAP3P2, COASY, COBLL1, COG7, COL1A1, COL21A1, COL3A1, COL5A2, COLEC12, COMMD3-BMI1, COPRS, COPZ1, CORIN, CORO2B, COX2, COX5A, CP, CPA4, CPD, CPSF3, CRISPLD1, CSF1, CSGALNACT1, CTBP2, CTBS, CTH, CTNND1, CTSB, CTSC, CTSL, CTSO, CUL7, CXADR, CXCL14, CXCL8, CYB5D2, CYTL1, DACT1, DBI, DBN1, DCTPP1, DDIT4, DDR2, DDX39A, DDX46, DECR1, DEDD, DEPDC1, DEPTOR, DGKD, DGKD, DGKD, DGKD, DGKD, DGKD, DHCR24, DHFR, DHRS3, DHX15, DHX9, DLGAP5, DLX1, DMKN, DOCK10, DPT, DPYD, DPYSL2, DPYSL3, DPYSL5, DSEL, DSN1, DSTN, DTNBP1, DUSP6, E2F8, EBI3, EBP, EDC4, EDEM1, EDIL3, EEF1B2, EEPD1, EFEMP2, EFTUD1, EGLN3, EGR1, EID1, EIF5, EIF5A, EIF6, ELAVL2, EMP1, ENC1, ENCASE, ENO2, ENPP1, ENPP2, ENTPD4, EPAS1, EPHX1, EPT1, ERGIC1, ERH, ERN1, ERO1A, ERRFI1, ETV1, ETV5, EXO1, EXT1, EXT1, EYA4, FAM101B, FAM111A, FAM111B, FAM114A1, FAM127B, FAM13A, FAM13C, FAM155A, FAM155A, FAM155A, FAM160A2, FAM161A, FAM162A, FAM200B, FAM20B, FAM214B, FAM219A, FAM234A, FAM46A, FAM83D, FANCA, FANCD2, FANC1, FBL, FBN1, FBXO32, FBXO36, FBXO44, FBXO7, FCHSD1, FDPS, FDX1L, FEM1C, FEM1C, FEN1, FGF7, FH, FIBIN, FJX1, FKBP10, FKBP1A, FKBP1A-SDCBP2, FKBP9, FLOT1, FLOT2, FLRT2, FN1, FNBP4, FOSL1, FOSL2, FOXF1, FOXF2, FOXK1, FOXM1, FRMD4B, FSCN1, FSTL1, FSTL4, FTSJ2, FUCA1, FUNDC2, FURIN, FUS, FUT11, FXYD5, FYCO1, GABRE, GALNT1, GALNT13, GANAB, GAR1, GATAD1, GBA, GBE1, GCLC, GCSH, GDI1, GFPT1, GFRA1, GFRA2, GINS1, GINS2, GLCCI1, GLI3, GLIPR2, GLIS3, GLRX2, GLT8D2, GLUL, CML, GMNN, GNAI1, GPAA1, GPATCH2L, GPATCH4, GPI, GPNMB, GPR137C, GPR34, GPRC5B, GPT2, GRAMD1A, GRINA, GRM8, GRWD1, GTF3A, GTPBP6, GTPBP6, H2AFV, H2AFX, H2AFY2, H6PD, HDAC9, HELLS, HGF, HIBCH, HILPDA, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E, HIST1H2AB, HIST1H2AG, HIST1H2AH, HIST1H2A1, HIST1H2AJ, HIST1H2AL, HIST1H2AM, HIST1H2BF, HIST1H2BG, HIST1H2BH, HIST1H2B1, HIST1H2BJ, HIST1H2BK, HIST1H2BL, HIST1H2BO, HIST1H3B, HIST1H3D, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H4B, HIST1H4C, HIST1H4D, HIST1H4H, HIST1H41, HIST2H2AA3, HIST2H2AA4, HIST2H2AB, HIST2H2AC, HIST2H2BE, HIST2H2BF, HIST2H3A, HIST2H3A, HIST2H3D, HIST2H4A, HIST2H4B, HIST3H2A, HIST3H2BB, HJURP, HK2, HLTF, HMGB3, HMGCS1, HMGCS2, HNRNPM, HOXA13, HOXA3, HOXB3, HPCAL1, HS6ST2, HSD17B13, HSF4, HSP90AA1, HSPA13, HSPB3, HSPH1, HTATSF1, HTR7, ID2, ID3, IDH2, ID11, IDO1, IER3, IFI16, IFI44L, IFITM1, IFITM2, IFITM3, IFNGR2, IGF2, IGF2BP3, IGFBP3, IGFBP5, IK, IL13RA1, IL13RA2, IL1R1, IL1RAP, IL20RB, IL32, IL6, INAFM1, INHBB, INSIG2, IRF9, ISY1, ITFG2, ITGA11, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA8, ITGAX, ITGB3, ITGB5, ITGB6, ITGBL1, ITM2C, ITPKB, JAK2, JAK2, JUN, KAZALD1, KCNQ3, KCTD11, KDM4C, KDM5C, KEAP1, KIAA0101, KIAA1456, KIF11, KIF14, KIF15, KIF15, KIF15, KIF15, KIF15, KIF18A, KIF20A, KIF22, KIF23, KIF2C, KIF4A, KIFC1, KLF10, KLF9, KLHL4, KNSTRN, KNTC1, KPNA2, KPTN, KRT17, KRT81, KYNU, LACTB, LAMA1, LAMB1, LAMTOR4, LANCL2, LBH, LEF1, LEFTY2, LHX8, LIF, LIFR, LIMCH1, LINC00473, LINGO2, LMAN1, LMBR1L, LMNB1, LMNB2, LMNTD2, LOC100130880, LOX, LPAR6, LPCAT1, LPXN, LRIG3, LRP1, LRRC1, LRRC15, LRRC17, LRRC23, LRRC8C, LRRTM4, LRRTM4, LSAMP, LSG1, LSM3, LSM5, LUZP1, LY6E, LYPD6B, MAGEA1, MAP1LC3C, MAP2K6, MAP3K7CL, MAP9, MAPK14, MAPK1IP1L, MAPK3, MAPRE3, MARS, MASP1, MATN2, MBOAT7, MCAT, MCFD2, MCM2, MCM3, MCM4, MCM5, MCM6, MCM7, MCM8, MCOLN1, MCTP2, MDH1B, MECOM, MEF2A, MEIS2, MELK, METTL15, MFAP3L, MFSD1, MFSD10, MGAT5, MGST3, MILR1, MIR99AHG, MK167, MMAB, MMD, MMP13, MMP3, MNS1, MOCOS, MOCS2, MOGS, MORF4L2, MOSPD2, MPI, MPP7, MPPED2, MPRIP, MRPL3, MRPL51, MRPL57, MRPS11, MSANTD2, MSH2, MT1B, MT1G, MT1IP, MT1L, MT1X, MT2A, MTCH2, MTERF3, MTHFD1, MTIF2, MTPAP, MX1, MYADM, MYBL2, MYLK, MYO6, MYO6, NAGK, NALCN, NAMPT, NANOS1, NAP1L1, NAPA, NASP, NCAM1, NCAPD2, NCAPG, NCAPH, NCK1, NCKAP5, NCL, NCOA4, NCOA7, ND4L, NDC80, NDNF, NDRG1, NDUFA4L2, NDUFS6, NDUFS8, NEIL3, NETO2, NEU1, NEXN, NFAT5, NFE2, NFE2L1, NFKB2, NFKBIA, NFYB, NHEJ1, NHP2, NMI, NOL3, NPIPA1, NPIPA5, NPIPA7, NPIPA7, NPIPA8, NR2C1, NR2F1, NR4A1, NSDHL, NSMAF, NSUN4, NUAK1, NUSAP1, NXPH4, NYAP2, OAS1, OAS2, OASL, OCIAD2, ODC1, OGN, OGT, OLA1, OLFML2B, OLFML3, OR8B12, ORAI3, ORC1, ORC6, OSBPL3, OSGEP, OSMR, OXCT1, P4HA1, P4HA2, PABPC4, PAFAH1B3, PAK1IP1, PAN2, PAQR6, PARD3B, PARM1, PARP14, PCDH10, PCF11, PCMTD1, PCNA, PCNX, PCP4, PCYOX1L, PDE10A, PDE4B, PDE5A, PDGFD, PDGFRA, PDIA4, PDK1, PDLIM5, PELI1, PELO, PEPD, PFKFB4, PFKP, PGAM1, PGK1, PHF19, PHLDA1, PIDD1, PIF1, PIK3R3, PITPNM1, PITX1, PLA2G6, PLACE, PLAGL1, PLAT, PLAU, PLD1, PLD1, PLEKHA2, PLEKHG1, PLEKHS1, PLIN2, PLK4, PLN, PLOD1, PLOD2, PLOD3, PLPP3, PLPP4, PLSCR1, PLXDC2, PLXNC1, PMEPA1, PMM2, PNPLA2, PNPLA6, PNRC1, PODXL, POLQ, POLR1E, POLR2J4, POLR3D, POMT1, PON2, POSTN, PPARGC1A, PPIL1, PPM1B, PPP1R37, PPP1R7, PPP1R8, PPP3CA, PQBP1, PRADC1, PRC1, PRH1, PRIM1, PRKAA2, PRKAB2, PRKAR1A, PRKDC, PRKG1, PROCR, PROZ, PRR4, PRRC2B, PRRT1, PRUNE2, PSAT1, PSD3, PSMA2, PSMB1, PSMD1, PSMD2, PSMD3, PSMD9, PSMG1, PSMG2, PTAR1, PTCHD1, PTGES, PTGES3L-AARSD1, PTGR2, PTGS2, PTPMT1, PTPN13, PTPRG, PTPRM, PTPRN2, PUS7L, PVRL2, QRICH2, RAB27A, RAB33B, RAB7B, RABEP2, RABGGTA, RAD51, RAD51AP1, RAD51C, RALGAPA2, RALGPS2, RANBP3L, RASA4, RASL11A, RBL1, RBL2, RBM3, RBM8A, RBPMS, RCN3, REC8, RECQL4, RELA, REPS1, RFC4, RFPL4A, RGL2, RGS10, RGS18, RGS2, RMI2, RNF144A, RNF145, RNF213, RNF24, RNPEP, RORA, RP11-307P5.1, RPP21, RPP30, RPP40, RPS26, RPS26, RPS6KA3, RRAGC, RRAS, RRBP1, RRM1, RRM2, RTKN2, RTN3, RUNX2, RWDD1, S100A10, SAFB2, SAMD15, SAMD5, SAMD8, SAT1, SATB2, SBNO2, SCAMP3, SCARA3, SCN9A, SCOC, SCRIB, SDC4, SEC14L2, SEC23B, SECISBP2L, SEL1L3, SEMA3C, SEMA4B, SEMA6D, SERHL2, SERINC5, SERPINA3, SETD5, SF3B1, SFR1, SFRP4, SGIP1, SGK1, SGOL2, SGSH, SH3BGRL3, SH3BP2, SHB, SHC1, SHC4, SHCBP1, SHISA5, SHMT1, SIDT2, SIGMAR1, SKA2, SLC14A1, SLC16A1, SLC16A1, SLC16A3, SLC16A4, SLC16A6, SLC1A3, SLC1A5, SLC20A1, SLC25A19, SLC25A36, SLC25A37, SLC26A11, SLC29A1, SLC29A4, SLC2A1, SLC2A14, SLC2A3, SLC35F5, SLC37A3, SLC43A2, SLC4A4, SLC6A6, SLC7A5, SLCO4A1, SLFN5, SLIT2, SLITRK2, SLPI, SMAD7, SMAD9, SMAGP, SMC3, SMIM3, SMOX, SMPD1, SMPDL3A, SNAI1, SNAPC3, SNED1, SNRNP25, SNRPF, SNX2, SNX33, SOBP, SOCS4, SOCS5, SORT1, SOST, SPC24, SPC25, SPDL1, SPOCD1, SPON2, SPP1, SPRY1, SPRY3, SPRY3, SPRY4, SQLE, SRM, SRPX2, SRRT, SSBP2, ST8SIA4, STAG3L4, STC1, STC2, STEAP1B, STEAP2, STEAP3, STIL, STK11IP, STRA6, STXBP5L, SURF4, SURF4, SURF4, SURF4, SUV39H1, SVIP, SYNC, SYNJ2, SYT14, SYTL2, TACC3, TADA3, TAF9, TAF9B, TAGLN2, TANGO6, TAPBP, TAS2R31, TBC1D1, TBC1D28, TBC1D31, TBL1X, TBXAS1, TCEAL2, TCEAL4, TCF19, TCHP, TCP1, TDO2, TEX264, TFAP2A, TFAP2C, TFPI, TFRC, TGFA, TGFB2, THTPA, TIMELESS, TIMM10, TIMP1, TIMP3, TIPARP, TM2D2, TM4SF1, TM9SF4, TMED4, TMED7-TICAM2, TMEM100, TMEM160, TMEM182, TMEM2, TMEM2, TMEM230, TMEM30A, TMEM39A, TMEM70, TMEM97, TMEM98, TMEM99, TMPO, TMSB15A, TMUB1, TNFRSF10B, TNFRSF1A, TNFRSF9, TNFSF10, TOE1, TOMM34, TOP2A, TOR3A, TP63, TPBG, TPCN1, TPM1, TPMT, TPX2, TRAPPC2L, TRAPPC4, TRAPPC5, TRIB2, TRIB3, TRIM22, TRIM25, TRIM36, TRIMS, TRIP10, TRIP13, TRIT1, TRMO, TROAP, TSPAN9, TSR2, TSR3, TTC25, TTC37, TTLL12, TUBG2, TVP23C, TWISTNB, TXN, TXNIP, TYMS, U2AF1, UBE2C, UBR7, UGGT2, UHRF1, UMPS, UNC93B1, UNG, USP3, VAT1, VCAM1, VCAN, VGF, VOPP1, VPS11, VRK1, VWA5A, WARS, WDR27, WDR34, WDR60, WDR62, WDR76, WDR90, WNT2B, WNT5B, WSB1, XBP1, XRCC2, XRCC3, XRCC6BP1, YEATS4, YIF1A, YY1AP1, ZBED6, ZBTB25, ZC4H2, ZDHHC15, ZDHHC4, ZNF160, ZNF326, ZNF358, ZNF382, ZNF395, ZNF414, ZNF511, ZNF512B, ZNF521, ZNF529-AS1, ZNF532, ZNF570, ZNF667, ZNF682, ZNF692, ZNF777, ZNF785, ZNF830, ZNF92, ZWILCH and ZWINT.
  • Genes regulated more than 2-fold with a FDR<0.1 following treatment with Compound #106 full 2′oMe: AARS, ABCA1, ABLIM1, ACAT2, ACSL5, ADAM9, ADAMTS16, ADAMTS19, ADAMTSL4, ADGRA2, ADRBK1, ADRM1, ADSSL1, AGPS, AGRN, AGT, AHNAK, AHNAK2, AHR, AJAP1, AK7, AKAP12, AKAP6, AKR1C2, AKR1C3, ALCAM, ALDH1L2, ALDH3A1, ALDOC, ALPK2, ALYREF, AMTN, ANK3, ANKRD44, ANPEP, ANTXR2, AOAH, AP4S1, APCDD1, AQP1, ARHGAP11B, ARHGDIB, ARHGEF2, ARL15, ARMC6, ARRDC3, ARRDC4, ARSG, ASPN, ATAD2, ATHL1, ATP13A2, ATP6AP1L, ATP6V1C1, ATXN1, AURKB, BANF1, BCAR3, BCAT1, BCL6, BCO1, BDNF, BEX1, BLID, BMP5, BNC2, BNIP3, BSG, BST2, BTAF1, BTG2, BTG3, BUB1, BUB1B, C10orf107, C14orf1, C14orf132, C1QTNF3, C3orf14, C3orf58, C4A, C4B, C8orf4, C9orf43, C9orf50, CA12, CA9, CACNG4, CALCB, CAMK4, CARS, CASK, CASP4, CBFA2T3, CCDC102B, CCDC34, CCNA2, CCPG1, CD24, CD55, CD82, CD96, CDC45, CDC6, CDCA3, CDCA5, CDCA8, CDH6, CDK1, CEBPG, CENPF, CENPI, CENPM, CENPN, CENPU, CEP128, CFH, CFI, CHAC1, CHEK1, CHL1, CHMP1B, CHRNA1, CHRNA9, CHST15, CLDND1, CLEC2B, CLIC2, CLIC5, CLMN, CLSTN2, CMKLR1, CMTM3, CNPPD1, CNTNAP1, CNTNAP3, CNTNAP3B, CNTNAP3B, CNTNAP3P2, COBLL1, COL1A1, COL3A1, COL5A2, COLEC12, CORIN, CP, CPA4, CSF1, CSGALNACT1, CSGALNACT2, CSNK1E, CTBP1, CTBS, CTH, CTNS, CTSC, CXADR, CXCL14, CXCL3, CXCL8, CYP51A1, CYTH3, DACT1, DACT1, DBI, DBN1, DDIT4, DDX39A, DDX58, DDX60, DECR1, DEPTOR, DET1, DGKD, DGKD, DGKD, DGKD, DGKD, DHCR24, DHCR7, DHFR, DHFR, DHRS3, DHX58, DLG3, DLGAP5, DLX1, DNAH5, DNAJB1, DOCK10, DPT, DPYSL3, DSEL, DSN1, DUSP10, DUSP6, EBP, EEPD1, EFEMP2, EFTUD1, EGLN3, EID1, EIF2AK2, ELAVL2, EMP1, ENC1, ENGASE, ENO1, ENO2, ENPP2, ENTPD4, EPAS1, ERICH1, ERO1A, ERRFI1, ETV1, EXO1, EXT1, EXT1, F3, FAM111A, FAM111B, FAM118B, FAM13A, FAM13C, FAM155A, FAM155A, FAM161A, FAM162A, FAM198B, FAM20C, FAM46A, FAM83D, FANCI, FAP, FAS, FBLN5, FBN1, FBXO32, FGF7, FJX1, FLOT1, FN1, FOXF2, FOXM1, FSTL1, FSTL4, FUT11, GABRE, GADD45A, GATAD1, GBE1, GCLC, GDF15, GDI1, GFRA1, GINS1, GINS2, GLRX, GLT8D2, GLUL, GMFG, GNAI1, GNPDA1, GPC4, GPCPD1, GPI, GPNMB, GPRC5B, GPS2, GPT2, GPX3, GRIP1, H2AFV, H2AFX, HACE1, HDAC9, HDLBP, HGF, HHAT, HIPK2, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E, HIST1H2AG, HIST1H2AH, HIST1H2A1, HIST1H2AJ, HIST1H2AL, HIST1H2AM, HIST1H2BF, HIST1H2BH, HIST1H2BI, HIST1H2BJ, HIST1H2BK, HIST1H2BL, HIST1H3B, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H4B, HIST1H4C, HIST1H4H, HIST2H2AA3, HIST2H2AA4, HIST2H2AB, HIST2H2AC, HIST2H2BE, HIST2H2BF, HIST2H3A, HIST2H3A, HIST2H3D, HIST2H4A, HIST2H4B, HIST3H2BB, HLA-DRA, HMCN1, HMGB3, HMGCR, HMGCS1, HMGN2, HNRNPM, HOXA3, HPCAL1, HS6ST2, HSD17B10, HSD17B13, HSF4, HSP90B1, HSPB3, HTR7, ID3, ID11, IDO1, IER3, IF116, IF127, IF144, IF144L, IF16, IFITM1, IFITM2, IFITM3, IGF1, IGFBP3, IGFBP5, IL13RA1, IL13RA2, IL1R1, IL20RB, IL6, IL7R, ILF2, INAFM1, INHBA, INHBB, INSIG1, INSIG2, IRF9, ITGA11, ITGA2, ITGA5, ITGA6, ITGA8, ITGAX, ITGB6, ITGBL1, ITPKB, JAK2, JUN, KBTBD11, KCNH1, KCNQ3, KIAA0101, KIAA1456, KIF11, KIF15, KIF15, KIF15, KIF20A, KIF22, KIF23, KIF26B, KIF2C, KIF4A, KIFC1, KIRREL3, KPNA2, KRT17, KRTAP9-3, KYNU, LACTB, LAMB1, LBH, LEF1, LEFTY1, LEMD1, LEPR, LFNG, LGR4, LIF, LIMCH1, LINC00473, LINC00663, LINC01565, LINGO2, LITAF, LMAN1, LMNB1, LMNB2, LOX, LPAR6, LPCAT1, LRIG3, LRRC15, LRRC23, LRRN1, LRRTM4, LSAMP, LSS, LST1, LXN, LY6E, LY6E, LYPD6B, MAP1LC3C, MAP2K6, MAP3K5, MAP3K7CL, MASP1, MB21D2, MCM2, MCM3, MCM4, MCM5, MCOLN1, MCTP2, MECOM, MEIS2, MELK, MERTK, MET, MFAP2, MFAP3L, MFAP4, MFSD10, MGLL, MGP, MILR1, MIR99AHG, MK167, MMD, MMP13, MOCOS, MPI, MPP7, MPPED2, MSC, MSH2, MT1X, MTFR2, MTHFD1, MTIF2, MX1, MX2, MYBL2, MYLK, MYO5B, MYO6, NAMPT, NANOS1, NBL1, NBN, NCAM1, NCAPD2, NCAPG, NCKAP1, NCOA7, NDC80, NDNF, NDOR1, NDUFA4L2, NES, NEXN, NFE2, NFKBIA, NKAP, NNT, NOL3, NPAS2, NPIPA1, NPIPA5, NPIPA7, NPIPA8, NQO1, NR2F1, NREP, NTM, NUAK1, NUCB2, NUDT22, NUSAP1, NXPH4, NYAP2, OAS1, OAS2, OBFC1, OLFM1, OLFML2A, OLFML2B, OLFML3, OR5H1, OSBPL3, OSGEP, OSMR, OXCT1, P2RX7, P4HA1, PABPC1, PABPC1L2A, PADI3, PADI3, PAN2, PARM1, PARP1, PARP14, PARP9, PAX9, PCDH10, PCNA, PCNX, PCP4, PDE10A, PDE5A, PDGFD, PDGFRA, PDIK1L, PDK1, PDK2, PDLIM5, PEPD, PFKFB4, PFKP, PGK1, PHLDA1, PIDD1, PIK3R3, PITX1, PKD1, PLACE, PLAT, PLAU, PLD1, PLD1, PLIN2, PLK1, PLK4, PLOD1, PLPP3, PLPP4, PLSCR1, PLXDC2, PMEPA1, PNPLA3, POFUT2, POLD2, POLR1E, POLR2J4, POSTN, POU6F1, PPARG, PPARGC1A, PPP1CC, PRC1, PREX2, PRICKLE1, PRIM1, PRKAA2, PRKD1, PROCR, PRR11, PRSS12, PRUNE2, PSD3, PSG4, PTCH1, PTCHD1, PTGES, PTGS2, PTPN13, PTPRM, PVRL2, PXDC1, PYROXD1, RAB27A, RAB43, RACGAP1, RAD54L, RALGAPA2, RANBP3L, RAP2B, RASL11A, RASL11B, RBL2, RBM3, RBPMS, RCN3, REC8, RELB, RGS10, RGS18, RGS2, RHOJ, RNF145, RNF217, RNFT2, RORA, RPS6KA3, RRAGC, RRM1, RTKN2, RUNX2, SAMD15, SAMD8, SAT1, SATB2, SBNO2, SC5D, SDC4, SDR42E1, SECISBP2L, SEL1L3, SEMA4B, SERINC5, SERPINB1, SERPINE2, SERTAD4, SESN3, SFRP4, SGIP1, SGK1, SGOL1, SGSH, SHC1, SHC4, SHCBP1, SHISA5, SHMT1, SIDT2, SIX1, SLC14A1, SLC16A3, SLC16A4, SLC16A6, SLC1A3, SLC20A1, SLC25A37, SLC29A1, SLC29A4, SLC2A14, SLC2A3, SLC39A8, SLC44A4, SLC4A4, SLC50A1, SLC7A5, SLC9A3R2, SLCO1C1, SLCO4A1, SLFN5, SLIT2, SLITRK2, SLPI, SMAD9, SNAI1, SNAP25, SNAPC1, SNX8, SORBS2, SORT1, SPAG4, SPC24, SPC25, SPDL1, SPECC1, SPOCD1, SPP1, SPRY1, SSBP2, ST8SIA4, STARD4, STAT1, STC1, STC2, STEAP2, STEAP3, STMN1, SULT1E1, SYNC, SYNGR1, SYNM, SYT14, TACC3, TAF9B, TBC1D2, TBC1D3L, TBL1X, TDO2, TET3, TFAP2C, TFB1M, TFPI, TFRC, TGFB2, TIMELESS, TIMP1, TIMP3, TIPARP, TK1, TLR3, TM4SF1, TMCO4, TMEM100, TMEM140, TMEM189, TMEM19, TMEM2, TMEM255A, TMEM257, TMEM97, TNC, TNFRSF10B, TNFRSF9, TNFSF10, TOB1, TOP2A, TP63, TPBG, TPM1, TPM2, TPX2, TRAPPC2L, TRIB2, TRIB3, TRIM36, TRIM49C, TSPAN2, TSPAN9, TUBA1A, TVP23C, TXK, TXNIP, TYMS, UAP1L1, UBR7, UHRF1, VASH2, VCAM1, VCAN, VEGFA, VGLL2, VWA5A, WARS, WDR60, WDR62, WDR76, WFDC3, WFS1, WNT2B, WSB1, XBP1, XRCC2, YARS, YIF1A, ZBTB25, ZFP36L2, ZNF395, ZNF521, ZNF667, ZNF804A and ZNF814.
  • Genes regulated more than 2-fold with a FDR<0.1 following treatment with Compound #106 full 2′MOE: ACAT2, ADI1, ARRDC4, CCPG1, CDCA5, COL3A1, CP, CXCL8, EFEMP2, ENC1, FANCD2, FBN1, HIST1H1B, HIST1H2AG, HIST1H2A1, HIST1H2AL, HIST1H2BA, HIST1H3B, HIST2H2AA4, HIST2H2BF, HIST3H2BB, HSF4, IF144L, IF16, IGFBP3, KHDC1, KIF20A, LEF1, LOX, LY6E, MGAT4C, MMP3, MX1, NDNF, NDUFA4L2, NUSAP1, PDGFD, PHLDA1, PTX3, RGS18, SFRP4, TPBG and VCAN.
    • Example 13
  • H4 neuroglioma cells seeded in 96 well plates 5000 pr well were treated with 10 μM final concentration of compounds for 5 days in 200 μL full growth medium. Progranulin expression levels were evaluated in the media after dilution 1:8 by ELISA from Abcam (ab252364) according to manufactorer's protocol. Progranulins levels were normalized to PBS treated cells and values above >1 therefore indicates an upregulation of PGRN protein levels. Table 4 list the compounds tested, their sequences and their corresponding target site on the PGRN mRNA as well as the Progranulin protein expression levels.
  • Lengthy table referenced here
    US20230287412A1-20230914-T00001
    Please refer to the end of the specification for access instructions.
  • Lengthy table referenced here
    US20230287412A1-20230914-T00002
    Please refer to the end of the specification for access instructions.
  • LENGTHY TABLES
    The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20230287412A1). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

Claims (47)

1. An antisense oligonucleotide progranulin agonist, wherein the antisense oligonucleotide is 8-40 nucleotides in length and comprises a contiguous nucleotide sequence of 8-40 nucleotides in length which are complementary to a human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript
2. The antisense oligonucleotide progranulin agonist of claim 1, wherein the human progranulin mature mRNA transcript is SEQ ID NO 1.
3. The antisense oligonucleotide progranulin agonist of claim 1, wherein the human progranulin precursor-mRNA (pre-mRNA) is SEQ ID NO 3949.
4. The antisense oligonucleotide progranulin agonist according to any one of claims 1-3, wherein the contiguous nucleotide sequence is of a length of at least 12 nucleotides in length.
5. The antisense oligonucleotide progranulin agonist according to claim 4, wherein the contiguous nucleotide sequence is 12-16 or 12-18 nucleotides in length.
6. The antisense oligonucleotide progranulin agonist according to claim 4, wherein the contiguous nucleotide sequence is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
7. The antisense oligonucleotide progranulin agonist according to any one of claims 1-6, wherein the contiguous nucleotide sequence is the same length as the antisense oligonucleotide.
8. The antisense oligonucleotide progranulin agonist according to any one of claims 1-7, wherein the contiguous nucleotide sequence is fully complementary to the human progranulin precursor-mRNA (pre-mRNA) or mature mRNA transcript.
9. The antisense oligonucleotide progranulin agonist according to any one of claims 1-8, wherein the contiguous nucleotide sequence is complementary to a 5′UTR region of a human progranulin mature mRNA transcript.
10. The antisense oligonucleotide progranulin agonist according to claim 9, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 2, SEQ ID NO 689, SEQ ID NO 683, or a sequence selected from the group consisting of SEQ ID NO 343-586.
11. The antisense oligonucleotide progranulin agonist according to any one of claims 1-9, wherein the contiguous nucleotide sequence is complementary to nucleotides 38-246 of SEQ ID NO 1.
12. The antisense oligonucleotide progranulin agonist according to any one of claims 1-9, wherein the contiguous nucleotide sequence is fully complementary to SEQ ID NO 2, or SEQ ID NO 689.
13. The antisense oligonucleotide progranulin agonist according to any one of claims 1-9, wherein the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 568, SEQ ID NO 571, SEQ ID NO 575, SEQ ID NO 576, SEQ ID NO 577, SEQ ID NO 578, SEQ ID NO 584 & SEQ ID NO 586.
14. The antisense oligonucleotide progranulin agonist according to any one of claims 1-13, wherein the contiguous nucleotide sequence is a sequence selected from the group consisting of SEQ ID NO 3-342, or at least 8 or at least 10 contiguous nucleotides thereof.
15. The antisense oligonucleotide progranulin agonist according to any one of claims 1-14, wherein the contiguous nucleotide sequence is selected from SEQ ID NO 105, SEQ ID NO 106, SEQ ID NO 110, SEQ ID NO 113, SEQ ID NO 114, SEQ ID NO 231 and SEQ ID NO 241 or at least 8 or at least 10 contiguous nucleotides thereof.
16. The antisense oligonucleotide progranulin agonist according to any one of claims 1-8, wherein contiguous nucleotide sequence is complementary to a 3′UTR region of a human progranulin mature mRNA transcript.
17. The antisense oligonucleotide progranulin agonist according to claim 16, wherein the contiguous nucleotide sequence is complementary to SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, SEQ ID NO 688, or a sequence selected from the group consisting of SEQ ID NO 587-682.
18. The antisense oligonucleotide progranulin agonist according to claim 16, wherein the contiguous nucleotide sequence is complementary to nucleotides 2039-2346 of SEQ ID NO 1.
19. The antisense oligonucleotide progranulin agonist according to any one of claims 16-18 wherein the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 684, SEQ ID NO 685, SEQ ID NO 686, SEQ ID NO 687, and SEQ ID NO 688.
20. The antisense oligonucleotide progranulin agonist according to any one of claims 16-19 wherein the contiguous nucleotide sequence is fully complementary to a sequence selected from the group consisting of SEQ ID NO 607, SEQ ID NO 608, SEQ ID NO 609, SEQ ID NO 610, SEQ ID NO 611, SEQ ID NO 612, SEQ ID NO 619, SEQ ID NO 620, SEQ ID NO 633, SEQ ID NO 640, SEQ ID NO 641, SEQ ID NO 645, SEQ ID NO 651, and SEQ ID NO 652.
21. The antisense oligonucleotide progranulin agonist according to any one of claims 16-20, wherein the contiguous nucleotide sequence is selected from SEQ ID NO 267, SEQ ID NO 268, SEQ ID NO 269, SEQ ID NO 270, SEQ ID NO 271, SEQ ID NO 272, SEQ ID NO 279, SEQ ID NO 280, SEQ ID NO 293, SEQ ID NO 300, SEQ ID NO 301, SEQ ID NO 305, SEQ ID NO 311, and SEQ ID NO 312, or at least 8 or at least 10 contiguous nucleotides thereof.
22. The antisense oligonucleotide progranulin agonist according to any one of claims 1-8, wherein the contiguous nucleotide sequence is complementary to a sequence selected from the group consisting of SEQ ID NO 2040-3386.
23. The antisense oligonucleotide progranulin agonist according to claim 22, wherein the contiguous nucleotide sequence is complementary to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2322, SEQ ID 2324, SEQ ID 2328, SEQ ID 2329, SEQ ID 2331, SEQ ID 2334, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2340, SEQ ID 2341, SEQ ID 2342, SEQ ID 2345, SEQ ID 2346, SEQ ID 2347, SEQ ID 2348, SEQ ID 2349, SEQ ID 2350, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2356, SEQ ID 2357, SEQ ID 2358, SEQ ID 2359, SEQ ID 2360, SEQ ID 2361, SEQ ID 2362, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2368, SEQ ID 2369, SEQ ID 2370, SEQ ID 2371, SEQ ID 2372, SEQ ID 2373, SEQ ID 2374, SEQ ID 2375, SEQ ID 2376, SEQ ID 2377, SEQ ID 2378, SEQ ID 2379, SEQ ID 2380, SEQ ID 2381, SEQ ID 2384, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2390, SEQ ID 2392, SEQ ID 2393, SEQ ID 2394, SEQ ID 2395, SEQ ID 2396, SEQ ID 2397, SEQ ID 2398, SEQ ID 2399, SEQ ID 2400, SEQ ID 2401, SEQ ID 2403, SEQ ID 2404, SEQ ID 2405, SEQ ID 2406, SEQ ID 2407, SEQ ID 2408, SEQ ID 2410, SEQ ID 2411, SEQ ID 2413, SEQ ID 2414, SEQ ID 2415, SEQ ID 2416, SEQ ID 2418, SEQ ID 2419, SEQ ID 2421, SEQ ID 2424, SEQ ID 2425, SEQ ID 2426, SEQ ID 2427, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2433, SEQ ID 2434, SEQ ID 2435, SEQ ID 2436, SEQ ID 2437, SEQ ID 2438, SEQ ID 2439, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2443, SEQ ID 2444, SEQ ID 2445, SEQ ID 2446, SEQ ID 2447, SEQ ID 2448, SEQ ID 2449, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2457, SEQ ID 2458, SEQ ID 2459, SEQ ID 2460, SEQ ID 2461, SEQ ID 2462, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2479, SEQ ID 2481, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2490, SEQ ID 2491, SEQ ID 2492, SEQ ID 2493, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2498, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2503, SEQ ID 2504, SEQ ID 2505, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2510, SEQ ID 2511, SEQ ID 2512, SEQ ID 2513, SEQ ID 2514, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2522, SEQ ID 2523, SEQ ID 2524, SEQ ID 2525, SEQ ID 2526, SEQ ID 2527, SEQ ID 2528, SEQ ID 2531, SEQ ID 2533, SEQ ID 2534, SEQ ID 2535, SEQ ID 2536, SEQ ID 2537, SEQ ID 2538, SEQ ID 2540, SEQ ID 2541, SEQ ID 2542, SEQ ID 2544, SEQ ID 2546, SEQ ID 2547, SEQ ID 2549, SEQ ID 2550, SEQ ID 2551, SEQ ID 2553, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2557, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2563, SEQ ID 2565, SEQ ID 2566, SEQ ID 2567, SEQ ID 2572, SEQ ID 2573, SEQ ID 2574, SEQ ID 2575, SEQ ID 2576, SEQ ID 2577, SEQ ID 2578, SEQ ID 2579, SEQ ID 2580, SEQ ID 2581, SEQ ID 2582, SEQ ID 2583, SEQ ID 2584, SEQ ID 2585, SEQ ID 2586, SEQ ID 2588, SEQ ID 2589, SEQ ID 2590, SEQ ID 2591, SEQ ID 2592, SEQ ID 2593, SEQ ID 2594, SEQ ID 2595, SEQ ID 2596, SEQ ID 2597, SEQ ID 2598, SEQ ID 2599, SEQ ID 2601, SEQ ID 2602, SEQ ID 2603, SEQ ID 2604, SEQ ID 2606, SEQ ID 2610, SEQ ID 2613, SEQ ID 2614, SEQ ID 2615, SEQ ID 2619, SEQ ID 2622, SEQ ID 2623, SEQ ID 2624, SEQ ID 2625, SEQ ID 2626, SEQ ID 2627, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2632, SEQ ID 2633, SEQ ID 2634, SEQ ID 2635, SEQ ID 2636, SEQ ID 2637, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2641, SEQ ID 2642, SEQ ID 2643, SEQ ID 2644, SEQ ID 2645, SEQ ID 2646, SEQ ID 2647, SEQ ID 2648, SEQ ID 2649, SEQ ID 2650, SEQ ID 2651, SEQ ID 2652, SEQ ID 2653, SEQ ID 2654, SEQ ID 2655, SEQ ID 2656, SEQ ID 2658, SEQ ID 2659, SEQ ID 2660, SEQ ID 2661, SEQ ID 2662, SEQ ID 2663, SEQ ID 2664, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2668, SEQ ID 2669, SEQ ID 2670, SEQ ID 2671, SEQ ID 2672, SEQ ID 2673, SEQ ID 2674, SEQ ID 2675, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2680, SEQ ID 2681, SEQ ID 2682, SEQ ID 2683, SEQ ID 2684, SEQ ID 2685, SEQ ID 2686, SEQ ID 2687, SEQ ID 2688, SEQ ID 2689, SEQ ID 2690, SEQ ID 2691, SEQ ID 2693, SEQ ID 2694, SEQ ID 2695, SEQ ID 2696, SEQ ID 2697, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2702, SEQ ID 2703, SEQ ID 2704, SEQ ID 2705, SEQ ID 2706, SEQ ID 2707, SEQ ID 2708, SEQ ID 2709, SEQ ID 2710, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2715, SEQ ID 2716, SEQ ID 2717, SEQ ID 2718, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2722, SEQ ID 2723, SEQ ID 2726, SEQ ID 2727, SEQ ID 2728, SEQ ID 2729, SEQ ID 2730, SEQ ID 2733, SEQ ID 2734, SEQ ID 2735, SEQ ID 2736, SEQ ID 2737, SEQ ID 2738, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2759, SEQ ID 2760, SEQ ID 2761, SEQ ID 2762, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2773, SEQ ID 2774, SEQ ID 2775, SEQ ID 2815, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2821, SEQ ID 2822, SEQ ID 2823, SEQ ID 2824, SEQ ID 2825, SEQ ID 2826, SEQ ID 2827, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2838, SEQ ID 2839, SEQ ID 2840, SEQ ID 2841, SEQ ID 2842, SEQ ID 2843, SEQ ID 2844, SEQ ID 2845, SEQ ID 2847, SEQ ID 2848, SEQ ID 2849, SEQ ID 2850, SEQ ID 2851, SEQ ID 2852, SEQ ID 2853, SEQ ID 2854, SEQ ID 2855, SEQ ID 2858, SEQ ID 2859, SEQ ID 2860, SEQ ID 2861, SEQ ID 2862, SEQ ID 2863, SEQ ID 2864, SEQ ID 2865, SEQ ID 2866, SEQ ID 2867, SEQ ID 2868, SEQ ID 2869, SEQ ID 2870, SEQ ID 2871, SEQ ID 2872, SEQ ID 2873, SEQ ID 2874, SEQ ID 2875, SEQ ID 2876, SEQ ID 2878, SEQ ID 2879, SEQ ID 2880, SEQ ID 2881, SEQ ID 2882, SEQ ID 2883, SEQ ID 2884, SEQ ID 2885, SEQ ID 2886, SEQ ID 2887, SEQ ID 2888, SEQ ID 2889, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2893, SEQ ID 2894, SEQ ID 2895, SEQ ID 2896, SEQ ID 2897, SEQ ID 2898, SEQ ID 2899, SEQ ID 2900, SEQ ID 2901, SEQ ID 2902, SEQ ID 2903, SEQ ID 2904, SEQ ID 2905, SEQ ID 2906, SEQ ID 2907, SEQ ID 2908, SEQ ID 2909, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2915, SEQ ID 2916, SEQ ID 2917, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2921, SEQ ID 2922, SEQ ID 2923, SEQ ID 2924, SEQ ID 2925, SEQ ID 2926, SEQ ID 2927, SEQ ID 2928, SEQ ID 2929, SEQ ID 2930, SEQ ID 2931, SEQ ID 2932, SEQ ID 2934, SEQ ID 2935, SEQ ID 2936, SEQ ID 2937, SEQ ID 2938, SEQ ID 2939, SEQ ID 2940, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2944, SEQ ID 2945, SEQ ID 2946, SEQ ID 2947, SEQ ID 2948, SEQ ID 2949, SEQ ID 2950, SEQ ID 2951, SEQ ID 2953, SEQ ID 2954, SEQ ID 2955, SEQ ID 2956, SEQ ID 2957, SEQ ID 2958, SEQ ID 2960, SEQ ID 2961, SEQ ID 2963, SEQ ID 2964, SEQ ID 2965, SEQ ID 2966, SEQ ID 2967, SEQ ID 2969, SEQ ID 2970, SEQ ID 2971, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2978, SEQ ID 2979, SEQ ID 2980, SEQ ID 2981, SEQ ID 2982, SEQ ID 2983, SEQ ID 2984, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3057, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3080, SEQ ID 3081, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3086, SEQ ID 3087, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3093, SEQ ID 3094, SEQ ID 3095, SEQ ID 3097, SEQ ID 3098, SEQ ID 3099, SEQ ID 3100, SEQ ID 3102, SEQ ID 3103, SEQ ID 3104, SEQ ID 3105, SEQ ID 3106, SEQ ID 3107, SEQ ID 3108, SEQ ID 3109, SEQ ID 3110, SEQ ID 3112, SEQ ID 3113, SEQ ID 3115, SEQ ID 3116, SEQ ID 3117, SEQ ID 3119, SEQ ID 3120, SEQ ID 3121, SEQ ID 3122, SEQ ID 3123, SEQ ID 3124, SEQ ID 3125, SEQ ID 3126, SEQ ID 3127, SEQ ID 3128, SEQ ID 3129, SEQ ID 3130, SEQ ID 3131, SEQ ID 3132, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3136, SEQ ID 3137, SEQ ID 3138, SEQ ID 3139, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3144, SEQ ID 3145, SEQ ID 3146, SEQ ID 3147, SEQ ID 3148, SEQ ID 3149, SEQ ID 3150, SEQ ID 3151, SEQ ID 3152, SEQ ID 3153, SEQ ID 3154, SEQ ID 3155, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3171, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3185, SEQ ID 3186, SEQ ID 3187, SEQ ID 3188, SEQ ID 3189, SEQ ID 3190, SEQ ID 3191, SEQ ID 3192, SEQ ID 3193, SEQ ID 3194, SEQ ID 3195, SEQ ID 3196, SEQ ID 3197, SEQ ID 3198, SEQ ID 3199, SEQ ID 3200, SEQ ID 3201, SEQ ID 3202, SEQ ID 3203, SEQ ID 3204, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3208, SEQ ID 3209, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3220, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3225, SEQ ID 3226, SEQ ID 3227, SEQ ID 3228, SEQ ID 3229, SEQ ID 3230, SEQ ID 3231, SEQ ID 3232, SEQ ID 3233, SEQ ID 3234, SEQ ID 3235, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3253, SEQ ID 3254, SEQ ID 3255, SEQ ID 3256, SEQ ID 3257, SEQ ID 3258, SEQ ID 3259, SEQ ID 3260, SEQ ID 3261, SEQ ID 3262, SEQ ID 3263, SEQ ID 3264, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3268, SEQ ID 3269, SEQ ID 3270, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3275, SEQ ID 3276, SEQ ID 3277, SEQ ID 3278, SEQ ID 3279, SEQ ID 3280, SEQ ID 3282, SEQ ID 3284, SEQ ID 3285, SEQ ID 3286, SEQ ID 3287, SEQ ID 3288, SEQ ID 3289, SEQ ID 3291, SEQ ID 3292, SEQ ID 3293, SEQ ID 3294, SEQ ID 3295, SEQ ID 3296, SEQ ID 3297, SEQ ID 3298, SEQ ID 3299, SEQ ID 3300, SEQ ID 3301, SEQ ID 3302, SEQ ID 3303, SEQ ID 3304, SEQ ID 3305, SEQ ID 3306, SEQ ID 3307, SEQ ID 3308, SEQ ID 3309, SEQ ID 3310, SEQ ID 3311, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3315, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3321, SEQ ID 3322, SEQ ID 3323, SEQ ID 3324, SEQ ID 3325, SEQ ID 3326, SEQ ID 3327, SEQ ID 3329, SEQ ID 3331, SEQ ID 3332, SEQ ID 3333, SEQ ID 3334, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3344, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3357, SEQ ID 3358, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3367, SEQ ID 3368, SEQ ID 3369, SEQ ID 3370, SEQ ID 3371, SEQ ID 3390, SEQ ID 3391, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3400, SEQ ID 3401, SEQ ID 3402, SEQ ID 3403, SEQ ID 3404, SEQ ID 3405, SEQ ID 3406, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3416, SEQ ID 3417, SEQ ID 3418, SEQ ID 3419, SEQ ID 3420, SEQ ID 3421, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3425, SEQ ID 3426, SEQ ID 3427, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3431, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3438, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3453, SEQ ID 3454, SEQ ID 3460, SEQ ID 3461, SEQ ID 3464, SEQ ID 3465, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3486, SEQ ID 3487, SEQ ID 3488, SEQ ID 3489, SEQ ID 3490, SEQ ID 3491, SEQ ID 3493, SEQ ID 3494, SEQ ID 3496, SEQ ID 3497, SEQ ID 3501, SEQ ID 3505, SEQ ID 3508, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3518, SEQ ID 3521, SEQ ID 3522, SEQ ID 3523, SEQ ID 3524, SEQ ID 3525, SEQ ID 3526, SEQ ID 3527, SEQ ID 3528, SEQ ID 3530, SEQ ID 3531, SEQ ID 3532, SEQ ID 3534, SEQ ID 3535, SEQ ID 3536, SEQ ID 3538, SEQ ID 3539, SEQ ID 3541, SEQ ID 3542, SEQ ID 3543, SEQ ID 3544, SEQ ID 3546, SEQ ID 3548, SEQ ID 3549, SEQ ID 3550, SEQ ID 3552, SEQ ID 3556, SEQ ID 3557, SEQ ID 3558, SEQ ID 3560, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3573, SEQ ID 3574, SEQ ID 3576, SEQ ID 3577, SEQ ID 3578, SEQ ID 3580, SEQ ID 3581, SEQ ID 3584, SEQ ID 3585, SEQ ID 3586, SEQ ID 3588, SEQ ID 3590, SEQ ID 3592, SEQ ID 3594, SEQ ID 3595, SEQ ID 3598, SEQ ID 3599, SEQ ID 3600, SEQ ID 3601, SEQ ID 3602, SEQ ID 3603, SEQ ID 3605, SEQ ID 3607, SEQ ID 3609, SEQ ID 3610, SEQ ID 3613, SEQ ID 3614, SEQ ID 3615, SEQ ID 3616, SEQ ID 3617, SEQ ID 3621, SEQ ID 3623, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3629, SEQ ID 3630, SEQ ID 3631, SEQ ID 3632, SEQ ID 3633, SEQ ID 3636, SEQ ID 3637, SEQ ID 3638, SEQ ID 3639, SEQ ID 3641, SEQ ID 3642, SEQ ID 3643, SEQ ID 3645, SEQ ID 3647, SEQ ID 3648, SEQ ID 3649, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3663, SEQ ID 3664, SEQ ID 3665, SEQ ID 3666, SEQ ID 3670, SEQ ID 3672, SEQ ID 3676, SEQ ID 3678, SEQ ID 3679, SEQ ID 3680, SEQ ID 3681, SEQ ID 3682, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3690, SEQ ID 3691, SEQ ID 3692, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3697, SEQ ID 3698, SEQ ID 3699, SEQ ID 3700, SEQ ID 3701, SEQ ID 3702, SEQ ID 3703, SEQ ID 3704, SEQ ID 3705, SEQ ID 3706, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3724, SEQ ID 3725, SEQ ID 3726, SEQ ID 3727, SEQ ID 3729, SEQ ID 3730, SEQ ID 3731, SEQ ID 3732, SEQ ID 3733, SEQ ID 3734, SEQ ID 3735, SEQ ID 3736, SEQ ID 3737, SEQ ID 3738, SEQ ID 3739, SEQ ID 3740, SEQ ID 3741, SEQ ID 3742, SEQ ID 3743, SEQ ID 3744, SEQ ID 3745, SEQ ID 3746, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3777, SEQ ID 3778, SEQ ID 3779, SEQ ID 3780, SEQ ID 3781, SEQ ID 3782, SEQ ID 3783, SEQ ID 3784, SEQ ID 3785, SEQ ID 3786, SEQ ID 3787, SEQ ID 3788, SEQ ID 3789, SEQ ID 3790, SEQ ID 3791, SEQ ID 3792, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3806, SEQ ID 3807, SEQ ID 3808, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3816, SEQ ID 3817, SEQ ID 3818, SEQ ID 3819, SEQ ID 3820, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3829, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3833, SEQ ID 3834, SEQ ID 3835, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3848, SEQ ID 3850, SEQ ID 3851, SEQ ID 3852, SEQ ID 3853, SEQ ID 3867, SEQ ID 3868, SEQ ID 3869, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3877, SEQ ID 3878, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3898, SEQ ID 3899, SEQ ID 3900, SEQ ID 3901, SEQ ID 3902, SEQ ID 3903, SEQ ID 3904, SEQ ID 3905, SEQ ID 3906, SEQ ID 3907, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3914, SEQ ID 3915, SEQ ID 3916, SEQ ID 3917, SEQ ID 3918, SEQ ID 3919, SEQ ID 3920, SEQ ID 3921, SEQ ID 3922, SEQ ID 3923, SEQ ID 3924, SEQ ID 3925, SEQ ID 3926, SEQ ID 3927, SEQ ID 3928, SEQ ID 3929, SEQ ID 3930, SEQ ID 3931, SEQ ID 3932, SEQ ID 3933, SEQ ID 3934, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3941, SEQ ID 3942, SEQ ID 3943, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948.
24. The antisense oligonucleotide progranulin agonist according to claim 22, wherein the contiguous nucleotide sequence is complementary to a sequence selected from the group consisting of SEQ ID 2321, SEQ ID 2335, SEQ ID 2336, SEQ ID 2337, SEQ ID 2338, SEQ ID 2339, SEQ ID 2348, SEQ ID 2349, SEQ ID 2351, SEQ ID 2352, SEQ ID 2353, SEQ ID 2354, SEQ ID 2355, SEQ ID 2358, SEQ ID 2360, SEQ ID 2364, SEQ ID 2365, SEQ ID 2366, SEQ ID 2367, SEQ ID 2369, SEQ ID 2371, SEQ ID 2373, SEQ ID 2375, SEQ ID 2386, SEQ ID 2387, SEQ ID 2388, SEQ ID 2389, SEQ ID 2394, SEQ ID 2403, SEQ ID 2426, SEQ ID 2428, SEQ ID 2429, SEQ ID 2430, SEQ ID 2431, SEQ ID 2432, SEQ ID 2435, SEQ ID 2440, SEQ ID 2441, SEQ ID 2442, SEQ ID 2444, SEQ ID 2446, SEQ ID 2447, SEQ ID 2450, SEQ ID 2451, SEQ ID 2452, SEQ ID 2453, SEQ ID 2454, SEQ ID 2455, SEQ ID 2456, SEQ ID 2458, SEQ ID 2459, SEQ ID 2461, SEQ ID 2463, SEQ ID 2464, SEQ ID 2465, SEQ ID 2466, SEQ ID 2467, SEQ ID 2468, SEQ ID 2469, SEQ ID 2470, SEQ ID 2471, SEQ ID 2472, SEQ ID 2473, SEQ ID 2474, SEQ ID 2475, SEQ ID 2476, SEQ ID 2477, SEQ ID 2478, SEQ ID 2482, SEQ ID 2483, SEQ ID 2484, SEQ ID 2485, SEQ ID 2487, SEQ ID 2489, SEQ ID 2494, SEQ ID 2495, SEQ ID 2496, SEQ ID 2497, SEQ ID 2499, SEQ ID 2501, SEQ ID 2502, SEQ ID 2504, SEQ ID 2506, SEQ ID 2507, SEQ ID 2508, SEQ ID 2509, SEQ ID 2511, SEQ ID 2513, SEQ ID 2515, SEQ ID 2516, SEQ ID 2518, SEQ ID 2519, SEQ ID 2520, SEQ ID 2521, SEQ ID 2523, SEQ ID 2525, SEQ ID 2534, SEQ ID 2537, SEQ ID 2544, SEQ ID 2546, SEQ ID 2554, SEQ ID 2555, SEQ ID 2556, SEQ ID 2560, SEQ ID 2561, SEQ ID 2562, SEQ ID 2595, SEQ ID 2626, SEQ ID 2628, SEQ ID 2629, SEQ ID 2630, SEQ ID 2631, SEQ ID 2633, SEQ ID 2638, SEQ ID 2639, SEQ ID 2640, SEQ ID 2649, SEQ ID 2651, SEQ ID 2652, SEQ ID 2655, SEQ ID 2658, SEQ ID 2665, SEQ ID 2666, SEQ ID 2667, SEQ ID 2669, SEQ ID 2670, SEQ ID 2676, SEQ ID 2677, SEQ ID 2678, SEQ ID 2679, SEQ ID 2682, SEQ ID 2686, SEQ ID 2688, SEQ ID 2689, SEQ ID 2691, SEQ ID 2694, SEQ ID 2698, SEQ ID 2699, SEQ ID 2700, SEQ ID 2701, SEQ ID 2703, SEQ ID 2706, SEQ ID 2709, SEQ ID 2711, SEQ ID 2712, SEQ ID 2713, SEQ ID 2714, SEQ ID 2719, SEQ ID 2720, SEQ ID 2721, SEQ ID 2737, SEQ ID 2739, SEQ ID 2740, SEQ ID 2741, SEQ ID 2742, SEQ ID 2743, SEQ ID 2744, SEQ ID 2745, SEQ ID 2746, SEQ ID 2747, SEQ ID 2748, SEQ ID 2749, SEQ ID 2750, SEQ ID 2751, SEQ ID 2752, SEQ ID 2753, SEQ ID 2754, SEQ ID 2755, SEQ ID 2756, SEQ ID 2757, SEQ ID 2758, SEQ ID 2760, SEQ ID 2763, SEQ ID 2764, SEQ ID 2765, SEQ ID 2766, SEQ ID 2767, SEQ ID 2768, SEQ ID 2769, SEQ ID 2770, SEQ ID 2771, SEQ ID 2772, SEQ ID 2774, SEQ ID 2816, SEQ ID 2817, SEQ ID 2818, SEQ ID 2819, SEQ ID 2820, SEQ ID 2824, SEQ ID 2828, SEQ ID 2829, SEQ ID 2830, SEQ ID 2831, SEQ ID 2832, SEQ ID 2833, SEQ ID 2834, SEQ ID 2835, SEQ ID 2836, SEQ ID 2837, SEQ ID 2851, SEQ ID 2852, SEQ ID 2866, SEQ ID 2871, SEQ ID 2872, SEQ ID 2886, SEQ ID 2887, SEQ ID 2890, SEQ ID 2891, SEQ ID 2892, SEQ ID 2895, SEQ ID 2896, SEQ ID 2899, SEQ ID 2904, SEQ ID 2910, SEQ ID 2911, SEQ ID 2912, SEQ ID 2913, SEQ ID 2914, SEQ ID 2916, SEQ ID 2918, SEQ ID 2919, SEQ ID 2920, SEQ ID 2922, SEQ ID 2925, SEQ ID 2926, SEQ ID 2932, SEQ ID 2939, SEQ ID 2941, SEQ ID 2942, SEQ ID 2943, SEQ ID 2972, SEQ ID 2973, SEQ ID 2974, SEQ ID 2975, SEQ ID 2976, SEQ ID 2977, SEQ ID 2980, SEQ ID 2983, SEQ ID 2985, SEQ ID 3053, SEQ ID 3054, SEQ ID 3055, SEQ ID 3056, SEQ ID 3058, SEQ ID 3059, SEQ ID 3060, SEQ ID 3061, SEQ ID 3062, SEQ ID 3063, SEQ ID 3064, SEQ ID 3065, SEQ ID 3066, SEQ ID 3068, SEQ ID 3069, SEQ ID 3070, SEQ ID 3071, SEQ ID 3072, SEQ ID 3073, SEQ ID 3074, SEQ ID 3075, SEQ ID 3076, SEQ ID 3077, SEQ ID 3078, SEQ ID 3079, SEQ ID 3082, SEQ ID 3083, SEQ ID 3084, SEQ ID 3085, SEQ ID 3088, SEQ ID 3089, SEQ ID 3090, SEQ ID 3091, SEQ ID 3092, SEQ ID 3095, SEQ ID 3097, SEQ ID 3102, SEQ ID 3106, SEQ ID 3108, SEQ ID 3110, SEQ ID 3116, SEQ ID 3120, SEQ ID 3121, SEQ ID 3125, SEQ ID 3126, SEQ ID 3133, SEQ ID 3134, SEQ ID 3135, SEQ ID 3137, SEQ ID 3138, SEQ ID 3140, SEQ ID 3141, SEQ ID 3142, SEQ ID 3143, SEQ ID 3145, SEQ ID 3148, SEQ ID 3152, SEQ ID 3153, SEQ ID 3156, SEQ ID 3157, SEQ ID 3158, SEQ ID 3159, SEQ ID 3160, SEQ ID 3161, SEQ ID 3162, SEQ ID 3163, SEQ ID 3164, SEQ ID 3165, SEQ ID 3166, SEQ ID 3167, SEQ ID 3168, SEQ ID 3169, SEQ ID 3170, SEQ ID 3172, SEQ ID 3173, SEQ ID 3174, SEQ ID 3175, SEQ ID 3176, SEQ ID 3177, SEQ ID 3178, SEQ ID 3179, SEQ ID 3180, SEQ ID 3181, SEQ ID 3182, SEQ ID 3183, SEQ ID 3184, SEQ ID 3186, SEQ ID 3188, SEQ ID 3191, SEQ ID 3193, SEQ ID 3196, SEQ ID 3197, SEQ ID 3203, SEQ ID 3205, SEQ ID 3206, SEQ ID 3207, SEQ ID 3210, SEQ ID 3211, SEQ ID 3212, SEQ ID 3213, SEQ ID 3214, SEQ ID 3215, SEQ ID 3216, SEQ ID 3217, SEQ ID 3218, SEQ ID 3219, SEQ ID 3221, SEQ ID 3222, SEQ ID 3223, SEQ ID 3224, SEQ ID 3227, SEQ ID 3236, SEQ ID 3237, SEQ ID 3238, SEQ ID 3239, SEQ ID 3240, SEQ ID 3241, SEQ ID 3242, SEQ ID 3243, SEQ ID 3244, SEQ ID 3245, SEQ ID 3246, SEQ ID 3248, SEQ ID 3249, SEQ ID 3250, SEQ ID 3251, SEQ ID 3252, SEQ ID 3254, SEQ ID 3258, SEQ ID 3259, SEQ ID 3261, SEQ ID 3263, SEQ ID 3265, SEQ ID 3266, SEQ ID 3267, SEQ ID 3271, SEQ ID 3272, SEQ ID 3273, SEQ ID 3276, SEQ ID 3277, SEQ ID 3279, SEQ ID 3286, SEQ ID 3295, SEQ ID 3297, SEQ ID 3305, SEQ ID 3307, SEQ ID 3309, SEQ ID 3312, SEQ ID 3313, SEQ ID 3314, SEQ ID 3316, SEQ ID 3317, SEQ ID 3318, SEQ ID 3320, SEQ ID 3332, SEQ ID 3335, SEQ ID 3336, SEQ ID 3337, SEQ ID 3338, SEQ ID 3339, SEQ ID 3340, SEQ ID 3342, SEQ ID 3343, SEQ ID 3345, SEQ ID 3346, SEQ ID 3347, SEQ ID 3348, SEQ ID 3349, SEQ ID 3350, SEQ ID 3351, SEQ ID 3352, SEQ ID 3353, SEQ ID 3354, SEQ ID 3355, SEQ ID 3356, SEQ ID 3359, SEQ ID 3360, SEQ ID 3361, SEQ ID 3362, SEQ ID 3363, SEQ ID 3364, SEQ ID 3365, SEQ ID 3366, SEQ ID 3369, SEQ ID 3370, SEQ ID 3390, SEQ ID 3392, SEQ ID 3393, SEQ ID 3394, SEQ ID 3395, SEQ ID 3396, SEQ ID 3397, SEQ ID 3398, SEQ ID 3399, SEQ ID 3401, SEQ ID 3403, SEQ ID 3404, SEQ ID 3407, SEQ ID 3408, SEQ ID 3409, SEQ ID 3410, SEQ ID 3411, SEQ ID 3412, SEQ ID 3413, SEQ ID 3414, SEQ ID 3415, SEQ ID 3417, SEQ ID 3419, SEQ ID 3420, SEQ ID 3422, SEQ ID 3423, SEQ ID 3424, SEQ ID 3428, SEQ ID 3429, SEQ ID 3430, SEQ ID 3432, SEQ ID 3433, SEQ ID 3434, SEQ ID 3435, SEQ ID 3436, SEQ ID 3437, SEQ ID 3439, SEQ ID 3440, SEQ ID 3441, SEQ ID 3442, SEQ ID 3443, SEQ ID 3444, SEQ ID 3445, SEQ ID 3446, SEQ ID 3447, SEQ ID 3448, SEQ ID 3449, SEQ ID 3450, SEQ ID 3451, SEQ ID 3452, SEQ ID 3460, SEQ ID 3461, SEQ ID 3466, SEQ ID 3467, SEQ ID 3468, SEQ ID 3490, SEQ ID 3494, SEQ ID 3496, SEQ ID 3501, SEQ ID 3505, SEQ ID 3511, SEQ ID 3512, SEQ ID 3516, SEQ ID 3517, SEQ ID 3521, SEQ ID 3522, SEQ ID 3556, SEQ ID 3557, SEQ ID 3561, SEQ ID 3566, SEQ ID 3567, SEQ ID 3568, SEQ ID 3569, SEQ ID 3571, SEQ ID 3572, SEQ ID 3576, SEQ ID 3578, SEQ ID 3580, SEQ ID 3584, SEQ ID 3594, SEQ ID 3613, SEQ ID 3614, SEQ ID 3624, SEQ ID 3625, SEQ ID 3626, SEQ ID 3627, SEQ ID 3628, SEQ ID 3633, SEQ ID 3641, SEQ ID 3643, SEQ ID 3648, SEQ ID 3651, SEQ ID 3654, SEQ ID 3656, SEQ ID 3659, SEQ ID 3660, SEQ ID 3661, SEQ ID 3670, SEQ ID 3676, SEQ ID 3680, SEQ ID 3681, SEQ ID 3683, SEQ ID 3684, SEQ ID 3685, SEQ ID 3686, SEQ ID 3687, SEQ ID 3688, SEQ ID 3689, SEQ ID 3691, SEQ ID 3693, SEQ ID 3694, SEQ ID 3695, SEQ ID 3696, SEQ ID 3698, SEQ ID 3700, SEQ ID 3701, SEQ ID 3703, SEQ ID 3704, SEQ ID 3707, SEQ ID 3708, SEQ ID 3709, SEQ ID 3710, SEQ ID 3711, SEQ ID 3712, SEQ ID 3713, SEQ ID 3714, SEQ ID 3715, SEQ ID 3716, SEQ ID 3717, SEQ ID 3718, SEQ ID 3719, SEQ ID 3720, SEQ ID 3721, SEQ ID 3722, SEQ ID 3723, SEQ ID 3725, SEQ ID 3744, SEQ ID 3747, SEQ ID 3748, SEQ ID 3749, SEQ ID 3750, SEQ ID 3751, SEQ ID 3752, SEQ ID 3753, SEQ ID 3754, SEQ ID 3755, SEQ ID 3774, SEQ ID 3775, SEQ ID 3776, SEQ ID 3786, SEQ ID 3788, SEQ ID 3790, SEQ ID 3791, SEQ ID 3793, SEQ ID 3794, SEQ ID 3795, SEQ ID 3796, SEQ ID 3797, SEQ ID 3798, SEQ ID 3799, SEQ ID 3800, SEQ ID 3801, SEQ ID 3802, SEQ ID 3803, SEQ ID 3804, SEQ ID 3805, SEQ ID 3809, SEQ ID 3810, SEQ ID 3811, SEQ ID 3812, SEQ ID 3813, SEQ ID 3814, SEQ ID 3815, SEQ ID 3821, SEQ ID 3822, SEQ ID 3823, SEQ ID 3824, SEQ ID 3825, SEQ ID 3826, SEQ ID 3827, SEQ ID 3828, SEQ ID 3830, SEQ ID 3831, SEQ ID 3832, SEQ ID 3834, SEQ ID 3836, SEQ ID 3837, SEQ ID 3838, SEQ ID 3839, SEQ ID 3840, SEQ ID 3841, SEQ ID 3842, SEQ ID 3844, SEQ ID 3850, SEQ ID 3852, SEQ ID 3867, SEQ ID 3868, SEQ ID 3870, SEQ ID 3871, SEQ ID 3872, SEQ ID 3873, SEQ ID 3874, SEQ ID 3875, SEQ ID 3876, SEQ ID 3879, SEQ ID 3880, SEQ ID 3881, SEQ ID 3882, SEQ ID 3883, SEQ ID 3884, SEQ ID 3885, SEQ ID 3886, SEQ ID 3887, SEQ ID 3888, SEQ ID 3889, SEQ ID 3890, SEQ ID 3891, SEQ ID 3892, SEQ ID 3893, SEQ ID 3894, SEQ ID 3895, SEQ ID 3896, SEQ ID 3897, SEQ ID 3908, SEQ ID 3909, SEQ ID 3910, SEQ ID 3911, SEQ ID 3912, SEQ ID 3913, SEQ ID 3922, SEQ ID 3923, SEQ ID 3930, SEQ ID 3935, SEQ ID 3936, SEQ ID 3937, SEQ ID 3938, SEQ ID 3939, SEQ ID 3940, SEQ ID 3944, SEQ ID 3945, SEQ ID 3946, SEQ ID 3947, and SEQ ID 3948.
25. The antisense oligonucleotide progranulin agonist according to any one of claims 22-24, wherein the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID NOs 693-2039.
26. The antisense oligonucleotide progranulin agonist according to any one of claims 22-25, wherein the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 694, SEQ ID 696, SEQ ID 700, SEQ ID 701, SEQ ID 703, SEQ ID 706, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 712, SEQ ID 713, SEQ ID 714, SEQ ID 717, SEQ ID 718, SEQ ID 719, SEQ ID 720, SEQ ID 721, SEQ ID 722, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 728, SEQ ID 729, SEQ ID 730, SEQ ID 731, SEQ ID 732, SEQ ID 733, SEQ ID 734, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 740, SEQ ID 741, SEQ ID 742, SEQ ID 743, SEQ ID 744, SEQ ID 745, SEQ ID 746, SEQ ID 747, SEQ ID 748, SEQ ID 749, SEQ ID 750, SEQ ID 751, SEQ ID 752, SEQ ID 753, SEQ ID 756, SEQ ID 758, SEQ ID 759, SEQ ID 760, SEQ ID 761, SEQ ID 762, SEQ ID 764, SEQ ID 765, SEQ ID 766, SEQ ID 767, SEQ ID 768, SEQ ID 769, SEQ ID 770, SEQ ID 771, SEQ ID 772, SEQ ID 773, SEQ ID 775, SEQ ID 776, SEQ ID 777, SEQ ID 778, SEQ ID 779, SEQ ID 780, SEQ ID 782, SEQ ID 783, SEQ ID 785, SEQ ID 786, SEQ ID 787, SEQ ID 788, SEQ ID 790, SEQ ID 791, SEQ ID 793, SEQ ID 796, SEQ ID 797, SEQ ID 798, SEQ ID 799, SEQ ID 800, SEQ ID 801, SEQ ID 802, SEQ ID 803, SEQ ID 804, SEQ ID 805, SEQ ID 806, SEQ ID 807, SEQ ID 808, SEQ ID 809, SEQ ID 810, SEQ ID 811, SEQ ID 812, SEQ ID 813, SEQ ID 814, SEQ ID 815, SEQ ID 816, SEQ ID 817, SEQ ID 818, SEQ ID 819, SEQ ID 820, SEQ ID 821, SEQ ID 822, SEQ ID 823, SEQ ID 824, SEQ ID 825, SEQ ID 826, SEQ ID 827, SEQ ID 828, SEQ ID 829, SEQ ID 830, SEQ ID 831, SEQ ID 832, SEQ ID 833, SEQ ID 834, SEQ ID 835, SEQ ID 836, SEQ ID 837, SEQ ID 838, SEQ ID 839, SEQ ID 840, SEQ ID 841, SEQ ID 842, SEQ ID 843, SEQ ID 844, SEQ ID 845, SEQ ID 846, SEQ ID 847, SEQ ID 848, SEQ ID 849, SEQ ID 850, SEQ ID 851, SEQ ID 853, SEQ ID 854, SEQ ID 855, SEQ ID 856, SEQ ID 857, SEQ ID 859, SEQ ID 861, SEQ ID 862, SEQ ID 863, SEQ ID 864, SEQ ID 865, SEQ ID 866, SEQ ID 867, SEQ ID 868, SEQ ID 869, SEQ ID 870, SEQ ID 871, SEQ ID 873, SEQ ID 874, SEQ ID 875, SEQ ID 876, SEQ ID 877, SEQ ID 878, SEQ ID 879, SEQ ID 880, SEQ ID 881, SEQ ID 882, SEQ ID 883, SEQ ID 884, SEQ ID 885, SEQ ID 886, SEQ ID 887, SEQ ID 888, SEQ ID 890, SEQ ID 891, SEQ ID 892, SEQ ID 893, SEQ ID 894, SEQ ID 895, SEQ ID 896, SEQ ID 897, SEQ ID 898, SEQ ID 899, SEQ ID 900, SEQ ID 903, SEQ ID 905, SEQ ID 906, SEQ ID 907, SEQ ID 908, SEQ ID 909, SEQ ID 910, SEQ ID 912, SEQ ID 913, SEQ ID 914, SEQ ID 916, SEQ ID 918, SEQ ID 919, SEQ ID 921, SEQ ID 922, SEQ ID 923, SEQ ID 925, SEQ ID 926, SEQ ID 927, SEQ ID 928, SEQ ID 929, SEQ ID 932, SEQ ID 933, SEQ ID 934, SEQ ID 935, SEQ ID 937, SEQ ID 938, SEQ ID 939, SEQ ID 944, SEQ ID 945, SEQ ID 946, SEQ ID 947, SEQ ID 948, SEQ ID 949, SEQ ID 950, SEQ ID 951, SEQ ID 952, SEQ ID 953, SEQ ID 954, SEQ ID 955, SEQ ID 956, SEQ ID 957, SEQ ID 958, SEQ ID 960, SEQ ID 961, SEQ ID 962, SEQ ID 963, SEQ ID 964, SEQ ID 965, SEQ ID 966, SEQ ID 967, SEQ ID 968, SEQ ID 969, SEQ ID 970, SEQ ID 971, SEQ ID 973, SEQ ID 974, SEQ ID 975, SEQ ID 976, SEQ ID 978, SEQ ID 982, SEQ ID 985, SEQ ID 986, SEQ ID 987, SEQ ID 991, SEQ ID 994, SEQ ID 995, SEQ ID 996, SEQ ID 997, SEQ ID 998, SEQ ID 999, SEQ ID 1000, SEQ ID 1001, SEQ ID 1002, SEQ ID 1003, SEQ ID 1004, SEQ ID 1005, SEQ ID 1006, SEQ ID 1007, SEQ ID 1008, SEQ ID 1009, SEQ ID 1010, SEQ ID 1011, SEQ ID 1012, SEQ ID 1013, SEQ ID 1014, SEQ ID 1015, SEQ ID 1016, SEQ ID 1017, SEQ ID 1018, SEQ ID 1019, SEQ ID 1020, SEQ ID 1021, SEQ ID 1022, SEQ ID 1023, SEQ ID 1024, SEQ ID 1025, SEQ ID 1026, SEQ ID 1027, SEQ ID 1028, SEQ ID 1030, SEQ ID 1031, SEQ ID 1032, SEQ ID 1033, SEQ ID 1034, SEQ ID 1035, SEQ ID 1036, SEQ ID 1037, SEQ ID 1038, SEQ ID 1039, SEQ ID 1040, SEQ ID 1041, SEQ ID 1042, SEQ ID 1043, SEQ ID 1044, SEQ ID 1045, SEQ ID 1046, SEQ ID 1047, SEQ ID 1048, SEQ ID 1049, SEQ ID 1050, SEQ ID 1051, SEQ ID 1052, SEQ ID 1053, SEQ ID 1054, SEQ ID 1055, SEQ ID 1056, SEQ ID 1057, SEQ ID 1058, SEQ ID 1059, SEQ ID 1060, SEQ ID 1061, SEQ ID 1062, SEQ ID 1063, SEQ ID 1065, SEQ ID 1066, SEQ ID 1067, SEQ ID 1068, SEQ ID 1069, SEQ ID 1070, SEQ ID 1071, SEQ ID 1072, SEQ ID 1073, SEQ ID 1074, SEQ ID 1075, SEQ ID 1076, SEQ ID 1077, SEQ ID 1078, SEQ ID 1079, SEQ ID 1080, SEQ ID 1081, SEQ ID 1082, SEQ ID 1083, SEQ ID 1084, SEQ ID 1085, SEQ ID 1086, SEQ ID 1087, SEQ ID 1088, SEQ ID 1089, SEQ ID 1090, SEQ ID 1091, SEQ ID 1092, SEQ ID 1093, SEQ ID 1094, SEQ ID 1095, SEQ ID 1098, SEQ ID 1099, SEQ ID 1100, SEQ ID 1101, SEQ ID 1102, SEQ ID 1105, SEQ ID 1106, SEQ ID 1107, SEQ ID 1108, SEQ ID 1109, SEQ ID 1110, SEQ ID 1111, SEQ ID 1112, SEQ ID 1113, SEQ ID 1114, SEQ ID 1115, SEQ ID 1116, SEQ ID 1117, SEQ ID 1118, SEQ ID 1119, SEQ ID 1120, SEQ ID 1121, SEQ ID 1122, SEQ ID 1123, SEQ ID 1124, SEQ ID 1125, SEQ ID 1126, SEQ ID 1127, SEQ ID 1128, SEQ ID 1129, SEQ ID 1130, SEQ ID 1131, SEQ ID 1132, SEQ ID 1133, SEQ ID 1134, SEQ ID 1135, SEQ ID 1136, SEQ ID 1137, SEQ ID 1138, SEQ ID 1139, SEQ ID 1140, SEQ ID 1141, SEQ ID 1142, SEQ ID 1143, SEQ ID 1144, SEQ ID 1145, SEQ ID 1146, SEQ ID 1147, SEQ ID 1187, SEQ ID 1188, SEQ ID 1189, SEQ ID 1190, SEQ ID 1191, SEQ ID 1192, SEQ ID 1193, SEQ ID 1194, SEQ ID 1195, SEQ ID 1196, SEQ ID 1197, SEQ ID 1198, SEQ ID 1199, SEQ ID 1200, SEQ ID 1201, SEQ ID 1202, SEQ ID 1203, SEQ ID 1204, SEQ ID 1205, SEQ ID 1206, SEQ ID 1207, SEQ ID 1208, SEQ ID 1209, SEQ ID 1210, SEQ ID 1211, SEQ ID 1212, SEQ ID 1213, SEQ ID 1214, SEQ ID 1215, SEQ ID 1216, SEQ ID 1217, SEQ ID 1219, SEQ ID 1220, SEQ ID 1221, SEQ ID 1222, SEQ ID 1223, SEQ ID 1224, SEQ ID 1225, SEQ ID 1226, SEQ ID 1227, SEQ ID 1230, SEQ ID 1231, SEQ ID 1232, SEQ ID 1233, SEQ ID 1234, SEQ ID 1235, SEQ ID 1236, SEQ ID 1237, SEQ ID 1238, SEQ ID 1239, SEQ ID 1240, SEQ ID 1241, SEQ ID 1242, SEQ ID 1243, SEQ ID 1244, SEQ ID 1245, SEQ ID 1246, SEQ ID 1247, SEQ ID 1248, SEQ ID 1250, SEQ ID 1251, SEQ ID 1252, SEQ ID 1253, SEQ ID 1254, SEQ ID 1255, SEQ ID 1256, SEQ ID 1257, SEQ ID 1258, SEQ ID 1259, SEQ ID 1260, SEQ ID 1261, SEQ ID 1262, SEQ ID 1263, SEQ ID 1264, SEQ ID 1265, SEQ ID 1266, SEQ ID 1267, SEQ ID 1268, SEQ ID 1269, SEQ ID 1270, SEQ ID 1271, SEQ ID 1272, SEQ ID 1273, SEQ ID 1274, SEQ ID 1275, SEQ ID 1276, SEQ ID 1277, SEQ ID 1278, SEQ ID 1279, SEQ ID 1280, SEQ ID 1281, SEQ ID 1282, SEQ ID 1283, SEQ ID 1284, SEQ ID 1285, SEQ ID 1286, SEQ ID 1287, SEQ ID 1288, SEQ ID 1289, SEQ ID 1290, SEQ ID 1291, SEQ ID 1292, SEQ ID 1293, SEQ ID 1294, SEQ ID 1295, SEQ ID 1296, SEQ ID 1297, SEQ ID 1298, SEQ ID 1299, SEQ ID 1300, SEQ ID 1301, SEQ ID 1302, SEQ ID 1303, SEQ ID 1304, SEQ ID 1306, SEQ ID 1307, SEQ ID 1308, SEQ ID 1309, SEQ ID 1310, SEQ ID 1311, SEQ ID 1312, SEQ ID 1313, SEQ ID 1314, SEQ ID 1315, SEQ ID 1316, SEQ ID 1317, SEQ ID 1318, SEQ ID 1319, SEQ ID 1320, SEQ ID 1321, SEQ ID 1322, SEQ ID 1323, SEQ ID 1325, SEQ ID 1326, SEQ ID 1327, SEQ ID 1328, SEQ ID 1329, SEQ ID 1330, SEQ ID 1332, SEQ ID 1333, SEQ ID 1335, SEQ ID 1336, SEQ ID 1337, SEQ ID 1338, SEQ ID 1339, SEQ ID 1341, SEQ ID 1342, SEQ ID 1343, SEQ ID 1344, SEQ ID 1345, SEQ ID 1346, SEQ ID 1347, SEQ ID 1348, SEQ ID 1349, SEQ ID 1350, SEQ ID 1351, SEQ ID 1352, SEQ ID 1353, SEQ ID 1354, SEQ ID 1355, SEQ ID 1356, SEQ ID 1357, SEQ ID 1425, SEQ ID 1426, SEQ ID 1427, SEQ ID 1428, SEQ ID 1429, SEQ ID 1430, SEQ ID 1431, SEQ ID 1432, SEQ ID 1433, SEQ ID 1434, SEQ ID 1435, SEQ ID 1436, SEQ ID 1437, SEQ ID 1438, SEQ ID 1440, SEQ ID 1441, SEQ ID 1442, SEQ ID 1443, SEQ ID 1444, SEQ ID 1445, SEQ ID 1446, SEQ ID 1447, SEQ ID 1448, SEQ ID 1449, SEQ ID 1450, SEQ ID 1451, SEQ ID 1452, SEQ ID 1453, SEQ ID 1454, SEQ ID 1455, SEQ ID 1456, SEQ ID 1457, SEQ ID 1458, SEQ ID 1459, SEQ ID 1460, SEQ ID 1461, SEQ ID 1462, SEQ ID 1463, SEQ ID 1464, SEQ ID 1465, SEQ ID 1466, SEQ ID 1467, SEQ ID 1469, SEQ ID 1470, SEQ ID 1471, SEQ ID 1472, SEQ ID 1474, SEQ ID 1475, SEQ ID 1476, SEQ ID 1477, SEQ ID 1478, SEQ ID 1479, SEQ ID 1480, SEQ ID 1481, SEQ ID 1482, SEQ ID 1484, SEQ ID 1485, SEQ ID 1487, SEQ ID 1488, SEQ ID 1489, SEQ ID 1491, SEQ ID 1492, SEQ ID 1493, SEQ ID 1494, SEQ ID 1495, SEQ ID 1496, SEQ ID 1497, SEQ ID 1498, SEQ ID 1499, SEQ ID 1500, SEQ ID 1501, SEQ ID 1502, SEQ ID 1503, SEQ ID 1504, SEQ ID 1505, SEQ ID 1506, SEQ ID 1507, SEQ ID 1508, SEQ ID 1509, SEQ ID 1510, SEQ ID 1511, SEQ ID 1512, SEQ ID 1513, SEQ ID 1514, SEQ ID 1515, SEQ ID 1516, SEQ ID 1517, SEQ ID 1518, SEQ ID 1519, SEQ ID 1520, SEQ ID 1521, SEQ ID 1522, SEQ ID 1523, SEQ ID 1524, SEQ ID 1525, SEQ ID 1526, SEQ ID 1527, SEQ ID 1528, SEQ ID 1529, SEQ ID 1530, SEQ ID 1531, SEQ ID 1532, SEQ ID 1533, SEQ ID 1534, SEQ ID 1535, SEQ ID 1536, SEQ ID 1537, SEQ ID 1538, SEQ ID 1539, SEQ ID 1540, SEQ ID 1541, SEQ ID 1542, SEQ ID 1543, SEQ ID 1544, SEQ ID 1545, SEQ ID 1546, SEQ ID 1547, SEQ ID 1548, SEQ ID 1549, SEQ ID 1550, SEQ ID 1551, SEQ ID 1552, SEQ ID 1553, SEQ ID 1554, SEQ ID 1555, SEQ ID 1556, SEQ ID 1557, SEQ ID 1558, SEQ ID 1559, SEQ ID 1560, SEQ ID 1561, SEQ ID 1562, SEQ ID 1563, SEQ ID 1564, SEQ ID 1565, SEQ ID 1566, SEQ ID 1567, SEQ ID 1568, SEQ ID 1569, SEQ ID 1570, SEQ ID 1571, SEQ ID 1572, SEQ ID 1573, SEQ ID 1574, SEQ ID 1575, SEQ ID 1576, SEQ ID 1577, SEQ ID 1578, SEQ ID 1579, SEQ ID 1580, SEQ ID 1581, SEQ ID 1582, SEQ ID 1583, SEQ ID 1584, SEQ ID 1585, SEQ ID 1586, SEQ ID 1587, SEQ ID 1588, SEQ ID 1589, SEQ ID 1590, SEQ ID 1591, SEQ ID 1592, SEQ ID 1593, SEQ ID 1594, SEQ ID 1595, SEQ ID 1596, SEQ ID 1597, SEQ ID 1598, SEQ ID 1599, SEQ ID 1600, SEQ ID 1601, SEQ ID 1602, SEQ ID 1603, SEQ ID 1604, SEQ ID 1605, SEQ ID 1606, SEQ ID 1607, SEQ ID 1608, SEQ ID 1609, SEQ ID 1610, SEQ ID 1611, SEQ ID 1612, SEQ ID 1613, SEQ ID 1614, SEQ ID 1615, SEQ ID 1616, SEQ ID 1617, SEQ ID 1618, SEQ ID 1620, SEQ ID 1621, SEQ ID 1622, SEQ ID 1623, SEQ ID 1624, SEQ ID 1625, SEQ ID 1626, SEQ ID 1627, SEQ ID 1628, SEQ ID 1629, SEQ ID 1630, SEQ ID 1631, SEQ ID 1632, SEQ ID 1633, SEQ ID 1634, SEQ ID 1635, SEQ ID 1636, SEQ ID 1637, SEQ ID 1638, SEQ ID 1639, SEQ ID 1640, SEQ ID 1641, SEQ ID 1642, SEQ ID 1643, SEQ ID 1644, SEQ ID 1645, SEQ ID 1647, SEQ ID 1648, SEQ ID 1649, SEQ ID 1650, SEQ ID 1651, SEQ ID 1652, SEQ ID 1654, SEQ ID 1656, SEQ ID 1657, SEQ ID 1658, SEQ ID 1659, SEQ ID 1660, SEQ ID 1661, SEQ ID 1663, SEQ ID 1664, SEQ ID 1665, SEQ ID 1666, SEQ ID 1667, SEQ ID 1668, SEQ ID 1669, SEQ ID 1670, SEQ ID 1671, SEQ ID 1672, SEQ ID 1673, SEQ ID 1674, SEQ ID 1675, SEQ ID 1676, SEQ ID 1677, SEQ ID 1678, SEQ ID 1679, SEQ ID 1680, SEQ ID 1681, SEQ ID 1682, SEQ ID 1683, SEQ ID 1684, SEQ ID 1685, SEQ ID 1686, SEQ ID 1687, SEQ ID 1688, SEQ ID 1689, SEQ ID 1690, SEQ ID 1692, SEQ ID 1693, SEQ ID 1694, SEQ ID 1695, SEQ ID 1696, SEQ ID 1697, SEQ ID 1698, SEQ ID 1699, SEQ ID 1701, SEQ ID 1703, SEQ ID 1704, SEQ ID 1705, SEQ ID 1706, SEQ ID 1707, SEQ ID 1708, SEQ ID 1709, SEQ ID 1710, SEQ ID 1711, SEQ ID 1712, SEQ ID 1714, SEQ ID 1715, SEQ ID 1716, SEQ ID 1717, SEQ ID 1718, SEQ ID 1719, SEQ ID 1720, SEQ ID 1721, SEQ ID 1722, SEQ ID 1723, SEQ ID 1724, SEQ ID 1725, SEQ ID 1726, SEQ ID 1727, SEQ ID 1728, SEQ ID 1729, SEQ ID 1730, SEQ ID 1731, SEQ ID 1732, SEQ ID 1733, SEQ ID 1734, SEQ ID 1735, SEQ ID 1736, SEQ ID 1737, SEQ ID 1738, SEQ ID 1739, SEQ ID 1740, SEQ ID 1741, SEQ ID 1742, SEQ ID 1743, SEQ ID 1762, SEQ ID 1763, SEQ ID 1764, SEQ ID 1765, SEQ ID 1766, SEQ ID 1767, SEQ ID 1768, SEQ ID 1769, SEQ ID 1770, SEQ ID 1771, SEQ ID 1772, SEQ ID 1773, SEQ ID 1774, SEQ ID 1775, SEQ ID 1776, SEQ ID 1777, SEQ ID 1778, SEQ ID 1779, SEQ ID 1780, SEQ ID 1781, SEQ ID 1782, SEQ ID 1783, SEQ ID 1784, SEQ ID 1785, SEQ ID 1786, SEQ ID 1787, SEQ ID 1788, SEQ ID 1789, SEQ ID 1790, SEQ ID 1791, SEQ ID 1792, SEQ ID 1793, SEQ ID 1794, SEQ ID 1795, SEQ ID 1796, SEQ ID 1797, SEQ ID 1798, SEQ ID 1799, SEQ ID 1800, SEQ ID 1801, SEQ ID 1802, SEQ ID 1803, SEQ ID 1804, SEQ ID 1805, SEQ ID 1806, SEQ ID 1807, SEQ ID 1808, SEQ ID 1809, SEQ ID 1810, SEQ ID 1811, SEQ ID 1812, SEQ ID 1813, SEQ ID 1814, SEQ ID 1815, SEQ ID 1816, SEQ ID 1817, SEQ ID 1818, SEQ ID 1819, SEQ ID 1820, SEQ ID 1821, SEQ ID 1822, SEQ ID 1823, SEQ ID 1824, SEQ ID 1825, SEQ ID 1826, SEQ ID 1832, SEQ ID 1833, SEQ ID 1836, SEQ ID 1837, SEQ ID 1838, SEQ ID 1839, SEQ ID 1840, SEQ ID 1858, SEQ ID 1859, SEQ ID 1860, SEQ ID 1861, SEQ ID 1862, SEQ ID 1863, SEQ ID 1865, SEQ ID 1866, SEQ ID 1868, SEQ ID 1869, SEQ ID 1873, SEQ ID 1877, SEQ ID 1880, SEQ ID 1883, SEQ ID 1884, SEQ ID 1888, SEQ ID 1889, SEQ ID 1890, SEQ ID 1893, SEQ ID 1894, SEQ ID 1895, SEQ ID 1896, SEQ ID 1897, SEQ ID 1898, SEQ ID 1899, SEQ ID 1900, SEQ ID 1902, SEQ ID 1903, SEQ ID 1904, SEQ ID 1906, SEQ ID 1907, SEQ ID 1908, SEQ ID 1910, SEQ ID 1911, SEQ ID 1913, SEQ ID 1914, SEQ ID 1915, SEQ ID 1916, SEQ ID 1918, SEQ ID 1920, SEQ ID 1921, SEQ ID 1922, SEQ ID 1924, SEQ ID 1928, SEQ ID 1929, SEQ ID 1930, SEQ ID 1932, SEQ ID 1933, SEQ ID 1938, SEQ ID 1939, SEQ ID 1940, SEQ ID 1941, SEQ ID 1943, SEQ ID 1944, SEQ ID 1945, SEQ ID 1946, SEQ ID 1948, SEQ ID 1949, SEQ ID 1950, SEQ ID 1952, SEQ ID 1953, SEQ ID 1956, SEQ ID 1957, SEQ ID 1958, SEQ ID 1960, SEQ ID 1962, SEQ ID 1964, SEQ ID 1966, SEQ ID 1967, SEQ ID 1970, SEQ ID 1971, SEQ ID 1972, SEQ ID 1973, SEQ ID 1974, SEQ ID 1975, SEQ ID 1977, SEQ ID 1979, SEQ ID 1981, SEQ ID 1982, SEQ ID 1985, SEQ ID 1986, SEQ ID 1987, SEQ ID 1988, SEQ ID 1989, SEQ ID 1993, SEQ ID 1995, SEQ ID 1996, SEQ ID 1997, SEQ ID 1998, SEQ ID 1999, SEQ ID 2000, SEQ ID 2001, SEQ ID 2002, SEQ ID 2003, SEQ ID 2004, SEQ ID 2005, SEQ ID 2008, SEQ ID 2009, SEQ ID 2010, SEQ ID 2011, SEQ ID 2013, SEQ ID 2014, SEQ ID 2015, SEQ ID 2017, SEQ ID 2019, SEQ ID 2020, SEQ ID 2021, SEQ ID 2023, SEQ ID 2026, SEQ ID 2028, SEQ ID 2031, SEQ ID 2032, SEQ ID 2033, SEQ ID 2035, SEQ ID 2036, SEQ ID 2037, SEQ ID 2038, SEQ ID 2042, SEQ ID 2044, SEQ ID 2048, SEQ ID 2050, SEQ ID 2051, SEQ ID 2052, SEQ ID 2053, SEQ ID 2054, SEQ ID 2055, SEQ ID 2056, SEQ ID 2057, SEQ ID 2058, SEQ ID 2059, SEQ ID 2060, SEQ ID 2061, SEQ ID 2062, SEQ ID 2063, SEQ ID 2064, SEQ ID 2065, SEQ ID 2066, SEQ ID 2067, SEQ ID 2068, SEQ ID 2069, SEQ ID 2070, SEQ ID 2071, SEQ ID 2072, SEQ ID 2073, SEQ ID 2074, SEQ ID 2075, SEQ ID 2076, SEQ ID 2077, SEQ ID 2078, SEQ ID 2079, SEQ ID 2080, SEQ ID 2081, SEQ ID 2082, SEQ ID 2083, SEQ ID 2084, SEQ ID 2085, SEQ ID 2086, SEQ ID 2087, SEQ ID 2088, SEQ ID 2089, SEQ ID 2090, SEQ ID 2091, SEQ ID 2092, SEQ ID 2093, SEQ ID 2094, SEQ ID 2095, SEQ ID 2096, SEQ ID 2097, SEQ ID 2098, SEQ ID 2099, SEQ ID 2101, SEQ ID 2102, SEQ ID 2103, SEQ ID 2104, SEQ ID 2105, SEQ ID 2106, SEQ ID 2107, SEQ ID 2108, SEQ ID 2109, SEQ ID 2110, SEQ ID 2111, SEQ ID 2112, SEQ ID 2113, SEQ ID 2114, SEQ ID 2115, SEQ ID 2116, SEQ ID 2117, SEQ ID 2118, SEQ ID 2119, SEQ ID 2120, SEQ ID 2121, SEQ ID 2122, SEQ ID 2123, SEQ ID 2124, SEQ ID 2125, SEQ ID 2126, SEQ ID 2127, SEQ ID 2146, SEQ ID 2147, SEQ ID 2148, SEQ ID 2149, SEQ ID 2150, SEQ ID 2151, SEQ ID 2152, SEQ ID 2153, SEQ ID 2154, SEQ ID 2155, SEQ ID 2156, SEQ ID 2157, SEQ ID 2158, SEQ ID 2159, SEQ ID 2160, SEQ ID 2161, SEQ ID 2162, SEQ ID 2163, SEQ ID 2164, SEQ ID 2165, SEQ ID 2166, SEQ ID 2167, SEQ ID 2168, SEQ ID 2169, SEQ ID 2170, SEQ ID 2171, SEQ ID 2172, SEQ ID 2173, SEQ ID 2174, SEQ ID 2175, SEQ ID 2176, SEQ ID 2177, SEQ ID 2178, SEQ ID 2179, SEQ ID 2180, SEQ ID 2181, SEQ ID 2182, SEQ ID 2183, SEQ ID 2184, SEQ ID 2185, SEQ ID 2186, SEQ ID 2187, SEQ ID 2188, SEQ ID 2189, SEQ ID 2190, SEQ ID 2191, SEQ ID 2192, SEQ ID 2193, SEQ ID 2194, SEQ ID 2195, SEQ ID 2196, SEQ ID 2197, SEQ ID 2198, SEQ ID 2199, SEQ ID 2200, SEQ ID 2201, SEQ ID 2202, SEQ ID 2203, SEQ ID 2204, SEQ ID 2205, SEQ ID 2206, SEQ ID 2207, SEQ ID 2208, SEQ ID 2209, SEQ ID 2210, SEQ ID 2211, SEQ ID 2212, SEQ ID 2213, SEQ ID 2214, SEQ ID 2216, SEQ ID 2220, SEQ ID 2222, SEQ ID 2223, SEQ ID 2224, SEQ ID 2225, SEQ ID 2239, SEQ ID 2240, SEQ ID 2241, SEQ ID 2242, SEQ ID 2243, SEQ ID 2244, SEQ ID 2245, SEQ ID 2246, SEQ ID 2247, SEQ ID 2248, SEQ ID 2249, SEQ ID 2250, SEQ ID 2251, SEQ ID 2252, SEQ ID 2253, SEQ ID 2254, SEQ ID 2255, SEQ ID 2256, SEQ ID 2257, SEQ ID 2258, SEQ ID 2259, SEQ ID 2260, SEQ ID 2261, SEQ ID 2262, SEQ ID 2263, SEQ ID 2264, SEQ ID 2265, SEQ ID 2266, SEQ ID 2267, SEQ ID 2268, SEQ ID 2269, SEQ ID 2270, SEQ ID 2271, SEQ ID 2272, SEQ ID 2273, SEQ ID 2274, SEQ ID 2275, SEQ ID 2276, SEQ ID 2277, SEQ ID 2278, SEQ ID 2279, SEQ ID 2280, SEQ ID 2281, SEQ ID 2282, SEQ ID 2283, SEQ ID 2284, SEQ ID 2285, SEQ ID 2286, SEQ ID 2287, SEQ ID 2288, SEQ ID 2289, SEQ ID 2290, SEQ ID 2291, SEQ ID 2292, SEQ ID 2293, SEQ ID 2294, SEQ ID 2295, SEQ ID 2296, SEQ ID 2297, SEQ ID 2298, SEQ ID 2299, SEQ ID 2300, SEQ ID 2301, SEQ ID 2302, SEQ ID 2303, SEQ ID 2304, SEQ ID 2305, SEQ ID 2306, SEQ ID 2307, SEQ ID 2308, SEQ ID 2309, SEQ ID 2310, SEQ ID 2311, SEQ ID 2312, SEQ ID 2313, SEQ ID 2314, SEQ ID 2315, SEQ ID 2316, SEQ ID 2317, SEQ ID 2318, SEQ ID 2319, and SEQ ID 2320.
27. The antisense oligonucleotide progranulin agonist according to any one of claims 22-26, wherein the antisense oligonucleotide progranulin agonist is selected from the group consisting of SEQ ID 693, SEQ ID 707, SEQ ID 708, SEQ ID 709, SEQ ID 710, SEQ ID 711, SEQ ID 720, SEQ ID 721, SEQ ID 723, SEQ ID 724, SEQ ID 725, SEQ ID 726, SEQ ID 727, SEQ ID 730, SEQ ID 732, SEQ ID 736, SEQ ID 737, SEQ ID 738, SEQ ID 739, SEQ ID 741, SEQ ID 743, SEQ ID 745, SEQ ID 747, SEQ ID 758, SEQ ID 759, SEQ ID 760, SEQ ID 761, SEQ ID 766, SEQ ID 775, SEQ ID 798, SEQ ID 800, SEQ ID 801, SEQ ID 802, SEQ ID 803, SEQ ID 804, SEQ ID 807, SEQ ID 812, SEQ ID 813, SEQ ID 814, SEQ ID 816, SEQ ID 818, SEQ ID 819, SEQ ID 822, SEQ ID 823, SEQ ID 824, SEQ ID 825, SEQ ID 826, SEQ ID 827, SEQ ID 828, SEQ ID 830, SEQ ID 831, SEQ ID 833, SEQ ID 835, SEQ ID 836, SEQ ID 837, SEQ ID 838, SEQ ID 839, SEQ ID 840, SEQ ID 841, SEQ ID 842, SEQ ID 843, SEQ ID 844, SEQ ID 845, SEQ ID 846, SEQ ID 847, SEQ ID 848, SEQ ID 849, SEQ ID 850, SEQ ID 854, SEQ ID 855, SEQ ID 856, SEQ ID 857, SEQ ID 859, SEQ ID 861, SEQ ID 866, SEQ ID 867, SEQ ID 868, SEQ ID 869, SEQ ID 871, SEQ ID 873, SEQ ID 874, SEQ ID 876, SEQ ID 878, SEQ ID 879, SEQ ID 880, SEQ ID 881, SEQ ID 883, SEQ ID 885, SEQ ID 887, SEQ ID 888, SEQ ID 890, SEQ ID 891, SEQ ID 892, SEQ ID 893, SEQ ID 895, SEQ ID 897, SEQ ID 906, SEQ ID 909, SEQ ID 916, SEQ ID 918, SEQ ID 926, SEQ ID 927, SEQ ID 928, SEQ ID 932, SEQ ID 933, SEQ ID 934, SEQ ID 967, SEQ ID 998, SEQ ID 1000, SEQ ID 1001, SEQ ID 1002, SEQ ID 1003, SEQ ID 1005, SEQ ID 1010, SEQ ID 1011, SEQ ID 1012, SEQ ID 1021, SEQ ID 1023, SEQ ID 1024, SEQ ID 1027, SEQ ID 1030, SEQ ID 1037, SEQ ID 1038, SEQ ID 1039, SEQ ID 1041, SEQ ID 1042, SEQ ID 1048, SEQ ID 1049, SEQ ID 1050, SEQ ID 1051, SEQ ID 1054, SEQ ID 1058, SEQ ID 1060, SEQ ID 1061, SEQ ID 1063, SEQ ID 1066, SEQ ID 1070, SEQ ID 1071, SEQ ID 1072, SEQ ID 1073, SEQ ID 1075, SEQ ID 1078, SEQ ID 1081, SEQ ID 1083, SEQ ID 1084, SEQ ID 1085, SEQ ID 1086, SEQ ID 1091, SEQ ID 1092, SEQ ID 1093, SEQ ID 1109, SEQ ID 1111, SEQ ID 1112, SEQ ID 1113, SEQ ID 1114, SEQ ID 1115, SEQ ID 1116, SEQ ID 1117, SEQ ID 1118, SEQ ID 1119, SEQ ID 1120, SEQ ID 1121, SEQ ID 1122, SEQ ID 1123, SEQ ID 1124, SEQ ID 1125, SEQ ID 1126, SEQ ID 1127, SEQ ID 1128, SEQ ID 1129, SEQ ID 1130, SEQ ID 1132, SEQ ID 1135, SEQ ID 1136, SEQ ID 1137, SEQ ID 1138, SEQ ID 1139, SEQ ID 1140, SEQ ID 1141, SEQ ID 1142, SEQ ID 1143, SEQ ID 1144, SEQ ID 1146, SEQ ID 1188, SEQ ID 1189, SEQ ID 1190, SEQ ID 1191, SEQ ID 1192, SEQ ID 1196, SEQ ID 1200, SEQ ID 1201, SEQ ID 1202, SEQ ID 1203, SEQ ID 1204, SEQ ID 1205, SEQ ID 1206, SEQ ID 1207, SEQ ID 1208, SEQ ID 1209, SEQ ID 1223, SEQ ID 1224, SEQ ID 1238, SEQ ID 1243, SEQ ID 1244, SEQ ID 1258, SEQ ID 1259, SEQ ID 1262, SEQ ID 1263, SEQ ID 1264, SEQ ID 1267, SEQ ID 1268, SEQ ID 1271, SEQ ID 1276, SEQ ID 1282, SEQ ID 1283, SEQ ID 1284, SEQ ID 1285, SEQ ID 1286, SEQ ID 1288, SEQ ID 1290, SEQ ID 1291, SEQ ID 1292, SEQ ID 1294, SEQ ID 1297, SEQ ID 1298, SEQ ID 1304, SEQ ID 1311, SEQ ID 1313, SEQ ID 1314, SEQ ID 1315, SEQ ID 1344, SEQ ID 1345, SEQ ID 1346, SEQ ID 1347, SEQ ID 1348, SEQ ID 1349, SEQ ID 1352, SEQ ID 1355, SEQ ID 1357, SEQ ID 1425, SEQ ID 1426, SEQ ID 1427, SEQ ID 1428, SEQ ID 1430, SEQ ID 1431, SEQ ID 1432, SEQ ID 1433, SEQ ID 1434, SEQ ID 1435, SEQ ID 1436, SEQ ID 1437, SEQ ID 1438, SEQ ID 1440, SEQ ID 1441, SEQ ID 1442, SEQ ID 1443, SEQ ID 1444, SEQ ID 1445, SEQ ID 1446, SEQ ID 1447, SEQ ID 1448, SEQ ID 1449, SEQ ID 1450, SEQ ID 1451, SEQ ID 1454, SEQ ID 1455, SEQ ID 1456, SEQ ID 1457, SEQ ID 1460, SEQ ID 1461, SEQ ID 1462, SEQ ID 1463, SEQ ID 1464, SEQ ID 1467, SEQ ID 1469, SEQ ID 1474, SEQ ID 1478, SEQ ID 1480, SEQ ID 1482, SEQ ID 1488, SEQ ID 1492, SEQ ID 1493, SEQ ID 1497, SEQ ID 1498, SEQ ID 1505, SEQ ID 1506, SEQ ID 1507, SEQ ID 1509, SEQ ID 1510, SEQ ID 1512, SEQ ID 1513, SEQ ID 1514, SEQ ID 1515, SEQ ID 1517, SEQ ID 1520, SEQ ID 1524, SEQ ID 1525, SEQ ID 1528, SEQ ID 1529, SEQ ID 1530, SEQ ID 1531, SEQ ID 1532, SEQ ID 1533, SEQ ID 1534, SEQ ID 1535, SEQ ID 1536, SEQ ID 1537, SEQ ID 1538, SEQ ID 1539, SEQ ID 1540, SEQ ID 1541, SEQ ID 1542, SEQ ID 1544, SEQ ID 1545, SEQ ID 1546, SEQ ID 1547, SEQ ID 1548, SEQ ID 1549, SEQ ID 1550, SEQ ID 1551, SEQ ID 1552, SEQ ID 1553, SEQ ID 1554, SEQ ID 1555, SEQ ID 1556, SEQ ID 1558, SEQ ID 1560, SEQ ID 1563, SEQ ID 1565, SEQ ID 1568, SEQ ID 1569, SEQ ID 1575, SEQ ID 1577, SEQ ID 1578, SEQ ID 1579, SEQ ID 1582, SEQ ID 1583, SEQ ID 1584, SEQ ID 1585, SEQ ID 1586, SEQ ID 1587, SEQ ID 1588, SEQ ID 1589, SEQ ID 1590, SEQ ID 1591, SEQ ID 1593, SEQ ID 1594, SEQ ID 1595, SEQ ID 1596, SEQ ID 1599, SEQ ID 1608, SEQ ID 1609, SEQ ID 1610, SEQ ID 1611, SEQ ID 1612, SEQ ID 1613, SEQ ID 1614, SEQ ID 1615, SEQ ID 1616, SEQ ID 1617, SEQ ID 1618, SEQ ID 1620, SEQ ID 1621, SEQ ID 1622, SEQ ID 1623, SEQ ID 1624, SEQ ID 1626, SEQ ID 1630, SEQ ID 1631, SEQ ID 1633, SEQ ID 1635, SEQ ID 1637, SEQ ID 1638, SEQ ID 1639, SEQ ID 1643, SEQ ID 1644, SEQ ID 1645, SEQ ID 1648, SEQ ID 1649, SEQ ID 1651, SEQ ID 1658, SEQ ID 1667, SEQ ID 1669, SEQ ID 1677, SEQ ID 1679, SEQ ID 1681, SEQ ID 1684, SEQ ID 1685, SEQ ID 1686, SEQ ID 1688, SEQ ID 1689, SEQ ID 1690, SEQ ID 1692, SEQ ID 1704, SEQ ID 1707, SEQ ID 1708, SEQ ID 1709, SEQ ID 1710, SEQ ID 1711, SEQ ID 1712, SEQ ID 1714, SEQ ID 1715, SEQ ID 1717, SEQ ID 1718, SEQ ID 1719, SEQ ID 1720, SEQ ID 1721, SEQ ID 1722, SEQ ID 1723, SEQ ID 1724, SEQ ID 1725, SEQ ID 1726, SEQ ID 1727, SEQ ID 1728, SEQ ID 1731, SEQ ID 1732, SEQ ID 1733, SEQ ID 1734, SEQ ID 1735, SEQ ID 1736, SEQ ID 1737, SEQ ID 1738, SEQ ID 1741, SEQ ID 1742, SEQ ID 1762, SEQ ID 1764, SEQ ID 1765, SEQ ID 1766, SEQ ID 1767, SEQ ID 1768, SEQ ID 1769, SEQ ID 1770, SEQ ID 1771, SEQ ID 1773, SEQ ID 1775, SEQ ID 1776, SEQ ID 1779, SEQ ID 1780, SEQ ID 1781, SEQ ID 1782, SEQ ID 1783, SEQ ID 1784, SEQ ID 1785, SEQ ID 1786, SEQ ID 1787, SEQ ID 1789, SEQ ID 1791, SEQ ID 1792, SEQ ID 1794, SEQ ID 1795, SEQ ID 1796, SEQ ID 1800, SEQ ID 1801, SEQ ID 1802, SEQ ID 1804, SEQ ID 1805, SEQ ID 1806, SEQ ID 1807, SEQ ID 1808, SEQ ID 1809, SEQ ID 1811, SEQ ID 1812, SEQ ID 1813, SEQ ID 1814, SEQ ID 1815, SEQ ID 1816, SEQ ID 1817, SEQ ID 1818, SEQ ID 1819, SEQ ID 1820, SEQ ID 1821, SEQ ID 1822, SEQ ID 1823, SEQ ID 1824, SEQ ID 1832, SEQ ID 1833, SEQ ID 1838, SEQ ID 1839, SEQ ID 1840, SEQ ID 1862, SEQ ID 1866, SEQ ID 1868, SEQ ID 1873, SEQ ID 1877, SEQ ID 1883, SEQ ID 1884, SEQ ID 1888, SEQ ID 1889, SEQ ID 1893, SEQ ID 1894, SEQ ID 1928, SEQ ID 1929, SEQ ID 1933, SEQ ID 1938, SEQ ID 1939, SEQ ID 1940, SEQ ID 1941, SEQ ID 1943, SEQ ID 1944, SEQ ID 1948, SEQ ID 1950, SEQ ID 1952, SEQ ID 1956, SEQ ID 1966, SEQ ID 1985, SEQ ID 1986, SEQ ID 1996, SEQ ID 1997, SEQ ID 1998, SEQ ID 1999, SEQ ID 2000, SEQ ID 2005, SEQ ID 2013, SEQ ID 2015, SEQ ID 2020, SEQ ID 2023, SEQ ID 2026, SEQ ID 2028, SEQ ID 2031, SEQ ID 2032, SEQ ID 2033, SEQ ID 2042, SEQ ID 2048, SEQ ID 2052, SEQ ID 2053, SEQ ID 2055, SEQ ID 2056, SEQ ID 2057, SEQ ID 2058, SEQ ID 2059, SEQ ID 2060, SEQ ID 2061, SEQ ID 2063, SEQ ID 2065, SEQ ID 2066, SEQ ID 2067, SEQ ID 2068, SEQ ID 2070, SEQ ID 2072, SEQ ID 2073, SEQ ID 2075, SEQ ID 2076, SEQ ID 2079, SEQ ID 2080, SEQ ID 2081, SEQ ID 2082, SEQ ID 2083, SEQ ID 2084, SEQ ID 2085, SEQ ID 2086, SEQ ID 2087, SEQ ID 2088, SEQ ID 2089, SEQ ID 2090, SEQ ID 2091, SEQ ID 2092, SEQ ID 2093, SEQ ID 2094, SEQ ID 2095, SEQ ID 2097, SEQ ID 2116, SEQ ID 2119, SEQ ID 2120, SEQ ID 2121, SEQ ID 2122, SEQ ID 2123, SEQ ID 2124, SEQ ID 2125, SEQ ID 2126, SEQ ID 2127, SEQ ID 2146, SEQ ID 2147, SEQ ID 2148, SEQ ID 2158, SEQ ID 2160, SEQ ID 2162, SEQ ID 2163, SEQ ID 2165, SEQ ID 2166, SEQ ID 2167, SEQ ID 2168, SEQ ID 2169, SEQ ID 2170, SEQ ID 2171, SEQ ID 2172, SEQ ID 2173, SEQ ID 2174, SEQ ID 2175, SEQ ID 2176, SEQ ID 2177, SEQ ID 2181, SEQ ID 2182, SEQ ID 2183, SEQ ID 2184, SEQ ID 2185, SEQ ID 2186, SEQ ID 2187, SEQ ID 2193, SEQ ID 2194, SEQ ID 2195, SEQ ID 2196, SEQ ID 2197, SEQ ID 2198, SEQ ID 2199, SEQ ID 2200, SEQ ID 2202, SEQ ID 2203, SEQ ID 2204, SEQ ID 2206, SEQ ID 2208, SEQ ID 2209, SEQ ID 2210, SEQ ID 2211, SEQ ID 2212, SEQ ID 2213, SEQ ID 2214, SEQ ID 2216, SEQ ID 2222, SEQ ID 2224, SEQ ID 2239, SEQ ID 2240, SEQ ID 2242, SEQ ID 2243, SEQ ID 2244, SEQ ID 2245, SEQ ID 2246, SEQ ID 2247, SEQ ID 2248, SEQ ID 2251, SEQ ID 2252, SEQ ID 2253, SEQ ID 2254, SEQ ID 2255, SEQ ID 2256, SEQ ID 2257, SEQ ID 2258, SEQ ID 2259, SEQ ID 2260, SEQ ID 2261, SEQ ID 2262, SEQ ID 2263, SEQ ID 2264, SEQ ID 2265, SEQ ID 2266, SEQ ID 2267, SEQ ID 2268, SEQ ID 2269, SEQ ID 2280, SEQ ID 2281, SEQ ID 2282, SEQ ID 2283, SEQ ID 2284, SEQ ID 2285, SEQ ID 2294, SEQ ID 2295, SEQ ID 2302, SEQ ID 2307, SEQ ID 2308, SEQ ID 2309, SEQ ID 2310, SEQ ID 2311, SEQ ID 2312, SEQ ID 2316, SEQ ID 2317, SEQ ID 2318, SEQ ID 2319, and SEQ ID 2320.
28. The antisense oligonucleotide progranulin agonist according to any one of claims 1-20, wherein the antisense oligonucleotide progranulin agonist is or comprises an antisense oligonucleotide mixmer or totalmer.
29. The antisense oligonucleotide progranulin agonist of any one of claims 1-28, wherein the antisense oligonucleotide progranulin agonist or contiguous nucleotide sequence thereof is 10-20 nucleotides in length.
30. An antisense oligonucleotide progranulin agonist having the structure:
Figure US20230287412A1-20230914-C00007
31. An antisense oligonucleotide progranulin agonist wherein the oligonucleotide is the oligonucleotide compound TgGccAggGatCagGG (SEQ ID NO: 106) wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages.
32. An antisense oligonucleotide progranulin agonist according to any one of claims 1-31 covalently attached to at least one conjugate moiety.
33. An antisense oligonucleotide progranulin agonist according to any one of claims 1-32 wherein the antisense oligonucleotide progranulin agonist is in the form of a pharmaceutically acceptable salt.
34. An antisense oligonucleotide progranulin agonist according to claim 33 wherein the salt is a sodium salt or a potassium salt.
35. A pharmaceutical composition comprising the antisense oligonucleotide progranulin agonist according to any one of claims 1-34 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
36. A pharmaceutical composition according to claim 35, wherein the pharmaceutical composition comprises an aqueous diluent or solvent, such as phosphate buffered saline.
37. An in vivo or in vitro method for enhancing the expression of progranulin in a cell which is expressing progranulin, said method comprising administering an antisense oligonucleotide progranulin agonist according to any one of claims 1-34, or the pharmaceutical composition according to claim 35 or claim 36 in an effective amount to said cell.
38. The method according to claim 37, wherein the cell is either a human cell or a mammalian cell.
39. A method for treating or preventing neurological disease comprising administering a therapeutically or prophylactically effective amount of an antisense oligonucleotide progranulin agonist according to any one of claims 1-34 or the pharmaceutical composition according to claim 35 or claim 365 to a subject suffering from or susceptible to neurological disease.
40. The antisense oligonucleotide progranulin agonist according to any one of claims 1-34, or the pharmaceutical composition according to claim 35 or claim 36 for use as a medicament.
41. The antisense oligonucleotide progranulin agonist according to any one of claims 1-33, or the pharmaceutical composition according to claim 35 or claim 36 for use in the treatment of a neurological disease.
42. The antisense oligonucleotide progranulin agonist or pharmaceutical composition for use in the treatment of a neurological disease according to claim 41, wherein the neurological disease is a TDP-43 pathology.
43. The antisense oligonucleotide progranulin agonist according to any one of claims 1-34 or the pharmaceutical composition according to claim 35 or claim 36 for use in the treatment of progranulin haploinsufficiency.
44. Use of the antisense oligonucleotide progranulin agonist according to claims 1-34, or the pharmaceutical composition according to claim 35 or claim 36 for the preparation of a medicament for treatment or prevention of a neurological disease.
45. Use of an antisense oligonucleotide progranulin agonist, or pharmaceutical composition according to claim 44, wherein the neurological disease is a TDP-43 pathology.
46. Use of the antisense oligonucleotide progranulin agonist according to claim 1-34, or the pharmaceutical composition according to claim 35 or claim 36, for the preparation of a medicament for treatment of progranulin haploinsufficiency.
47. The method or use according to any one of claims 37-46, wherein the method or use is for the treatment of fronto temporal dementia (FTD), neuropathologic frontotemporal lobar degeneration or neuroinflammation.
US17/986,101 2020-05-13 2022-11-14 Oligonucleotide Agonists Targeting Progranulin Pending US20230287412A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20174322 2020-05-13
EP20174322.6 2020-05-13
EP20210822 2020-11-30
EP20210822.1 2020-11-30
PCT/EP2021/062785 WO2021229036A1 (en) 2020-05-13 2021-05-13 Oligonucleotide agonists targeting progranulin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/062785 Continuation WO2021229036A1 (en) 2020-05-13 2021-05-13 Oligonucleotide agonists targeting progranulin

Publications (1)

Publication Number Publication Date
US20230287412A1 true US20230287412A1 (en) 2023-09-14

Family

ID=76138051

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/320,139 Pending US20210388357A1 (en) 2020-05-13 2021-05-13 Oligonucleotide agonists targeting progranulin
US17/986,101 Pending US20230287412A1 (en) 2020-05-13 2022-11-14 Oligonucleotide Agonists Targeting Progranulin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US17/320,139 Pending US20210388357A1 (en) 2020-05-13 2021-05-13 Oligonucleotide agonists targeting progranulin

Country Status (6)

Country Link
US (2) US20210388357A1 (en)
EP (1) EP4150083A1 (en)
JP (1) JP2023526267A (en)
CN (1) CN116096888A (en)
TW (1) TW202208628A (en)
WO (1) WO2021229036A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210395747A1 (en) * 2020-06-19 2021-12-23 Saint Louis University Methods and compositions for treatment of frontotemporal dementia
EP4263831A1 (en) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Antisense oligonucleotides for targeting progranulin
WO2023092057A1 (en) * 2021-11-18 2023-05-25 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating progranulin expression
WO2023242324A1 (en) * 2022-06-17 2023-12-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for targeting progranulin

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
JP4236812B2 (en) 1997-09-12 2009-03-11 エクシコン エ／エス Oligonucleotide analogues
US20050014711A1 (en) * 1998-06-09 2005-01-20 Nyce Jonathan W. Composition, formulations & methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammation
ES2234563T5 (en) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited New nucleoside and oligonucleotide analogs
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2752488B1 (en) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Antisense design
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
DK2314594T3 (en) 2006-01-27 2014-10-27 Isis Pharmaceuticals Inc 6-modified bicyclic nucleic acid analogues
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP5123936B2 (en) * 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Detection and treatment of dementia
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2853829C (en) * 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013173635A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
CN117126846A (en) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 Oligonucleotide conjugates
CA2935426C (en) 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
KR102598819B1 (en) * 2014-06-23 2023-11-03 더 제너럴 하스피탈 코포레이션 Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
US10822369B2 (en) * 2014-11-14 2020-11-03 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
MX2020005561A (en) * 2017-12-01 2020-10-12 Encoded Therapeutics Inc Engineered dna binding proteins.
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3942049A4 (en) * 2019-03-20 2023-10-18 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases

Also Published As

Publication number Publication date
JP2023526267A (en) 2023-06-21
WO2021229036A9 (en) 2022-11-10
US20210388357A1 (en) 2021-12-16
EP4150083A1 (en) 2023-03-22
WO2021229036A1 (en) 2021-11-18
TW202208628A (en) 2022-03-01
CN116096888A (en) 2023-05-09

Similar Documents

Publication Publication Date Title
US20230287412A1 (en) Oligonucleotide Agonists Targeting Progranulin
US10253319B2 (en) miRNA modulators of thermogenesis
US10577604B2 (en) Methods for monitoring C9ORF72 expression
US20180100201A1 (en) Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
EP2839005B1 (en) Mirna modulators of thermogenesis
Simionescu-Bankston et al. Noncoding RNAs in the regulation of skeletal muscle biology in health and disease
US10316318B2 (en) Oligonucleotide compositions and uses thereof
JP2015518714A (en) Compositions and methods for regulating gene expression
US20110021600A1 (en) Novel nucleic acid
US20170037398A1 (en) Artificial mimic mirna for controlling gene expression, and use of same
Liu et al. Thymopentin alleviates premature ovarian failure in mice by activating YY2/Lin28A and inhibiting the expression of let‐7 family microRNAs
WO2019229133A1 (en) Methods of treating or preventing an aging-related disease
Xu et al. Effect of siRNA‑induced inhibition of IL‑6 expression in rat cerebral gliocytes on cerebral edema following traumatic brain injury
KR20130008560A (en) Method for proliferating cardiomyocytes using micro-rna
WO2017156591A1 (en) Osteoarthritis mirnas
EP2331143B1 (en) Treatment of scleroderma
WO2019182055A1 (en) Inflammation-suppressing composition
JP7005020B2 (en) Muscle differentiation inducer
US20200157537A1 (en) Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
US20160319286A1 (en) Composition for preventing or treating osteoporosis, containing progranulin inhibitor as active ingredient
JP2021509914A (en) A pharmaceutical composition for the prevention or treatment of muscle disease or cachexia, which comprises as an active ingredient miRNA or a variant thereof located in a Dlk1-Dio3 cluster.
Dlamini et al. OPEN ACCESS EDITED BY
TW202136510A (en) Enhanced oligonucleotides for inhibiting scn9a expression
Siti Construction and characterization of a cell model of Spinal Muscular Atrophy (SMA)

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCHE INNOVATION CENTER COPENHAGEN A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOENSON, LARS;RASMUSSEN, SOREN;TEHLER, DISA;AND OTHERS;SIGNING DATES FROM 20210216 TO 20210307;REEL/FRAME:062298/0077

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE INNOVATION CENTER COPENHAGEN A/S;REEL/FRAME:062300/0726

Effective date: 20210420

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JAGASIA, RAVI;REEL/FRAME:062298/0477

Effective date: 20210403

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:062301/0216

Effective date: 20210420

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION